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“According	to	Darwin’s	Origin	of	Species,	
it	is	not	the	most	intellectual	of	the	species	that	survives;	
it	is	not	the	strongest	that	survives;	
but	the	species	that	survives	is	the	one	
that	is	able	best	to	adapt	and	adjust	
	to	the	changing	environment	
in	which	it	finds	itself.”	
Leon	C.	Megginson	paraphrasing	
Charles	Darwin’s	Origin	of	Species	
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Abstract	
Multiple	 Sclerosis	 (MS)	 is	 a	 chronic	 neurodegenerative	 disease	 of	 the	 central	 nervous	
system	 characterized	 by	 autoimmune-mediated	 mechanisms.	 T	 cells	 have	 been	
associated	 as	 central	 pro-inflammatory	 mediators	 in	 MS	 pathogenesis.	 In	 healthy	
individuals,	 immune	 cells	 adapt	metabolic	 programs	 like	mitochondrial	 respiration	 and	
glycolysis	based	on	their	function	and	inflammatory	phenotype.	However,	the	relevance	
of	 metabolic	 reprogramming	 and	 associated	 pro-inflammatory	 mechanisms	 in	 T	 cell	
subpopulations	 in	 MS	 disease	 is	 not	 well	 understood	 yet.	 To	 address	 this	 question,	
Relapsing	Remitting	MS	(RRMS)	patients	and	meticulously	matched	healthy	control	(HC)	
participants	were	recruited	as	part	of	the	clinical	study	Depression	and	Immune	Function	
in	MS	(n=62).	Blood	samples,	after	a	period	of	fasting,	were	collected	and	CD4+	and	CD8+	
T	 cells	 isolated	 from	 peripheral	 blood	mononuclear	 cells	 (PBMC).	 The	 results	 obtained	
demonstrated	decreased	mitochondrial	 and	glycolytic	 activity	 specific	 to	CD4+	T	 cells	 in	
the	MS	 patient	 cohort	 compared	 to	 the	HC	 participant	 cohort.	 Furthermore,	 increased	
CPT1a	 mitochondrial	 membrane	 protein	 levels	 were	 detected	 in	 CD4+	 T	 cell	
subpopulations	 in	 the	MS	patient	 cohort	 as	 assessed	 in	 comprehensive	 flow	 cytometry	
PBMC	phenotype	 investigations.	 The	 analysis	 of	 the	 CD4+	 CD25-	 CD127+	 conventional	 T	
cell	 subpopulation	moreover	 revealed	 a	 trend	 of	 decreased	 IL7-Rα	 expression	 levels	 in	
MS	patients.	Gene	expression	measurements	of	pro-inflammatory	and	metabolic	 genes	
did	not	 reveal	alterations	 in	MS	patients’	T	 cell	 subpopulations.	The	 results	obtained	 in	
this	study	allude	to	dysfunctions	in	metabolic	reprogramming	in	T	cell	subpopulations	in	
MS	patients	and	help	to	better	understand	the	contribution	of	immunometabolism	in	the	
pathogenesis	of	MS	disease.		
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Zusammenfassung	
Multiple	Sklerose	(MS)	ist	eine	chronische	neuro-degenerative	Erkrankung	des	zentralen	
Nervensystems,	 die	 durch	 auto-immun-bedingte	 Prozesse	 charakterisiert	 ist.	 T	 Zellen	
wurden	als	wesentliche	pro-inflammatorische	Mediatoren	mit	 der	Pathogenese	der	MS	
assoziiert.	 In	 gesunden	 Individuen	 passen	 Immunzellen	 ihren	 Metabolismus,	 wie	 die	
mitochondriale	 Atmung	 und	 Glykolyse,	 ihrer	 jeweiligen	 Funktion	 und	 ihrem	
inflammatorischen	 Phänotyp	 an.	 Im	 Krankheitsverlauf	 der	 MS	 ist	 die	 Bedeutung	 der	
metabolischen	 Anpassung	 und	 der	 damit	 verbundenen	 pro-inflammatorischen	
Mechanismen	 von	 T	 Zell-Subpopulationen	 noch	 nicht	 eindringlich	 erforscht.	 Um	 dieser	
Fragestellung	 nachzugehen	 wurden	 Relapsing	 Remitting	 MS	 (schubförmig,	 RRMS)	
Patienten	 und	 sorgfältig	 aufeinander	 abgestimmte	 gesunde	 Kontrollprobanden	 als	 Teil	
der	 Studie	Depression	 und	 Immunfuktion	 bei	 MS	 rekrutiert	 (n=62).	 Den	 Patienten	 und	
gesunden	 Kontrollprobanden	 wurde	 Nüchternblut	 entnommen,	 woraus	 periphäre	
mononukleäre	Blutzellen	(PBMC)	aufgearbeitet	wurden,	um	anschließend	CD4+	und	CD8+	
T	 Zellen	 zu	 isolieren.	 Die	 erzielten	 Ergebnisse	 zeigten	 CD4+	 T	 Zell-spezifische	
Verringerungen	 der	 mitochondrialen	 Atmung	 und	 glykolytischen	 Aktivität	 in	 der	 MS	
Patienten	 Kohorte	 im	 Vergleich	 zur	 Kohorte	 der	 gesunden	 Kontrollprobanden.	
Darüberhinaus	 wurden,	 zusätzlich	 zu	 den	 umfangreichen	 phänotypischen	
Charakterisierungen	 der	 PBMCs	 via	 Durchflußzytometrie,	 erhöhte	 Werte	 des	
mitochondrialen	 Membranproteins	 CPT1a	 in	 CD4+	 T	 Zell-Subpopulationen	 in	 der	 MS	
Patienten	Kohorte	detektiert.	Die	Analyse	der	CD4+	CD25-	CD127+	konventionellen	T	Zell-
Subpopulation	 ergab	 leicht	 erniedrigte	 Werte	 von	 IL7-Rα	 in	 MS	 Patienten.	
Genexpressionsanalysen,	 die	 mit	 pro-inflammatorischen	 und	 metabolischen	 Genen	
assoziiert	 sind,	 ergaben	 keine	 Veränderungen	 in	 den	 T	 Zell-Subpopulationen	 der	 MS	
Patienten.	 Die	 in	 dieser	 Studie	 erzielten	 Ergebnisse	weisen	 auf	 Funktionsstörungen	 bei	
der	metabolischen	Anpassung	in	T-Zell-Subpopulationen	bei	MS	Patienten	hin	und	helfen,	
den	Beitrag	des	Immunmetabolismus	bei	der	Pathogenese	der	MS	Erkrankung	besser	zu	
verstehen.
Table	of	Contents	
VI	
	
Table	of	Contents	
Abstract	________________________________________________________________	IV	
Zusammenfassung	________________________________________________________	V	
1	 INTRODUCTION	 _______________________________________________________	1	
1.1	 Multiple	Sclerosis	_____________________________________________________	1	
1.1.1	 Disease	Progression,	Symptoms	and	Risk	Factors	_________________________	1	
1.1.2	 Current	Treatment	_________________________________________________	5	
1.2	 Principals	of	the	Immune	System	________________________________________	5	
1.2.1	 The	Innate	Immune	System	__________________________________________	6	
1.2.1.1	 Natural	Killer	cells	______________________________________________	7	
1.2.1.2	 Monocytes	____________________________________________________	8	
1.2.2	 The	Adaptive	Immune	System	________________________________________	9	
1.2.2.1	 T	lymphocytes	–	development,	differentiation	and	activation	 ___________	9	
1.2.2.1.1	 CD4+	T	lymphocytes	 ________________________________________	11	
1.2.2.1.2	 CD8+	T	lymphocytes	 ________________________________________	14	
1.2.2.2	 B	lymphocytes	-	development,	differentiation	and	activation	___________	15	
1.3	 Immunometabolism	 _________________________________________________	18	
1.3.1	 Main	Cellular	Energy	Pathways	______________________________________	18	
1.3.1.1	 Fatty	Acid	β-oxidation	and	the	Mitochondrial	Membrane	Protein	CPT1a	__	21	
1.3.1.2	 Electron	Transport	Chain	and	Oxidative	Phosphorylation	______________	22	
1.3.1.3	 Glycolysis	and	the	Glucose	Transporter	GLUT1	 ______________________	24	
1.3.1.4	 Tri-citric	Acid	Cycle	 ____________________________________________	25	
1.3.1.5	 Pentose	Phosphate	Pathway	_____________________________________	26	
1.3.1.6	 Amino	Acid	and	Glutamine	Metabolism	____________________________	26	
1.3.2	 Regulation	of	Immune	Cells	by	Adapting	Energy	Metabolism	 ______________	26	
1.3.3	 HPA-axis	Stress	Response	Signaling	___________________________________	29	
1.3.4	 T	cell	Exhaustion	__________________________________________________	31	
1.4	 Multiple	Sclerosis	and	Immunometabolism	_______________________________	31	
1.5	 Aims	______________________________________________________________	34	
2	 MATERIALS	AND	METHODS	_____________________________________________	36	
2.1	 Clinical	Study	Depression	and	Immune	Function	(DENIM)	___________________	36	
2.1.1	 Background	and	Aim	of	the	Clinical	Study	DENIM	 _______________________	36	
2.1.2	 DENIM	Study	Organization	and	Set-up	________________________________	36	
2.1.2.1	 Study	Organization	 ____________________________________________	36	
2.1.2.2	 Study	Visit	Set-up	 _____________________________________________	37	
2.1.2.3	 Inclusion	and	Exclusion	Criteria	___________________________________	37	
2.1.2.4	 Telephone	Screening	for	Study	Eligibility	___________________________	38	
2.1.2.5	 Case	Report	Forms	–	Questionnaires,	Assessments,	Tests	______________	38	
2.1.2.6	 Biological	Material	Collected	_____________________________________	39	
2.1.3	 DENIM	Study	Recruitment	Period	and	Outcome	 ________________________	40	
Table	of	Contents	
VII	
	
2.1.3.1	 Recruitment	Period	____________________________________________	40	
2.1.3.2	 Sample	Analysis	_______________________________________________	40	
2.2	 Materials	 __________________________________________________________	41	
2.2.1	 Laboratory	Equipment	_____________________________________________	41	
2.2.2	 Glass	and	Plastic	Equipment	 ________________________________________	42	
2.2.3	 Reagents	and	Chemicals	 ___________________________________________	43	
2.2.4	 Cell	Culture	Media	________________________________________________	44	
2.2.5	 Materials	for	RNA	isolation	and	cDNA	Synthesis	_________________________	44	
2.2.6	 Materials	and	Reagents	for	qRT-PCR	Analyses	__________________________	44	
2.2.7	 Buffer	and	Stock	Solutions	for	Magnetically	Activated	Cell	Sorting	and		
												Flow	Cytometry	Analyses	___________________________________________	45	
2.2.8	 Magnetically	Activated	Cell	Sorting	and	Flow	Cytometry	Antibodies	_________	46	
2.2.9	 Software	used	for	analyses	 _________________________________________	48	
2.3	 Methods	___________________________________________________________	49	
2.3.1	 Cellular	Biology	___________________________________________________	49	
2.3.1.1	 Cryo-preservation	of	Peripheral	Blood	Mononuclear	Cells	(PBMC)	_______	49	
2.3.1.2	 Thawing	of	PBMCs	_____________________________________________	49	
2.3.1.3	 MACS	Positive	Selection	 ________________________________________	50	
2.3.1.4	 Cell	Culture	of	Sorted	PBMC	subtypes	 _____________________________	50	
2.3.2	 In	vitro	Metabolic	Analyses	using	the	Seahorse	XFe96	Analyzer	_____________	51	
2.3.2.1	 Establishing	the	Mitochondrial	Stress	Test	Analysis	Protocol	 ___________	51	
2.3.2.2	 Metabolic	Analyses	of	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	55	
2.3.2.3	 Evaluation	of	MS	Patient	and	HC	Participant	Samples	_________________	56	
2.3.3	 Flow	Cytometry	Analyses	___________________________________________	58	
2.3.3.1	 Intracellular	and	Extracellular	Staining	_____________________________	58	
2.3.3.2	 Titration	of	Antibodies	 _________________________________________	59	
2.3.3.3	 Gating	Strategy	 _______________________________________________	59	
2.3.4	 Gene	Expression	Analyses	__________________________________________	64	
2.3.4.1	 Preparation	and	Conservation	of	RNA	 _____________________________	64	
2.3.4.2	 RNA	Isolation	and	cDNA	Synthesis	 ________________________________	65	
2.3.4.3	 qRT-PCR	Analyses	 _____________________________________________	65	
2.3.5	 ELISA	Analyses	of	Salivary	Cortisol	Hormone	 ___________________________	66	
2.3.6	 Statistical	Analyses	________________________________________________	66	
3	 RESULTS	 ____________________________________________________________	67	
3.1	 MS	Patient	and	Healthy	Participant	Cohort	Characteristics	__________________	67	
3.2	 In	vitro	Analysis	of	Immune	Cell	Energy	Metabolism	using	the		
										Seahorse	XFe96	Analyzer	______________________________________________	71	
3.2.1	 Metabolic	Assay	Verification	________________________________________	71	
3.2.2	 Mitochondrial	Energy	Metabolism	Profile	of	Purified	CD4+	T	cells	___________	72	
3.2.3	 Mitochondrial	Energy	Metabolism	Profile	of	Purified	CD8+	T	cells	___________	73	
3.2.4	 Mitochondrial	Energy	Metabolism	Profile	of	non-CD4+/CD8+	T	cells	_________	74	
3.2.5	 Glycolytic	Activity	of	Purified	Immune	Cells	 ____________________________	76	
3.2.6	 Metabolic	Phenotype	of	Purified	Immune	Cells	_________________________	77	
Table	of	Contents	
VIII	
	
3.3	 Flow	Cytometry	Analyses	_____________________________________________	79	
3.3.1	 Phenotypic	Characterization	of	Immune	Cell	Subpopulations	______________	79	
3.3.2	 CPT1a	Expression	in	Immune	Cell	Subpopulations	_______________________	81	
3.3.3	 PD-1	Expression	in	Immune	Cell	Subpopulations	________________________	84	
3.3.4	 IL7-Rα	and	IL2-Rα	expression	in	conventional	T	cells	_____________________	85	
3.4	 mRNA	Gene	Expression	in	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	__	86	
3.4.1	 mRNA	Analysis	of	Pro-Inflammatory	and	Energy	Metabolism	Genes	TNF-a,	
NFκB1,	NFκB3,	GLUT1	and	CPT1a	__________________________________________	87	
3.4.2	 mRNA	Analysis	of	Glucocorticoid	Receptor	(GR)	and	Glucocorticoid-induced	
Leucine	Zipper	(GILZ)	 ___________________________________________________	88	
3.5	 Cortisol	Levels	in	Saliva	Samples	 _______________________________________	89	
3.6	 Clinical	Data	Correlation	Analyses	 ______________________________________	90	
4	 DISCUSSION	 _________________________________________________________	92	
4.1	 The	DENIM	Study	Provides	a	Robust	MS	Patient	and	HC	Participant	Cohort	______	92	
4.2	 Detection	of	Comparable	Phenotyping	Profiles	of	Major	T	cell	Subpopulations		
										in	MS	Patients	and	HC	Participants	______________________________________	93	
4.3	 Decreased	Immunometabolic	Potential	is	specific	to	CD4+	T	cells	from																										
										MS	Patients	 ________________________________________________________	96	
4.4	 CD4+	and	CD8+	T	cell	Subpopulations	from	MS	Patients	Express	Increased		
										Levels	of	the	Mitochondrial	Membrane	Protein	CPT1a	 _____________________	100	
4.5	 HPA	Axis	Activity	Corresponds	between	MS	Patients	and	HC	Participants		
										While	GR	and	GILZ	Gene	Expression	is	Altered	in	CD4+	and	CD8+	T	cells	________	106	
4.6	 B	cells	and	NK	cells	show	Modified	Phenotype	Profiles	and	CPT1a	Protein	
										Levels	in	MS	Patients	versus	HC	Participants	 _____________________________	108	
Limitations,	Strengths,	Outlook	____________________________________________	112	
List	of	Abbreviations	 ____________________________________________________	114	
References	 ____________________________________________________________	117	
Figure	Index	 ___________________________________________________________	133	
Table	Index	____________________________________________________________	135	
Supplements	___________________________________________________________	136	
Appendix	______________________________________________________________	137	
										Flow	Cytometry	Analyses	____________________________________________	137	
										DENIM	Study	Flyer	 _________________________________________________	140	
										DENIM	Study	Case	Report	Form	_______________________________________	142	
Acknowledgements	_____________________________________________________	198	
Peer-reviewed	Publications	_______________________________________________	199	
Eigenständigkeitserklärung		 ______________________________________________	200	
Introduction	
1	
	
1 Introduction	
1.1 Multiple	Sclerosis	
Multiple	 Sclerosis	 (MS)	 is	 a	 chronic	 neurodegenerative	 disease	 of	 the	 central	 nervous	
system	 (CNS)	 characterized	by	 the	demyelination	of	neurons	believed	 to	be	 induced	by	
autoimmune	mechanisms.	Worldwide,	 approximately	 2.5	million	 people	 are	 diagnosed	
with	MS	and	about	200	000	people	in	Germany.	
Disease	 influencing	 factors	 include	environmental	and	genetic	 components	 leading	 to	a	
broad	 and	 heterogeneous	 clinical	 presentation.	 To	 date,	 magnetic	 resonance	 imaging	
(MRI)	 as	 well	 as	 cerebral	 spinal	 fluid	 (CSF)	 analyses	 provide	 the	 basis	 for	 the	 clinical	
diagnosis,	characterization	and	progression	of	MS	and	contribute	to	the	understanding	of	
the	disease.	
1.1.1 Disease	Progression,	Symptoms	and	Risk	Factors		
MS	is	characterized	by	a	chronic	state	of	neuroinflammation	of	the	CNS,	which	progresses	
over	 time.	 The	average	age	of	disease	onset	 is	 30	 years	 and	due	 to	 increasing	physical	
impairments,	 considering	 current	 treatment,	 approximately	 50%	 of	 patients	 require	 a	
wheelchair	25	years	after	diagnosis	 [1].	The	course	of	disease	and	disability	progression	
depends	on	the	kind	of	MS.	
Disease	development	can	generally	be	characterized	by	three	stages:	1)	a	pre-clinical,	2)	a	
relapsing-remitting	MS	(RRMS)	and	3)	a	progressive	stage.		Figure	1	shows	the	course	of	
disease	 with	 an	 overall	 increasing	 disease	 burden	 including	 clinical	 disability	 and	 MRI	
activity	 as	well	 as	 decreasing	brain	 volume	over	 time.	 The	pre-clinical	 stage	oftentimes	
goes	unrecognized	unless	MRI	scans	 incidentally	discover	typical	neuronal	 inflammatory	
regions,	defined	as	brain	lesions.	This	stage	of	MS	is	mostly	asymptomatic	and	defined	as	
the	radiologically	isolated	syndrome	(RIS).	Following	the	RIS,	usually	the	clinically	isolated	
syndrome	(CIS)	manifests	itself	and	is	followed	by	the	RRMS	stage.	Now,	in	CIS	and	RRMS,	
patients	 show	 distinct	 clinical	 symptoms,	 most	 prominently	 optical	 neuritis,	 sensory	
deficits	 and	motor	 dysfunctions.	 As	 relapses	 increase	 over	 time,	 symptoms	 accumulate	
and	 disability	 worsens.	 In	 the	 RRMS	 stage,	 relapses	 with	 neurological	 dysfunction	 and	
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neuronal	 inflammation	 are	 redeemed	 by	 phases	 of	 remission	 during	 which	 symptoms	
decline	 or,	 especially	 in	 the	 early	 phases,	 subside	 to	 a	 great	 extent.	 However,	 with	
accumulating	 relapses,	 the	 disease	 burden	 increases,	 brain	 volume	 decreases	 and	
patients	 enter	 the	 third	 clinical	 stage,	 progressive	 MS.	 At	 this	 stage,	 neurological	
dysfunction	 progressively	 worsens	 without	 phases	 of	 remission	 occurring.	 Clinical	
manifestation	 of	 progressive	 MS	 following	 RRMS	 is	 termed	 secondary	 progressive	 MS	
(SPMS).	If	the	disease	onset	is	progressive	from	onset	on,	however,	it	follows	the	course	
of	primary	progressive	MS	(PPMS)	(Figure	1).		
	
Figure	1:	Stages	and	disease	progression	in	Multiple	Sclerosis.	The	course	of	MS	shows	an	overall	
increase	of	disease	burden	accompanied	by	an	 increased	clinical	disability	and	decreasing	brain	
volume	over	time.	The	pre-clinical	stage	includes	the	radiological	isolated	syndrome	(RIS),	which	is	
often	asymptomatic	and	incidentally	discovered	on	MRI	scans.	RIS	develops	into	the	clinical	stage,	
clinically	isolated	syndrome	(CIS).	CIS	is	followed	by	a	relapsing	remitting	course	of	disease	(RRMS)	
during	 which	 symptoms	 with	 periods	 of	 relapses	 and	 neurological	 dysfunction	 as	 well	 as	 pro-
inflammation	 manifest	 and	 get	 replaced	 by	 periods	 of	 remission.	 	 The	 final	 clinical	 stage	 is	
secondary	 progressive	 MS	 (SPMS),	 which	 evolves	 from	 RRMS	 and	 lacks	 remission	 phases.	 If	
disease	onset	progresses	from	the	beginning,	 it	 is	termed	primary	progressive	MS	(PPMS).	Brain	
volume	and	atrophy	is	measured	by	Magnetic	Resonance	Imaging	(MRI)	scans	as	a	biomarker	for	
MS	providing	information	about	newly	occurring,	active	and	persistent	brain	lesions	and	with	that	
disease	progression	over	time.	(tailored	based	on	[2])	
To	date,	MRI	scans	of	the	CNS	are	the	most	common	biomarker	 for	MS	disease	activity	
[2].	 Using	 MRI	 scans,	 active,	 newly	 occurring	 and	 persistent	 lesions	 can	 be	 detected,	
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visualized	 and	 observed	 over	 time	 allowing	 the	 measurement	 of	 disease	 burden	 and	
progression.	CNS	lesions	and	inflammation	are	a	hallmark	of	MS	and	are	accompanied	by	
a	blood	brain	barrier	(BBB)	leakage	allowing	the	scarcely	restricted	infiltration	of	immune	
cells	 from	 the	 peripheral	 blood	 stream	 [1].	 	 One	 of	 the	 first	 cell	 populations	 found	 in	
lesions	 inside	 the	 CNS	 include	 lymphocytes	 [3].	 Therefore,	 MS	 is	 presumed	 to	 be	 of	
autoimmune	etiology	initiated	by	over-	and	auto-reactive	T	lymphocytes	finally	targeting	
myelin	 sheaths	 of	 neurons.	 This	 process	 of	 BBB	 leakage	 and	 CNS	 infiltration	 has	 been	
described	especially	in	RRMS	patients	and	leads	to	the	diverse	clinical	symptoms.	
The	main	symptoms	patients	present	with	include	muscle	weakness,	fatigue,	impairments	
in	motor	function	and	coordination,	cognitive	impairments	and	major	depressive	disorder	
(MDD).	MDD	is	the	most	prevalent	psychiatric	comorbidity	in	MS	patients	with	a	lifetime	
prevalence	 of	 developing	 depression	 of	 up	 to	 50%	 [4].	 Studies	 have	 shown	 strong	
associations	 between	 an	 increased	 inflammatory	 profile	 in	MS	 patients	 with	 increased	
fatigue	 and	 depression	 scores	 further	 contributing	 to	 the	 inflammatory	 processes	
observed	in	MS	patients	[5]–[7].	Importantly,	symptoms	can	be	very	diverse	and	depend	
on	the	degree	of	disability	and	overall	disease	burden	of	a	patient.	
Causes	 for	 the	 onset	 of	 MS	 are	 multifaceted	 and	 include	 genetic	 and	 environmental	
factors,	sex	differences	and	hormone	regulation	(comprehensively	reviewed	in	[8]).			
While	the	kind	of	MS	and	disease	severity	do	not	show	a	genetic	component,	with	first-
degree	relatives	having	a	2-5%	higher	risk	for	developing	MS,	disease	susceptibility	seems	
to	 relate	 to	genetic	effects.	Numerous	studies	showed	that	most	genes	associated	with	
MS	 seem	 to	 relate	 to	 either	 the	 innate	 or	 adaptive	 immune	 system.	 One	 of	 the	most	
dominant	risk	factors	is	the	HLA-DRB1*15:01	allele	in	the	class	II	major	histocompatibility	
complex	(MHC)	gene	[9].	Examples	for	non-MHC	associated	MS-susceptibility	loci	are	the	
interleukin-7	receptor	α	(IL7-Rα	or	CD127)	and	 interleukin-2	receptor	α	(IL2-Rα	or	CD25)	
genes.	Genome	wide	association	studies	(GWAS)	detected	small	nuclear	polymorphisms	
(SNP)	in	the	IL7Rα	gene	in	MS	patients,	where	the	SNP	most	likely	induces	an	increased	
abundance	of	soluble	IL7-Rα	protein	[10].	The	IL7-Rα	 is	essential	 in	T	and	B	lymphocyte	
maturation,	 development	 and	 homeostasis	 and	 downstream	 activation	 of	 the	 janus	
kinase	 (JAK)	 and	 signal	 transducer	 activators	 of	 transcription	 (STAT)	 pathways-	 both	
involved	in	gene	transcriptions	following	immune	responses	and	in	direct	interaction	with	
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the	nuclear	factor	 'kappa-light-chain-enhancer'	of	activated	B-cells	(NFκB)	pathway	[11].	
The	 IL2-Rα	 is	 upregulated	 on	 activated	 T	 cells	 and	 therefore	 essential	 in	 cellular	
proliferation,	 survival	 and	 T	 cell	 homeostasis	 [12],[13].	 Taken	 together,	 genetic	 risk	
factors	 for	 MS	 hint	 toward	 strong	 associations	 with	 immune	 regulation,	 however,	 no	
single	genes	have	been	defined	to	be	involved	in	causing	MS.	
Another	contributor	 to	MS	development	and	progression	are	environmental	 influences.	
One	of	 the	most	widely	discussed	environmental	 factor	 in	MS	disease	 is	 the	protective	
effect	of	ultra	violet	(UV)	radiation	exposure.	Especially	early	in	life	before	the	age	of	20,	
elevated	 UV	 radiation	 exposure	 and	 with	 that	 increased	 vitamin	 D	 levels	 have	 been	
shown	 to	 reduce	 MS-risk	 later	 in	 life	 [14].	 Vitamin	 D	 signaling	 greatly	 affects	 anti-
inflammatory	immune	cell	pathways	via	T	and	B	lymphocyte	suppression	and	regulatory	T	
cell	 (T	 regs)	 induction,	with	 that	promoting	protective	 immune	 tolerogenic	effects	 [15].	
Vitamin	D	 levels	have	also	been	shown	to	have	protective	effects	 in	other	autoimmune	
diseases	like	type	1	diabetes	(T1D),	systemic	lupus	erythematosus	(SLE)	and	rheumatoid	
arthritis	(RA)	[16],	indicating	it	being	an	essential	influence	in	immunity.				
The	effects	of	 sex	differences	and	hormones	have	also	been	 studied	extensively	 in	MS.	
The	2.5:1	ratio	of	females:males	affected	by	MS	is	striking.	This	ratio	has	been	explained	
with	parent	of	origin	effects	where,	 for	example	disease	associations	 like	 the	 risk	allele	
HLA-DRB1*15:01	 show	a	 stronger	 association	with	 females	 [17].	 Additionally,	 X-	 and	 Y-
chromosome-linked	 genes	 have	 been	 shown	 to	 contribute	 to	 gene-dosage	 effects	 and	
immune	 regulation	 of	 innate	 and	 adaptive	 immune	 responses	 [18].	 Furthermore,	
hormone	 regulation	 greatly	 affects	 cells	 of	 the	 innate	 and	 adaptive	 immune	 system	
displaying	 distinct	 differences	 and	 adaptations	 in	 females	 and	 males	 (particularly	
estrogen	and	testosterone,	 respectively).	This	effect	 is	most	prominent,	considering	 the	
strong	protective	effect	of	pregnancy	from	relapses	[19].		
Taken	 together,	 genetics,	 environmental	 influences,	 sex	 and	 hormones	 allow	 a	 deeper	
understanding	 of	 MS	 disease	 and	 help	 to	 better	 comprehend	 the	 underlying	 causes	
leading	to	the	complex	pathogenesis.				
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1.1.2 Current	Treatment	
Treatment	 for	 MS	 includes	 medications	 to	 treat	 occurring	 symptoms	 as	 well	 as	 basic	
immune-modulatory	medication.	Symptom	management	aims	to	 increase	the	quality	of	
life	and	reduce	MS	symptoms.	Especially	during	relapses,	patients	oftentimes	are	treated	
with	cortisone	to	manage	peripheral	and	CNS	inflammation.		
Current	 immune-modulatory	 medications	 to	 treat	 RRMS	 are	 targeted	 at	 innate	 and	
adaptive	immune	cells.	They	suppress	pro-inflammatory	signaling	and	have	become	more	
advanced	in	the	last	decade	with	to	date	more	than	ten	drugs	approved	by	the	American	
Food	 and	 Drug	 Administration	 (FDA).	 Baecher-Allan	 and	 colleagues	 most	 recently	
published	an	extensive	review	summarizing	current	drugs,	 their	specific	 targets	and	the	
mechanisms	 of	 action	 [2].	 	 In	 summary,	 the	modes	 of	 action	 include	 the	 trapping	 of	 T	
lymphocytes	inside	the	lymph	nodes	and	with	that	prevention	of	T	lymphocyte	migration	
via	the	BBB	into	the	CNS,	the	promotion	of	T	regs	and	decrease	of	MS-disease	 inducing	
Th1/Th17	 cells	 as	 well	 as	 the	 inhibition	 and	 depletion	 of	 B	 lymphocytes.	 Considering	
efficacy,	 side	 effects,	 relapse	 history	 and	 CNS	 lesions,	 the	 clinician	 and	 patient	 decide	
which	drugs	to	use.	The	efficacy	of	the	drug	is	measured	by	the	reduction	in	relapses	and	
a	 decrease	 of	 inflammation.	Using	MRI	 scans,	 disease	 progression	 and	brain	 atrophy	 is	
determined	[20].			
Almost	 all	 of	 the	 FDA	 approved	 drugs	 target	 the	 relapsing	 inflammatory	 stage	 and	 are	
largely	not	effective	 in	 the	progressive	 forms	of	MS.	Furthermore,	 to	date,	medications	
are	effective	in	limiting	relapses,	but	do	not	fully	prevent	disease	progression.	
Broadening	 the	 understanding	 of	 the	molecular	mechanisms	 of	 immune	 activity	 in	MS	
may	allow	a	deeper	understanding	of	causative	mechanisms	underlying	the	disease.		
1.2 Principals	of	the	Immune	System	
The	 human	 immune	 system	 is	 composed	 of	 an	 enormous	multitude	 of	mechanisms	 all	
prepared	to	target	threats	to	the	body	and	fight	infections.	It	entails	molecular	structures,	
cells,	tissues	and	organs	whose	main	function	is	the	elimination	of	pathogenic	agents	as	
well	as	aged	or	cancerous	body	cells.		
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The	 immune	response	requires	the	regulation	and	 interaction	with	other	body	systems,	
like	 the	 central	 nervous	 system	 and	 (neuro-)	 endocrine	mechanisms	 as	 well	 as	 energy	
demand	 and	 response	 signaling	 pathways.	 It	 is	 classified	 into	 innate	 and	 adaptive	
immunity,	 which	 constantly	 interact	 to	 initiate	 effective	 defense	mechanisms	 involving	
humoral	(non-cellular)	and	cellular	structures.	The	cellular	components	of	the	blood	arise	
from	 pluripotent	 hematopoetic	 stem	 cells	 (HSC)	 in	 the	 bone	marrow	 that	 possess	 the	
ability	 to	 develop	 into	 common	 lymphoid	 progenitor	 cells	 (T	 and	 B	 lymphocytes	 and	
natural	 killer	 cells)	 as	 well	 as	 common	 myeloid	 progenitor	 cells	 (monocytes,	 dendritic	
cells,	granulocytes).	Peripheral	blood	mononuclear	cells	(PBMCs)	are	composed	of	about	
25-60%	CD4+	T	lymphocytes,	5-30%	CD8+	lymphocytes,	5-10%	B	lymphocytes,	10-30%	NK	
cells,	 5-10%	 monocytes	 and	 1-2%	 dendritic	 cell	 [21].	 The	 various	 cell	 types	 and	 their	
functions	within	innate	and	adaptive	immunity	are	subsequently	discussed	in	detail.	
1.2.1 The	Innate	Immune	System	
Innate	immune	response	mechanisms	are	coded	in	the	germline	and	compromise	the	first	
line	 of	 defense	 against	 pathogens	 like	 bacteria,	 viruses,	 worms	 or	 fungi.	 Examples	 for	
innate	 immune	 cells	 are	 neutrophils,	 basophils,	 eosinophils	 (all	 granulocytes),	 natural	
killer	 (NK)	 cells	 and	monocytes.	 They	 circulate	within	 the	 peripheral	 blood	 stream	 and	
constantly	 monitor	 for	 invading	 pathogens.	 Humoral	 components	 include	 the	
complement	 system,	 cytokines,	 chemokines	 and	 pattern	 recognition	 receptors	 (PRRs).	
Cytokines	 are	 small	 proteins	 involved	 in	 cell-specific	 signaling	 and	 communication.	 A	
subtype	of	cytokines	are	chemokines,	which	possess	the	ability	to	recruit	cells	to	the	site	
of	 inflammation.	 Both,	 cytokines	 and	 chemokines	 can	 be	 secreted	 by	 cells	 and	 bind	 to	
their	specific	cytokine	and	chemokine	cell	surface	receptors.	PRRs	can	also	be	membrane	
bound	or	soluble,	recognizing	conserved	pathogen	associated	molecular	patters	(PAMPs).	
Examples	for	highly	conserved	PRRs	are	toll	like	receptors	(TLRs).	To	date,	more	than	13	
TLRs	 have	 been	 identified	 [22],	 each	 able	 to	 recognize	 one	 or	 multiple	 ligands,	 e.g.	
microbial	motifs	and	debris	from	necrotic	cells.		
The	 recognition	 of	 PAMPs	 induces	 an	 immediate	 immune	 response.	 The	 release	 of	
cytotoxic	molecules	by	innate	immune	cells	induces	the	killing	of	extracellular	pathogens	
or	apoptosis	(programmed	cell	death)	of	infected	cells.	Chemokines	and	cytokines	recruit	
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additional	 immune	 cells	 causing	 further	 pro-inflammatory	 responses	 and	 pathogen	
clearance.		
Additionally,	 most	 innate	 immune	 cells	 function	 as	 antigen	 presenting	 cells	 (APCs).	
Following	the	recognition	by	their	TLR,	APCs	can	present	processed	antigen	via	their	MHC	
class	 II	 for	 antigen	 recognition	 by	 T	 lymphocytes	 of	 the	 adaptive	 immune	 system.	
Furthermore,	MHC-II	presentation	can	also	occur	after	phagocytosis,	 the	engulfment	of	
cells	or	particles,	of	pathogens	or	 infected	cells.	 The	 interaction	of	 innate	and	adaptive	
immune	 cells	 and	 their	 humoral	 components	 is	 a	 central	 element	of	 immune	 response	
mechanisms.		
Phagocytosis	and	antigen	processing	as	well	as	the	release	of	cytotoxic	molecules	are	two	
central	elements	in	innate	immunity.	NK	cells	and	monocytes	are	two	cell	subpopulations	
involved	in	these	processes	and	are	subsequently	described	in	more	detail.	
1.2.1.1 Natural	Killer	cells	
NK	cells	are	granular	lymphocytes	of	the	innate	immune	system	essential	in	anti-bacterial	
and	 anti-viral	 immune	 responses	 [23].	 They	 predominantly	 detect	 cells	 that	 lack	 MHC	
class	I	expression	and	with	that	the	identification	of	a	cell	as	self.	The	main	functions	of	
NK	 cells	 include	 the	 secretion	of	 immune	 activating	 cytokines	 and	 chemokines	 and	 the	
killing	of	infected	or	transformed	cells	via	pathways	including	perforin/granzyme	or	death	
receptor-related	 pathways	 [24]–[26].	 They	 express	 TLRs	 involved	 in	 the	 recognition	 of	
bacterial	and	viral	PAMPs	(e.g.	TLR2,	TLR5,	TLR7/8,	TLR9)	[22]	and	also	play	a	central	role	
in	tumor	immunity	[25]	and	human	pregnancy	[27].	
The	activation	of	NK	cells	by	TLR	ligands	is	accompanied	by	the	production	of	interferon	γ	
(INFγ)	 and	 granulocyte-monocyte	 colony	 stimulating	 factor	 (GM-CSF)	 and	 requires	 the	
presence	of	assessor	cytokines	 like	 IL-2	and	 IL-12,	 IL-2	and	 IL-18	or	 IL-15	and	 IL-18	[28].	
Consequently,	 NK	 cell	 activation	 is	 coupled	 to	 assessor	 processes	 safeguarding	 over-
reactivity.	
Based	on	 their	 function,	cytokine	secretion	profile	and	cell	 surface	 receptor	expression,	
NK	 cells	 are	 subdivided	 into	 regulatory	 and	 cytotoxic	 subtypes.	 Regulatory	NK	 cells	 are	
characterized	as	CD56+	CD16-/low	and	are	mainly	found	in	lymph	nodes,	lacking	cytotoxic	
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potential.	Cytotoxic	NK	cells	are	defined	as	CD56+	CD16+/high,	are	more	differentiated	and	
have	the	potential	to	mediate	cytotoxicity	[29].		
INFγ	 is	 the	 signature	 cytokine	 of	 CD56bright	 NK	 cells	 and	 known	 to	 shape	 Th1-mediated	
adaptive	 immunity	 [26]	as	well	as	 to	 induce	macrophages	 to	kill	 intracellular	pathogens	
and	activate	APCs	to	up-regulate	MHC	class	I	molecules	[30].	Additionally,	INFγ	secretion	
by	NK	cells	has	anti-proliferative	effects	on	cells	that	have	been	transformed	due	to	viral	
infection	or	malignancies	[31].		
Taken	together,	NK	cells	play	an	 important	role	 in	 innate	 immune	response	and	cellular	
activation	as	well	as	in	the	induction	of	adaptive	immune	mechanisms.		
1.2.1.2 Monocytes		
Monocytes	 are	 central	APCs	of	 the	 innate	 immune	 system.	 	 They	 get	 released	 into	 the	
periphery	where	three	monocyte	subpopulations	have	been	characterized	based	on	their	
cell	 surface	 receptor	 expression:	 classical	 monocytes	 (CD14++	 CD16-),	 intermediate	
monocytes	 (CD14++	 CD16+)	 and	 non-classical	 monocytes	 (CD14+	 CD16++)	 [32].	 After	
circulating	 in	 the	 blood,	 they	 reach	 tissue	where	 they	 differentiate	 and	 further	mature	
into	tissue	resident	dendritic	cells	(DC)	or	macrophages.		
The	main	functions	of	monocytes	include	pro-inflammatory	cytokine	production	following	
the	 recognition	 and	 phagocytosis	 of	 pathogens	 and	 the	 antigen	 presentation	 via	MHC	
class	I	and	II	molecules.	The	signature	cytokines	released	include	TNFα,	IL-1	and	IL-6	[33].		
Monocytes	express	numerous	TLRs	(e.g.	TLR2,	TLR9)	for	antigen	recognition	[34],[35]	and	
phagocytosis.	The	latter	takes	place	by	direct	binding	to	pathogens	via	PAMP	recognition	
or	by	detection	of	antibody-	or	complement-coated	pathogens	(opsonization).	Unlike	NK	
cells,	monocytes	do	not	require	the	presence	of	assessor	cytokines	for	their	activation.		
Once	 they	are	activated,	 they	 release	pro-inflammatory	 cytokines	and	with	 that	 induce	
the	transmigration	of	other	innate	and	adaptive	immune	cells	to	the	site	of	inflammation.	
Depending	on	the	intruding	pathogen,	monocytes	have	been	shown	to	be	able	to	induce	
helper	 T	 cell	mediated	 immune	 responses	 and	with	 that	 the	 activation	of	 the	 adaptive	
immune	system	[33].	Moreover,	monocytes	have	been	shown	to	act	as	suppressor	cells	
inducing	Treg	development	and	inhibiting	T	lymphocyte	proliferation	[36].	
Introduction	
9	
	
Taken	 together,	 monocytes	 display	 an	 essential	 role	 in	 rapid	 innate	 immune	 response	
mechanisms	 and	 are	 key	 components	 in	 adaptive	 immune	 cell	 activation,	 proliferation	
and	suppression.		
1.2.2 The	Adaptive	Immune	System	 	
The	 adaptive	 immune	 system	 compromises	 defense	 mechanisms	 that	 are	 acquired,	
develop	from	the	time	of	birth	and	evolve	over	the	course	of	a	lifetime.	As	described	for	
innate	 immune	 responses,	 adaptive	 immunity	 also	 entails	 cellular	 and	 humoral	
components.	However,	contrary	to	innate	immunity,	adaptive	immunity	is	highly	antigen-
specific.	Main	cell	 types	constituting	adaptive	 immunity	 include	T	and	B	 lymphocytes.	T	
lymphocyte	subpopulations	include	helper	and	cytotoxic	T	lymphocytes	with	specific	cell	
surface	 receptor	 expression	 and	 antigen-specific	 functions.	 B	 lymphocytes	 produce	
antigen-specific	 antibodies,	 which	 are	 part	 of	 the	 humoral	 structures	 in	 adaptive	
immunity.	Furthermore,	both,	T	and	B	lymphocytes,	possess	the	ability	to	form	memory	
cells	 after	 antigen	 clearance,	 a	 crucial	 process	 that	 allows	 an	 immediate	 immune	
response	during	a	secondary	infection	with	the	same	antigen.		
The	ability	of	specialized	cell	subpopulations	to	respond	to	specific	antigens	and	generate	
immune	 memory	 are	 key	 characteristics	 of	 adaptive	 immunity	 and	 are	 subsequently	
described	in	more	detail.	
1.2.2.1 T	lymphocytes	–	development,	differentiation	and	activation	
T	lymphocytes	originate	from	stem	cells	in	the	bone	marrow.	Once	released,	they	travel	
to	 the	 thymus	 (thymocytes)	 and	mature	 into	 functional	 CD4+	 and	 CD8+	 T	 lymphocytes	
(subsequently	 termed	 CD4+	 and	 CD8+	 T	 cells).	 In	 the	 process	 of	 thymic	 maturation,	 a	
broad	repertoire	of	antigen-specific	T	cell	receptors	(TCR)	is	established.		
Most	TCRs	entail	an	α-	and	a	β-chain	(>85%	of	T	cells)	and	only	the	remaining	fraction	is	
made	up	of	γ:δ-TCRs.	The	TCR	protein	structure	comprises	a	constant	unmodified	region	
and	a	variable	 region.	The	variable	 region	 is	 the	site	of	antigen-recognition	and	specific	
for	each	T	cell.	During	T	cell	development,	the	α	and	β	genes	of	the	variable	region	of	the	
TCR	 undergo	 somatic	 recombination	 of	 the	 variable-joining	 (V-J,	α-chain)	 and	 variable-
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diversity-joining	 (V-D-J,	 β-chain)	 gene	 segments.	 This	 process	 allows	 the	 tremendous	
diversity	 of	 the	 TCR	 antigen-recognition	 repertoire,	 which	 is	 estimated	 with	
approximately	1011	specificities	[37].		
The	TCR	is	part	of	a	group	of	a	membrane-bound	CD3-protein	complex,	whose	interaction	
is	required	during	antigen	recognition.	The	CD3-complex	is	made	up	of	a	γ	and	δ	chain	as	
well	as	two	ε	and	two	ζ	chains.	Additionally,	T	cell	co-receptors	are	required	for	antigen-
recognition	and	T	cell	activation,	including	CD40L	(CD154),	CD28	and	CD4	(on	CD4+	T	cell	
subpopulations)	or	CD8	(on	CD8+	T	cell	subpopulations)	[38].	
During	thymic	maturation,	thymocytes	are	selected	based	on	their	ability	to	recognize	self	
and	 foreign	 antigen	 via	 their	 TCR.	 Briefly,	 during	 the	 first	major	 stage	 of	 thymic	 T	 cell	
differentiation,	 double-negative	 CD4-	 CD8-	 T	 cells	 undergo	 TCR	 rearrangement.	 This	
allows	 them	 to	 progress	 to	 the	 second	 major	 stage	 of	 differentiation	 where	 they	 are	
termed	double-positive	T	cells	expressing	both	CD4	and	CD8	co-receptors.	At	this	point,	
APCs	 present	 a	multitude	 of	 antigens	 and	 self-peptides	 via	MHC	 classes	 I	 and	 II	 to	 the	
premature	T	cells.	Now,	positive	and	negative	selection	occurs	during	which	highly	self-
reactive	T	cells	(binding	to	self-antigens	on	the	MHCs)	and	T	cells	that	do	not	bind	MHC	
are	 eliminated.	 T	 cells	 that	 are	weakly	 reacting	 to	 self-peptides	 receive	 survival	 signals	
allowing	them	to	mature	into	the	third	stage	of	differentiation.	During	this	stage,	either	
the	CD4	or	CD8	receptor	is	down-regulated	yielding	single-positive	(SP)	naïve	CD4+	CD8-	T	
cells	and	SP	naïve	CD4-	CD8+	T	cells.	They	emigrate	from	the	thymus	into	the	blood	stream	
as	well	as	secondary	lymphoid	organs	(like	the	spleen,	Peyer’s	patches	in	the	gut,	mucosal	
tissue,	 tonsils	 or	 adenoids).	 Their	 main	 function	 is	 immune	 surveillance.	 Once	 they	
encounter	their	specific	antigen,	they	mature	into	functional	helper	or	effector	T	cells.		
T	 cell	 activation	 requires	 the	 binding	 of	 the	 antigen-specific	 TCR-complex	 to	 the	MHC-
antigen	complex	on	the	cell	surface	of	APCs.	 	The	MHC-complex	 is	composed	of	the	co-
stimulatory	 receptors	 CD80	 or	 CD86	 (binding	 to	 CD28	 on	 the	 TCR)	 as	 well	 as	 CD40	
(binding	 to	 CD40	 L	 on	 the	 TCR).	 CD4+	 T	 cells	 recognize	 antigens	 from	 pathogens	 like	
extracellular	bacteria,	worms	or	toxins	that	have	been	processed	by	APCs	and	presented	
on	 their	 MHC	 class	 II.	 In	 contrast,	 CD8+	 T	 cells	 recognize	 antigens	 from	 intracellular	
bacteria,	 viruses	 and	 endogenous	 molecules	 like	 tumor	 proteins	 that	 have	 been	
processed	by	APCs	and	presented	on	their	MHC	class	I.		
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Taken	together,	the	activation	of	T	cells	requires	the	binding	of	the	TCR-complex	to	the	
MHC-antigen	complex	including	all	co-receptors.		T	cell	activation	induces	a	cytokine	and	
chemokine	 environment	 (also	 involving	 other	 immune	 cells),	 which	 results	 in	 the	
differentiation	into	specific	CD4+	helper	T	cell	subsets	and	CD8+	effector	T	cells	as	well	as	
the	recruitment	of	other	immune	cells	to	the	site	of	inflammation.	
Following	an	antigen	encounter,	memory	T	cells	are	formed.	They	possess	the	ability	to	
undergo	 clonal	 expansion,	 proliferation	 as	 well	 as	 activation	 of	 other	 immune	 cells	
inducing	a	fast	immune	response	to	a	previously	intruding	antigen.	Three	memory	T	cell	
subsets	are	classified	based	on	their	function	and	expression	of	surface	receptors:	central	
memory	T	cells	(TCM),	effector	memory	T	cells	(TEM)	and	terminally	differentiated	effector	
memory	cells	re-	expressing	CD45RA	(TEMRA)	(summarized	in	Table	1).	Upon	activation	and	
differentiation	 to	 memory	 T	 cells,	 CCR7+	 naïve	 T	 cells	 (TN)	 down-regulate	 the	 CD45RA	
isoform	 and	 express	 the	 CD45RO	 isoform.	 TCM	 are	 CCR7+,	 have	 high	 proliferative	
capacities	and	lower	effector	functions.	TEM	are	CCR7-,	resident	in	peripheral	tissues	and	
possess	 the	ability	 to	quickly	 adapt	 a	CD4+	effector	or	CD8+	 cytotoxic	 T	 cell	 phenotype.	
The	 third	 memory	 subtype	 are	 TEMRA,	 which	 are	 CCR7-,	 show	 low	 proliferative	 and	
functional	capacities	and	characteristics	of	senescent	cells	[39].		
	
Taken	 together,	 CD4+	 and	 CD8+	 memory	 T	 cell	 subpopulations	 monitor	 and	 patrol	 the	
body	for	 intruding	pathogens	in	tissues	and	the	periphery.	They	are	highly	effective	and	
time-efficient	during	a	secondary	immune	response	to	a	previously	targeted	pathogen	in	
the	 primary	 immune	 response.	 This	 is	 the	 essence	 of	 adaptive	 immunity	 allowing	
pathogen-specific	immune	responses.		
1.2.2.1.1 CD4+	T	lymphocytes		
Upon	 activation,	 CD4+	 TN	 differentiate	 into	 effector	 T	 cells	 including	 helper	 T	 cell	 (Th)	
types	Th1,	 Th2,	 Th17	and	Th1/17.	Helper	T	 cells	mediate	 cellular	 and	humoral	 immune	
responses	 specific	 to	 the	 intruding	 pathogen.	 They	 are	 characterized	 based	 on	 their	
chemokine	receptor	and	cytokine	profile	as	well	as	individual	transcription	factors	(Table	
1	 provides	 a	 summary).	 An	 additional	 CD4+	 T	 cell	 subpopulation	 are	 regulatory	 T	 cells	
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(Treg),	which	complement	immune	activation	and	are	essential	for	immune	homeostasis	
and	self-tolerance.		
Th1	cells	produce	IFNγ	and	are	activated	and	induced	by	interleukin	(IL)-12	as	well	as	the	
transcription	 factors	T-bet,	 STAT1	and	STAT4	 [40].	 Th1	 cells	 are	 characterized	based	on	
the	 chemokine	 receptors	 CXC-chemokine	 receptor	 (CXCR)	 3	 and	 chemokine	 receptor	
(CCR)	 5	 [41].	 A	 Th1-mediated	 immune	 response	 leads	 to	 the	 targeted	 reaction	 to	
intracellular	bacteria	and	the	activation	of	infected	macrophages	within	the	inflammatory	
micro-environment.		
Th2	cell	development	is	promoted	by	IL-4	as	well	as	the	transcription	factors	STAT-6	and	
GATA-3	[42].	Characteristic	transcription	factors	are	CCR4	and	Chemoattractant	receptor-
homologous	molecule	 expressed	 on	 Th2	 cells	 (CRTh2)	 [43].	 They	 secrete	 IL-4,	 IL-5,	 IL-9	
and	 IL-13	and	stimulate	histamine-	and	heparin-secreting	mast	 cells	 contributing	 to	 the	
elimination	 of	 extracellular	 pathogens	 like	 bacteria	 or	 worms.	 Furthermore,	 Th2	 cell	
stimulation	 leads	 to	 the	 activation	 of	 B	 lymphocytes	 inducing	 antigen-specific	 antibody	
production.	
Th17	cells	induce	a	strong	pro-inflammatory	immune	response	to	extracellular	pathogens	
like	 bacteria	 and	 fungi.	 They	 are	 characterized	 based	 on	 CCR4	 and	 CCR6	 chemokine	
expression	[41].	Cytokines	promoting	the	induction	of	Th17	cells	include	IL-6,	IL-17,	IL-23	
and	transforming	growth	factor-β	(TGF-β),	which	also	induce	the	expression	of	the	Th17-
specific	transcription	factors	retinoic	acid	receptor-related	orphan	nuclear	receptor	(ROR)	
γt,	RORα	and	STAT-3	and	vice	versa	[42].	Following	pathogen	intrusion,	Th17	cells	induce	
neutrophil	 activation,	 which	 promotes	 a	 fast	 line	 of	 defense	 via	 the	 release	 of	 anti-
microbials,	 the	 elimination	 of	 pathogens	 by	 phagocytosis	 and	 the	 induction	 of	
chemotaxis.	 Th17	 immune	 response	mechanism	 can	 be	 inhibited	 by	 Th2	 cells,	 thereby	
preventing	an	overreaction	of	the	immune	system	and	with	that	a	damage	of	self-tissue.	
Th1/17	 cells	 have	 been	 described	 as	 a	 transitional	 state	 between	 Th17	 and	 Th1	 cells	
producing	 IFNγ	 and	 IL-17	 [41].	 The	 conversion	of	 Th1	 to	 Th17	 cells	 has	 been	 shown	 to	
impact	both,	MS	disease	progression	as	well	as	regulatory	functions	[44].	
T	 regs	are	classified	as	Forkhead	box	P3+	 (FoxP3)	CD25+	CD4+	T	cells.	They	are	primarily	
generated	during	thymic	selection	(referred	to	as	tT	regs	or	natural	T	regs)	and	possess	a	
relatively	 high	 affinity	 to	 self-antigens	 on	 the	 border	 to	 being	 negatively	 selected	 [45].	
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Additionally,	peripheral	T	regs	(pT	regs)	can	be	generated	extrathymically	and	induced	T	
regs	(iT	regs)	can	be	generated	in	cell	culture	stimulated	by	transforming	growth	factor-β	
(TGF-β).	The	transcription	factor	FoxP3	 is	 the	master	regulator	of	T	regs	and	along	with	
CTLA-4	essential	for	T	reg	functionality.	Importantly,	T	regs	express	no	or	only	low	levels	
of	IL-7	(CD127),	while	CD4+	CD25-	CD127+	conventional	T	cells	(all	CD4+	T	cells	but	T	regs)	
express	 IL-7Rα	 on	 their	 surface	 [46].	 IL-10,	 IL-35	and	TGF-β	 are	 the	 signature	 cytokines	
secreted	by	T	regs	and	induce	T	reg	activation	and	proliferation.	T	regs	are	crucial	for	the	
suppression	of	excessive	immune	responses	as	well	as	the	maintenance	of	immunological	
unresponsiveness	to	self-antigens.			
	
Table	1	provides	a	comprehensive	overview	of	the	CD4+	T	helper	cell	and	memory	T	cell	
subtypes	 including	 the	 chemokine	 receptor	 expression	 profiles	 characteristic	 for	 each	
phenotype.	 It	 summarizes	 the	 previously	 described	 subsets	 and	 their	 descriptive	
transcription	factors,	cytokine	profiles,	as	well	as	natural	functions.	
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Table	1:	CD4+	helper	T	cell	and	memory	cell	subtypes,	transcription	factors,	cytokine	
profiles,	phenotype	and	natural	function.	Modified	based	on	[39],[43],[47].	
T	cell	
subset		 TF	
inducing	
cytokines	
secreted	
cytokines	
pheno-
type	 natural	function	
Th1		 T-bet	 IL-12	 IFNγ,		
GM-CSF	
CXCR3+	
CCR5+	
cell-mediated	immunity,	
intracellular	pathogens	
Th2		 GATA3	 IL-4	 IL-4,	IL-5,		
IL-10,	IL-13	
CCR4+	
CRTh2+	
humoral	immunity,	
extracellular	parasites	
Th17		 RORγt	 IL-1β,	IL-6,		
IL-23,	TGF-β	
IL-17,		
GM-CSF	
CCR6+	
CCR4+	
mucosal	immunity,	
extracellular	fungi	and	
bacteria	
Tregs		 FoxP3	 -	 TGF-β	 CD25+,	
CD127-	
immune	homeostasis,	
(self-)tolerance	
TN	 	 	 IL-2	 CD45RA+
CCR7+	
progenitor	cells,	immune	
surveillance	
TCM	 	 	 IL-2,	IL-21	 CD45RO+
CCR7+	
immune	memory,	B	cell	
help,	secondary	expansion	
TEM	 	 	 IL-4,	IL-5,	
IL-17,	TNF-α,	
IFNγ	
CD45RO+
CCR7-	
immune	memory,	B	cell	
help,	protection	in	tissues	
TEMRA	 	 	 	 CD45RA+
CCR7-	
immune	memory,	
terminally	differentiated	
cells	
IL:	 interleukin,	 TF:	 transcription	 factor,	 Th:	 helper	 T	 cell,	 IFN-γ:	 interferon	 γ,	 GM-CSF:	
granulocyte-macrophage	 colony-stimulating	 factor,	 mTOR:	 mechanistic	 target	 of	
rapamycin,	ERR:	estrogen	receptor,	HIF-1α:	hypoxia-inducible	factor-1α,	FoxP3:	forkhead	
P3,	 TGF:	 transforming	 growth	 factor,	 AMPK:	 AMP-activated	 protein	 kinase,	 TN:	 naïve	 T	
cells,	CM:	central	memory,	EM:	effector	memory,	TEMRA:	terminally	differentiated	effector	
memory	 cells	 re-	 expressing	 CD45RA,	 TNF-α:	 tumor	 necrosis	 factor-α,	 CCR:	 Chemokine	
Receptor,	CXC:	CXC-Chemokine	Receptor,	CRTh2:	Chemoattractant	receptor-homologous	
molecule	 expressed	 on	 Th2	 cells,	 RORγt:	 retinoic	 acid	 receptor-related	 orphan	 nuclear	
receptor	γt. 
1.2.2.1.2 CD8+	T	lymphocytes	
CD8+	T	cells	are	a	T	lymphocyte	subpopulation	that,	in	contrast	to	CD4+	T	cells,	recognize	
MHC	 class	 I	 molecules	 on	 APCs	 via	 their	 CD8	 TCR	 complex	 and	 are	 very	 potent	 pro-
inflammatory	immune	activators	(described	in	1.2.2.1).	They	differentiate	and	proliferate	
into	 cytotoxic	CD8+	T	 cells	 inducing	a	 cascade	of	pro-inflammatory	 signaling	 to	 fight	off	
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the	intruding	pathogen	or	neoplastic	cells.	Signature	cytokines	of	cytotoxic	T	cells	include	
IL-2,	TNF-α	and	INF-γ.	Additionally,	due	to	their	function	in	clearing	intracellular	viruses,	
bacteria	 and	 cancer	 cells,	 CD8+	 T	 cells	 secrete	 perforin,	 granzyme	 and	 granulolysin	
inducing	a	strong	 immune	attack.	To	prevent	an	 immune	overreaction,	cytotoxic	T	cells	
require	at	 least	 three	signals	 to	become	activated:	TCR	specific	antigen	 recognition,	 co-
receptor	binding	(e.g.	CD28)	and	IL-2	signaling	(which	may	include	Th	cells	that	provide	IL-
2)	[48].	
To	date,	three	main	CD8+	cytotoxic	T	cell	subpopulations	have	been	described.	They	are	
differentiated	based	on	their	chemokine	expression	and	are	unique	to	their	 locations	 in	
the	body.	CCR4,	CCR6	and	CXCR3	are	used	for	their	characterization.	The	specific	immune	
functions	of	 the	subpopulations	have	been	studied	to	a	greater	extend,	but	still	 remain	
somewhat	 elusive.	 CD8+	 CCR4+	 CCR6-	 CXCR3-	 T	 cells	 are	 predominantly	 found	 in	 the	
epithelium	and	 lung	 [49]	and	are	 involved	 in	Th2-mediated	 immunity	 [50].	 	CD8+	CCR6+	
CCR4-	CXCR3-	T	cells	are	mainly	located	in	the	gut	and	have	been	shown	to	be	essential	in	
Th17-mediated	 immune	 responses,	 while	 CD8+	 CXCR3+	 CCR4-	 CCR6-	 T	 cells	 display	 key	
immune	functions	in	Th1	immunity	[50].	
CD8+	 cytotoxic	 T	 cells	 act	 on	 pathogen	 infected	 cells	 or	 neoplastic	 cells	 by	 releasing	
granzyme,	granulolysin	and	perforin.	These	factors	are	released	from	granules	within	the	
cytoplasm	 of	 cytotoxic	 T	 cells	 and	 are	 exerted	 onto	 the	 target	 cells.	 They	 induce	
apoptosis,	 form	holes	 in	 the	 target	 cell	membranes,	 inhibit	 virus	 replication	 and	 act	 as	
anti-microbials	by	creating	a	pro-inflammatory	micro-environment.	
1.2.2.2 B	lymphocytes	-	development,	differentiation	and	activation	
Just	 like	 T	 cells,	 B	 lymphocytes	 (subsequently	 termed	 B	 cells)	 are	 lymphocytes	 derived	
from	 pluripotent	 hematopoetic	 stem	 cells	 in	 the	 bone	 marrow	 and	 are	 part	 of	 the	
adaptive	immune	system.	B	cells	and	the	immunoglobulins	(Ig,	also	known	as	antibodies)	
they	 produce	 make	 up	 an	 essential	 part	 of	 humoral	 immunity	 protecting	 against	 an	
enormous	variety	of	pathogens.	The	B	cell	antibody	repertoire	entails	antibodies	that	can	
recognize	more	than	5x1013	specificities	 [51].	B	cells	can	produce	five	different	 types	of	
immunoglobulins:	 IgM,	 Ig,A,	 IgG,	 IgD	 and	 IgE.	 All	 of	 them	 differ	 in	 size,	 specificity	 and	
functionality	[51].		
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The	protein	structure	(variable	and	constant	regions)	as	well	as	the	genetic	mechanisms	
underlying	 the	 production	 of	 antibodies	 resemble	 that	 of	 the	 TCR	 on	 T	 cells.	 Briefly,	
during	 cellular	 development	 in	 the	bone	marrow,	B	 cells	 undergo	 the	 following	 stages:	
stem	cell,	early	pro-B	cell,	late	pro-B	cell,	large	pro-B	cell,	small	pre-B	cell	and	immature	B	
cell	[52].	When	the	precursor	forms	of	the	B	cells	undergo	these	stages,	rearrangements	
of	 the	 variable	 (V),	 joining	 (J)	 and	 diversity	 (D)	 regions	 of	 the	 heavy	 chain	 and	 VJ	
rearrangement	 of	 the	 light	 chain	 occurs.	 Heavy-chain	 rearrangement	 occurs	 after	 the	
early	pro-B	cell	stage	and	its	success	is	tested	selecting	for	functional	heavy	chains.	If	the	
cell	 passes	 that	 first	 functionality	 checkpoint,	 it	 undergoes	 light-chain	 rearrangement	
followed	by	a	second	checkpoint	selecting	for	functional	light	chains.	If	that	succeeds,	the	
cell	moves	on	to	the	immature	B	cell	stage.		
Following	these	briefly	summarized	developmental	stages,	the	immature	B	cell	possesses	
an	antigen-specific	immunoglobulin	(Ig),	which	is	embedded	into	the	cell	membrane	and	
part	 of	 the	 B	 cell	 receptor	 (BCR)	 complex.	 Immunoreceptor	 tyrosine-based	 activation	
motifs	(ITAMS)	are	linked	to	Ig	on	the	BCR	and	induce	activation	signaling	upon	antigen-
specific	immunoglobulin	binding	[53].	
Immature	B	cells	that	recognize	self-antigens	in	the	bone	marrow	are	eliminated,	rescued	
or	 become	 tolerant.	 The	 process	 of	 central	 tolerance	 includes	 BCR	 editing,	 clonal	
elimination,	depletion,	inactivation	or	anergy.	Immature	B	cells	that	do	not	recognize	self-
antigens	in	the	bone	marrow	migrate	into	the	lymphatic	system	as	immature	transitional	
B	cells	where	they	undergo	the	process	of	peripheral	tolerance	after	encountering	their	
BCR	specific	antigen.	They	either	become	anergic,	undergo	clonal	deletion	or	move	on	to	
mature.	BCR-specific	antigen	recognition	as	well	as	IgM	and	IgD	expression	characterizes	
mature	 naïve	 B	 cells.	 Mature	 naïve	 B	 cells	 are	 further	 characterized	 as	 CD20+	 CD3-	
lymphocytes	[54]	and	have	been	described	to	secrete	the	immunosuppressive	cytokine	IL-
10	 [55].	 CD20	 is	 expressed	 from	 the	 pre-B	 cell	 stage	 until	 the	mature	 naïve	 as	well	 as	
memory	 B	 cell	 stage,	 however,	 plasma	 cells	 lack	 CD20.	 Mature	 naïve	 B	 cells	 circulate	
between	 lymphoid	vessels	and	the	blood	stream	where	they	encounter	APCs	as	well	as	
helper	T	cells	and	patrol	for	intruding	pathogenic	antigens.		
Interestingly,	 mature	 B	 cells	 undergo	 a	 process	 termed	 somatic	 hypermutation.	 In	
addition	to	immunoglobulin	gene	rearrangement	in	the	BM,	this	highlights	a	second	step	
in	 B	 cell	 antigen	 recognition	 diversification.	 During	 somatic	 hypermutation,	 high-
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frequency	point	mutations	occur	at	the	hypervariable	sites	of	the	variable	regions	on	the	
light	and	heavy	chains.	These	sites	are	the	points	of	contact	with	antigens.	Therefore,	the	
affinity	of	the	antibody	to	an	antigen	can	get	increased	or	decreased	allowing	antibodies	
with	medium	or	 low	antigen	affinities	to	become	highly-specific	for	pathogenic	antigens	
[51].	Somatic	hypermutation	is	specific	to	B	cells	and	has	not	been	described	in	T	cells.		
Compared	to	T	cells,	B	cells	do	not	depend	on	MHC	presentation	for	activation.	B	cells	can	
recognize	and	bind	antigen	directly	 via	 their	BCR	along	with	 co-receptors	 and	have	 the	
ability	to	bind	non-protein	antigens	like	foreign	polysaccharides	and	DNA	independent	of	
T	cell	engagement	 [56].	Nevertheless,	B	cells	can	bind	antigens	by	their	antigen-specific	
BCR.	 The	 BCR-antigen	 complex	 gets	 engulfed	 and	 the	 foreign	 antigen	 is	 processed	 and	
subsequently	presented	on	the	cell	surface	via	MHC	class	II	for	recognition	by	e.g.	helper	
or	memory	T	cells.	B	cells	are	essential	APCs	 for	helper	T	cells	and	 initiate	helper	T	cell	
activation,	expansion	as	well	as	differentiation.	Similarly,	B	cells	may	depend	on	helper	T	
cell-mediated	 initiation	 of	 activation,	 proliferation	 and	 differentiation	 following	 antigen	
presentation	 by	 T	 cells	 [57].	 Once	 the	 B	 cell	 recognizes	 its	 specific	 antigen,	 the	 cell	
undergoes	clonal	expansion	and	develops	into	an	antibody-producing	plasma	cell	fighting	
off	 the	pathogen	and	activating	additional	 immune	mechanisms	and	cells	of	 the	 innate	
and	adaptive	immune	system.		
In	 addition	 to	 B	 cells	 undergoing	 clonal	 expansion,	 antigen-specific	memory	 B	 cells	 are	
formed,	which	able	to	effectively	and	efficiently	fight	re-occurring	antigens	[58].	These	
long-lived	memory	B	cells	are	CD20+	and	able	 to	persist	 for	years	 [59].	They	have	been	
described	to	be	CD27+	and	produce	pro-inflammatory	cytokines	like	IL-12,	lympho	toxin	α	
(LTα)	and	TNF-α	[55].	
In	 summary,	 B	 cells	 are	 very	 potent	 antigen-specific	 lymphocytes	 with	 a	 tremendous	
antigen	recognition	repertoire	that	is	vital	in	complementing	T	cell	immune	responses.		
The	described	developmental	 stages	and	numerous	 functions	of	B	cells	 require	 the	 fine	
interaction	 and	 modulation	 of	 cellular	 energy	 pathways.	 Here,	 the	 ability	 to	 switch	
between	low	and	high	energetic	states	is	fundamental	and	allows	successful	immune	cell	
functionality.		The	following	text	discusses	the	central	role	of	metabolism	in	immune	cell	
function.		
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1.3 Immunometabolism	
The	 word	metabolism	 is	 derived	 from	 the	 Greek	 word	 μεταβολισμός	 (metavolismós),	
which	means	 change.	 	 Immune	 cells	 have	 numerous	 specifications,	 functionalities	 and	
responsibilities	and	with	that	need	to	display	very	distinct	metabolic	profiles	to	meet	their	
individual	 tasks	 and	 fulfill	 their	 target	 functions.	 Therefore,	 the	 ability	 to	 adapt	 and	
change	 their	metabolic	 profile	 is	 crucial	 for	healthy	 immune	 response	mechanisms	and	
host	survival.	
One	of	 the	 first	 researchers	analyzing	 cellular	metabolic	 function	was	Otto	Warburg.	 In	
1956,	 he	 described	 that	 even	 under	 aerobic	 conditions	 cancer	 cells	 heavily	 depend	 on	
glycolysis	instead	of	oxidative	phosphorylation	(OXPHOS)	to	meet	their	increased	energy	
demand-	an	observation	that	has	subsequently	been	termed	the	Warburg	Effect	[60],[61].	
From	 there	 on,	 the	 analysis	 of	 cell-specific	 energy	 pathways	 has	 spread	 to	 all	 kinds	 of	
research	areas	including	immunology.	
Subsequently,	the	main	cellular	energy	generating	pathways	are	described	and	linked	to	
immune	cell	function.	
1.3.1 Main	Cellular	Energy	Pathways	
Cells	 are	 regulated	 by	 extrinsic	 and	 intrinsic	mechanisms	 and	 therefore	modulate	 their	
specific	 activities	 and	 metabolic	 pathways	 based	 on	 their	 requirements	 for	 survival,	
growth	 or	 development.	 The	 ability	 to	 use	 and	 switch	 between	 different	 pathways	 to	
generate	 energy	 from	nutrients	 like	 sugars,	 proteins	 and	 fats	 are	 key	 characteristics	 of	
cellular	energy	metabolism.	Typically,	the	energy	is	stored	in	the	chemical	bonds	of	these	
nutrients	and	the	catabolism	(break	down)	of	these	bonds	releases	energy,	which	is	used	
to	 generate	 energy	 rich	 molecules	 like	 adenosine	 triphosphate	 (ATP)	 that	 the	 cell	 can	
subsequently	use.	
Importantly,	cellular	chemical	reactions	have	exceptionally	high	reactive	potential	and	are	
therefore	always	profoundly	controlled	for.	Energy	signaling	pathways	in	eukaryotic	cells,	
including	human	immune	cells,	occur	either	in	the	cellular	cytosol	or	within	mitochondria.	
The	 cytosol	 is	 defined	 as	 the	 liquid	 inside	 the	 cell	 and	 is	 surrounded	 by	 the	 cell	
membrane.	 Glycolysis,	 the	 pentose	 phosphate	 pathway	 (PPP)	 and	 amino	 acid	 (AA)	
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metabolism	 including	 glutaminolysis	 take	 place	 in	 the	 cytosol.	 It	 separates	 numerous	
compartments	within	 the	 cell,	with	distinct	 functions	 and	 responsibilities.	One	of	 these	
specialized	 compartments	 within	 eukaryotic	 cells	 are	 mitochondria.	 Mitochondria	 are	
thread	like	structures	that	are	highly	adaptable	to	cellular	energy	needs.	They	are	the	site	
of	the	tri-citric	acid	(TCA)	cycle	as	well	as	the	electron	transport	chain	(ETC)	and	OXPHOS.	
Mitochondria	are	made	up	of	an	 inner	and	an	outer	mitochondrial	membrane	with	 the	
inter-membrane	space	in	between.	 	The	inner	membrane	forms	engulfings	(cristae)	 into	
the	 inside	 of	 the	 mitochondria,	 the	 mitochondrial	 matrix.	 Cristae	 are	 the	 site	 of	 ETC	
complexes	and	energy	production	in	the	form	of	ATP.		
To	 meet	 the	 cell’s	 energy	 demand,	 mitochondria	 possess	 the	 ability	 to	 adapt	 their	
morphology.	 They	 can	 fuse	 together,	 a	 process	 termed	 mitochondrial	 fusion	 and	
observed	 to	 be	 required	 in	 fatty	 acid	 oxidation	 (FAO)	 and	memory	 T	 cell	 development	
[62],[63].	During	 fusion,	mitochondrial	cristae	move	further	apart	and	thereby	decrease	
ETC	 efficiency	 and	 energy	 production	 in	 the	 form	 of	 ATP.	 Additionally,	 the	 division	 of	
mitochondria,	 termed	mitochondrial	 fission,	 has	 been	 observed	 in	 effector	 T	 cells	 and	
increases	 mitochondrial	 energy	 production.	 Fission	 induces	 mitochondrial	 cristae,	 and	
with	 that	 ETC	 complexes,	 to	 move	 closer	 together	 and	 thereby	 allows	 for	 a	 greater	
efficiency	of	energy	production,	specifically,	ATP	generation	[62],[63].		
Fusion	and	fission	are	also	required	for	the	regulation	of	mitophagy.	Mitophagy	has	first	
been	 described	 by	 Lemaster	 and	 colleagues	 as	 the	 process	 of	 degradation	 of	 damaged	
mitochondria	 [64].	 In	 cellular	 division,	 fission	 processes	 allow	 the	 equal	 distribution	 of	
mitochondria	 between	 cells,	 induce	 the	 segregation	 of	 damaged	 mitochondria	 and	
initiation	of	mitophagy	 [65],[66].	A	most	 recent	 comprehensive	 review	by	Williams	and	
Ding	 summarizes	 the	 complex	 field	 of	 mitophagy	 and	 the	 underlying	 molecular	
mechanisms	and	pathophysiological	roles	[67].	Briefly,	the	authors	describe	nuclear	and	
mitochondrial	 genes	 involved	 in	 mitophagy	 processes	 and	 the	 relevance	 of	 mitophagy	
processes	 in	 innate	 and	 adaptive	 immunity.	 E.g.,	 in	 T	 cells,	 mitophagy	 is	 essential	 for	
cellular	 differentiation	 and	 mitophagy	 deficiency	 has	 been	 shown	 to	 increase	
mitochondria	 abundance,	 toxic	 reactive	 oxygen	 species	 and	 with	 that	 lead	 to	 overall	
impaired	peripheral	T	cell	survival	[68].	The	relevance	of	mitophagy	with	respect	to	auto-
immune	diseases	requires	future	investigations.	
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Mitochondria	 possess	 their	 own	mitochondrial	 DNA	 (mt-DNA)	 as	well	 as	 ribosomes	 for	
protein	synthesis.	Mt-DNA	is	believed	to	have	its	origin	in	the	endosymbiotic	theory	and	
encodes	about	37	genes	that	are	coding	for	ETC	molecules	and	amino	acids	[69],[70].		In	
sexual	reproduction,	mitochondria	are	inherited	via	the	egg	cell	from	the	mother.		
Mitochondria-associated	 membranes	 (MAMs)	 directly	 connected	 mitochondria	 to	 the	
endoplasmic	 reticulum	 (ER)	 and	 the	 nucleus	 allowing	 immediate	 and	 efficient	
communication	between	the	cell	 structures.	Among	other	molecules,	 lipids	and	calcium	
ions	(Ca2+)	can	be	shuttled	between	the	ER	and	mitochondria,	which	is	essential	in	energy	
metabolic	homeostasis	[71].			
An	 overview	of	 the	major	metabolic	 pathways	 is	 given	 in	 Figure	 2.	Glycolysis,	 the	 PPP,	
FAO,	glutaminolysis,	 the	TCA	cycle,	the	ETC	and	OXPHOS	are	shown	as	the	main	energy	
producing	pathways	within	the	cell.		
	
Figure	2:	Overview	of	main	cellular	energy	pathways.	In	energy	production	pathways,	nutrients	
are	 taken	up	 from	 the	 interstitial	 fluid	outside	 the	 cell	 into	 the	 cytosol.	 Subsequently,	 they	 get	
catabolized	 via	 numerous	 chemical	 reactions	 yielding	 energy-rich	 ATP,	 NADH	 and	 FADH2	
molecules.	Glycolysis,	PPP,	glutaminolysis	(all	taking	place	in	the	cytosol),	FAO,	ETC	and	OXPHOS	
(all	occurring	 in	 the	mitochondria)	are	 the	main	pathways	during	which	glucose,	 fatty	acids	and	
glutamine	are	broken	down.	OXPHOS	requires	the	presence	of	molecular	oxygen	(O2).	Metabolic	
waste	products	 like	carbon	dioxide	(CO2),	ethanol	and	 lactic	acid	are	secreted	from	the	cell.	AA:	
Amino	Acids,	ATP:	Adenosine	Triphosphate,	ETC:	Electron	Transport	Chain,	FADH2:	Flavin	Adenine	
Dinucleotide	 H2,	 FAO:	 Fatty	 Acid	 Oxidation,	 NADH:	 Nicotinamide	 Adenine	 Dinucleotide	 H,	
OXPHOS:	Oxidative	Phosphorylation,	PPP:	Pentose	Phosphate	Pathway,	TCA:	Tri-citric	Acid	Cycle.	
(designed	based	on	[62],[63],[72]–[76])	
Each	signaling	cascade	is	described	in	the	subsequent	text	passages	beginning	with	FAO.		
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1.3.1.1 Fatty	Acid	β-oxidation	and	the	Mitochondrial	Membrane	Protein	CPT1a	
Fatty	acid	β-oxidation	(short	β-oxidation	or	FAO)	describes	the	catabolism	of	fatty	acids	to	
numerous	products	that	the	cell	can	use	for	energy	production.	The	starting	point	of	this	
reaction	is	the	beta	carbon	of	the	fatty	acid	molecule,	hence	the	name	β-oxidation.		
In	 order	 for	 FAO	 to	 commence,	 fatty	 acids	 need	 to	 be	 activated	 and	 subsequently	
transferred	 from	 the	 cytosol	 via	 the	mitochondrial	membrane	 into	 the	mitochondrion.	
The	activation	of	fatty	acids	involves	an	enzyme-mediated	reaction	in	the	cytosol	during	
which	acetyl-coenzyme	A	(acetyl-CoA)	 is	bound	to	the	fatty	acid.	Short-chain	 fatty	acids	
(between	 2	 and	 6	 carbon	 atoms	 in	 size)	 can	 diffuse	 into	 the	 mitochondria.	 However,	
medium-	 and	 long-chain	 fatty	 acids	 (larger	 than	 6	 carbon	 atoms)	 cannot	 diffuse	 into	
mitochondria	and	require	a	specific	transporter	[72],[74].	
The	 central	molecule	 facilitating	 this	 transfer	 is	 CPT1a	 (Carnitine	 palmitoyltransferase	 I	
isoform	a),	which	 is	 located	 in	 the	mitochondrial	membrane.	CPT1a	 is	a	member	of	 the	
carnitine/choline	acetyltransferase	 family	and	 located	on	 chromosome	eleven	 [49].	 The	
mitochondrial	trans-membrane	protein	forms	homohexamer	and	homotrimer	complexes	
with	Acyl-CoA	Synthetase	Long	Chain	Family	Member	1	(ACSL1)	and	Voltage	Dependent	
Anion	Channel	 (VDAC)	1	and	has	also	been	found	 in	complexes	with	VDAC2	and	VDAC3	
[49].	
CPT1a	activates	fatty	acid	by	conjugating	medium-	and	long-chain	fatty	acids	to	carnitine.	
This	 allows	 the	 conjugated	 fatty	 acid	 acyl-CoA	 to	 be	 shuttled	 into	 the	 mitochondrion	
where	it	is	transferred	back	to	fatty	acid	acyl-CoA	by	CPT2	(Carnitine	palmitoyltransferase	
2)	 [76].	 Now,	 FAO	 can	 begin	 yielding	 acetyl-CoA,	 NADH	 (Nicotinamide	 Adenine	
Dinucleotide	 H)	 and	 FADH2	 (Flavin	 Adenine	 Dinucleotide	 H2).	 The	 lipid	 synthesis	
intermediate	 malonyl-CoA	 inhibits	 CPT1a	 once	 fatty	 acid	 synthesis	 (FAS)	 occurs	 in	 a	
nutrient	 abundant	 environment.	 Therefore,	 the	 transfer	 of	 fatty	 acids	 via	 CPT1a	 is	 the	
rate-limiting	step	and	CPT1a	the	key	regulatory	protein	in	FAO.	
Compared	to	glycolysis,	FAO	is	very	efficient	and	allows	the	generation	of	large	amounts	
of	 ATP	 from	 complex	 fatty	 acid	 molecules.	 For	 example,	 the	 complete	 FAO	 of	 one	
palmitate	 molecule	 can	 produce	 more	 than	 100	 ATP	 molecules,	 while	 one	 glucose	
molecule	can	only	yield	up	to	36	ATP	molecules	[79].			
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The	generated	NADH	and	FADH2	molecules	from	FAO	are	electron	donors	for	the	ETC	and	
finally	OXPHOS	for	the	generation	of	ATP,	which	is	subsequently	described	in	more	detail.	
1.3.1.2 Electron	Transport	Chain	and	Oxidative	Phosphorylation	
During	 oxidative	 phosphorylation	 (OXPHOS),	 electrons	 are	 transported	 down	 an	
electrochemical	proton	gradient	of	the	electron	transport	chain	(ETC).	The	ETC	is	made	up	
of	complex	I	to	complex	V	and	is	integrated	into	the	inner	mitochondrial	membrane	[80]	
[81].	 It	 is	a	 series	of	 redox	 (reduction	and	oxidation)	 reactions	performed	by	numerous	
enzymes	 during	 which	 electrons	 are	 transferred	 from	 electron	 donors	 to	 acceptors,	
allowing	the	transfer	of	hydrogen	protons	(H+)	from	the	mitochondrial	matrix	to	the	inter-
membrane	 space.	 This	 generates	 a	 proton	 gradient,	 which	 is	 used	 for	 ATP	 synthesis.	
Importantly,	 the	 process	 of	 ADP	 (adenosine	 diphosphate)-phosphorylation	 to	 form	
energy-rich	 ATP	 requires	 the	 presence	 of	 molecular	 oxygen	 (O2)-	 hence	 it	 is	 termed	
OXPHOS.	 Therefore,	 the	 generation	 of	 energy	 via	 the	 ETC	 is	 a	 process	 of	 aerobic	
respiration	and	an	oxygen-dependent	metabolic	pathway.		
The	five	complexes	of	the	ETC	(Figure	3)	each	have	distinct	properties	and	complement	
each	other.	In	complex	I,	also	termed	NADH	dehydrogenase,	two	electrons	are	removed	
from	the	electron	donor	NADH.	In	addition	to	NAD+,	the	redox	reaction	yields	hydrogen	
protons	 (H+),	 which	 are	 pumped	 into	 the	 mitochondrial	 inter-membrane	 space.	 The	
reaction	 also	 yields	 electrons,	 which	 are	 transported	 to	 the	 next	 complex	 in	 the	 ETC,	
complex	 II.	 	 The	 function	 of	 complex	 I	 can	 be	 inhibited	 by	 e.g.	 rotenone	 (Table	 2)	
preventing	the	electron	transfer	to	complex	II	and	causing	an	accumulation	of	electrons	in	
the	mitochondrial	matrix	 as	well	 as	 the	 inhibition	of	 hydrogen	proton	 transfer	 into	 the	
inter-membrane	space.		
Complex	 II	 (succinate	 dehydrogenase)	 is	made	 up	 of	 four	 subunits	 and	 the	 succeeding	
complex	in	the	ETC.	In	addition	to	electrons	derived	from	complex	I,	complex	II	receives	
electrons	 from	electron	donors	 like	 succinate	via	 its	 cofactor	FADH2.	This	complex	does	
not	contribute	to	the	proton	transfer	into	the	inter-membrane	space,	however	transfers	
its	electrons	to	the	next	complex	in	the	ETC:	
In	complex	III	(termed	bc1	complex	(ubiquinol:cytochrome	c	oxidoreductase),	a	series	of	
redox	 reactions	 yields	 electrons	 that	 are	 transferred	 to	 complex	 IV	 via	 cytochrome	 c.	
Introduction	
23	
	
Additionally,	 hydrogen	 protons	 are	 pumped	 into	 the	 inter-membrane	 space	 further	
contributing	to	the	build	up	of	the	electrochemical	proton	gradient.	 	Complex	 III	can	be	
inhibited	by	antimycin	A	(Table	2).		
The	succeeding	complex	in	the	ETC	is	complex	IV.	The	transmembrane	protein	complex	is	
also	known	as	cytochrome	c	oxidase.	It	receives	electrons	from	cytochrome	c	of	complex	
III	 and	 transfers	 them	 to	 molecular	 oxygen,	 which	 yields	 a	 H2O	 molecule.	 During	 this	
process,	hydrogen	protons	are	transferred	into	the	inter-membrane	space.		
The	 uneven	 difference	 in	 hydrogen	 proton	 concentration	 between	 the	 mitochondrial	
matrix	 and	 inter-membrane	 space	 is	 used	 by	 ATP-synthase,	 complex	 V,	 of	 the	 ETC.	 	 It	
constitutes	 two	 regions	with	numerous	 subunits	and	 is	 the	 final	 step	of	 the	ETC	during	
which	ATP-generation	occurs	from	ADP	and	phosphate.	The	hydrogen	protons	are	passed	
via	the	ATP-synthase	into	the	matrix	allowing	ATP	synthesis	to	occur.	The	process	of	ADP-
phosphorylation	 can	 be	 disrupted	 by	 the	 chemical	 agent	 FCCP	 (Carbonyl	 cyanide-4-
(trifluoromethoxy)phenylhydrazone)	(Table	2),	which	is	an	uncoupling	agent	transporting	
hydrogen	protons	 into	the	mitochondrial	matrix,	thereby	disrupting	the	proton	gradient	
and	with	that	preventing	the	process	of	ATP	synthesis.		
	
Figure	 3:	 Display	 of	 the	 mitochondrial	 electron	 transport	 chain.	 The	 electron	 transport	 chain	
(ETC)	 is	 located	at	 the	 inner	membrane	of	mitochondria.	Electrons	are	donated	 to	complex	 I	of	
the	ETC	and	transported	in	a	series	of	redox	reactions	to	complex	II,	III,	IV	and	V.	This	allows	the	
transfer	 of	 hydrogen	 protons	 (H+)	 from	 the	mitochondrial	matrix	 to	 the	 inter-membrane	 space	
generating	a	proton	gradient	between	the	mitochondrial	matrix	and	the	 inter-membrane	space.	
This	proton	gradient	 is	used	for	ATP	synthesis	by	complex	V.	ADP:	Adenosine	diphosphate,	ATP:	
Adenosine	triphosphate,	Pi:	inorganic	phosphate,	FAD:	Flavin	Adenine	Dinucleotide,	FADH2:	Flavin	
Adenine	Dinucleotide	H2,	H+:	Hydrogen	proton,	H2O;	water	molecule,	NAD:	Nicotinamide	Adenine	
Dinucleotide	 H,	 NAD:	 Nicotinamide	 Adenine	 Dinucleotide,	 redox:	 reduction	 and	 oxidation	
reaction,	O2:	oxygen.	(designed	based	on	[80])	
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Table	2:	Inhibitors	of	mitochondrial	electron	transport	chain	complexes.	Table	adapted	
from	[82]–[85].	
inhibitors	 	mechanism	of	toxicity	
oligomycin	 inhibits	ATP-synthase	(complex	V)	and	induces	a	hyperpolarization	of	
the	inter-membrane	space		
FCCP	 uncouples	mitochondrial	inner	membrane,	inhibits	ATP	synthesis	by	
allowing	free	flow	of	H+	between	the	inter-membrane	space	and	matrix	
rotenone	 inhibits	complex	I-induced	NADH	oxidation	to	NAD	
antimycin	A	 complex	III	inhibition	
	
In	summary,	the	ETC	and	OXPHOS	are	a	series	of	efficient	and	highly	specialized	reactions	
within	 the	 mitochondrion	 that	 require	 the	 presence	 of	 molecular	 oxygen	 and	 yield	
tremendous	 amounts	 of	 energy-rich	 ATP	 molecules	 that	 the	 cell	 can	 use	 for	 any	
metabolic	 reactions.	 Predominantly,	 this	 energy	 is	 received	 from	 the	 oxidation	 of	 fatty	
acids	that	yield	NADH	and	FADH2	molecules.	Furthermore,	in	addition	to	FAO,	energy	can	
be	generated	from	glucose	molecules	in	a	process	termed	glycolysis.	
1.3.1.3 Glycolysis	and	the	Glucose	Transporter	GLUT1	
Glycolysis	takes	place	in	the	cytosol	and	is	a	key	metabolic	pathway	during	which	glucose	
(C6H12O6)	 is	 catabolized	 in	 consecutive	 reactions	 into	 pyruvate	 along	 with	 numerous	
byproducts.	The	glycolytic	pathway	begins	with	the	uptake	of	extracellular	glucose	from	
the	 interstitial	 fluid,	 the	 immediate	 cellular	 microenvironment	 surrounding	 the	 cell.	
Glucose	molecules	require	a	transporter	in	order	to	cross	the	cell	membrane.	One	of	the	
main	 trans-membrane	 glucose	 transporter	 proteins	 with	 a	 high	 affinity	 of	 glucose	 is	
Glucose	transporter	1	(GLUT1),	which	is	encoded	by	the	gene	Scl2a1.	It	is	part	of	a	family	
of	glucose	transporters	 including	GLUT1	to	GLUT14,	each	of	which	expressed	 in	specific	
body	tissues	and	cells	[75].		
The	 intracellular	 processing	 of	 glucose	 in	 the	 glycolytic	 pathway	 entails	 a	 series	 of	
enzymatic	 reactions	 yielding	 pyruvate	molecules.	Under	 anaerobic	 conditions,	 pyruvate	
can	 be	 processed	 into	 lactate	 and	 ethanol.	 Under	 aerobic	 conditions,	 pyruvate	 is	
processed	 to	 acetyl-CoA	 and	 entered	 into	 the	 TCA	 cycle,	 which	 takes	 place	 in	 the	
mitochondrial	matrix.	Anaerobic	glycolysis	 can	occur	even	 though	oxygen	 is	abundantly	
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present	in	the	cell,	e.g.	during	inflammatory	processes	or	in	cancer	cells	(Warburg	effect).	
However,	anaerobic	glycolysis	 is	 less	efficient	 in	 the	generation	of	energy-rich	ATP.	The	
catabolism	of	one	glucose	molecule	 yields	 two	ATPs	during	anaerobic	glycolysis	 and	36	
ATPs	 if	processed	via	the	TCA	cycle	and	ETC	respiration	[76].	Lactate	and	CO2	are	waste	
products	 that	 are	 secreted	 by	 the	 cell	 and	 are	 associated	 with	 an	 increased	 acidic	
microenvironment	[86].		
Nevertheless,	there	are	central	benefits	of	glycolysis,	including	the	generation	of	the	co-
factor	 NADH,	 which	 is	 essential	 in	 cellular	 anabolism.	 Furthermore,	 glycolysis	 provides	
intermediates	 for	 the	 biosynthesis	 of	 fatty	 acids,	 amino	 acids	 as	 well	 as	 ribose	 for	
nucleotides.	 Consequently,	 cellular	 dependency	 of	 glycolysis	 has	 been	 observed	 in	
growing,	activated	and	proliferating	cells,	which	require	large	amounts	of	biomaterial.		
1.3.1.4 Tri-citric	Acid	Cycle		
An	 additional	 major	 cellular	 metabolic	 pathway	 is	 the	 tri-citric	 acid	 (TCA)	 cycle,	 also	
known	as	 the	Krebs	cycle	named	after	Hans	Krebs,	who	discovered	 it	 in	1957	 [87].	The	
TCA	cycle	takes	place	in	the	matrix	of	mitochondria	and	receives	products	from	multiple	
nutrients.	 Acetyl-CoA	 from	 glucose-derived	 pyruvate	 or	 fatty	 acids	 and	α-ketoglutarate	
from	glutamate	metabolism	enter	 the	cycle	at	different	 stages.	 In	a	 series	of	 reactions,	
the	 TCA	 cycle	 yields	 NADH	 and	 FADH2	 that	 transfer	 their	 electrons	 to	 the	 ETC	 for	 the	
generation	of	ATP	during	OXPHOS	(reviewed	in	Figure	2).	
The	TCA	cycle,	along	with	the	ETC	and	OXPHOS,	is	a	highly	efficient	energy	pathway	that	
is	 predominantly	 performed	by	 cells	 that	 are	quiescent	 or	 non-proliferating	 and	whose	
main	requirement	is	longevity	[76].	However,	if	specific	growth	signals	are	present,	they	
can	promote	the	production	of	amino	acid	and	lipids	from	TCA	cycle	intermediates.	This	
modification	 of	 TCA	 cycle	 reactions	 requires	 nutrient	 abundance	 and	 diversion	 to	 the	
cycle.	 The	process	 of	 amino	 acid	 and	 lipid	 production	 is	 also	 observed	 in	 the	 glycolytic	
pathway	[76].	
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1.3.1.5 Pentose	Phosphate	Pathway	
The	Pentose	Phosphate	Pathway	(PPP)	takes	place	in	the	cytosol	and	uses	intermediates	
from	the	glycolytic	pathway	 (Figure	2)	 for	 the	production	of	nucleotide	and	amino	acid	
precursors	 (e.g.	 for	DNA	and	RNA	 synthesis)	 as	well	 as	NADPH	 (phosphorylated	NADH)	
[73],	which	 is	 an	essential	 electron	donor	and	 important	antioxidant.	 The	PPP	 supports	
cellular	survival,	growth	and	proliferation.	The	pathway	does	not	require	or	produce	ATP	
and	is	oxygen-independent.		
1.3.1.6 Amino	Acid	and	Glutamine	Metabolism	
Amino	 acids	 are	 essential	 building	 blocks	 for	 protein	 synthesis	 associated	with	 the	 PPP	
and	 are	 used	 as	 substrates	 in	 different	 metabolic	 reactions,	 e.g.	 FAS.	 The	 amino	 acid	
Glutamine	 can	 be	 taken	 up	 by	 the	 cell,	 converted	 to	 glutamate	 and	 finally	 α-
ketoglutarate,	 which	 is	 entered	 into	 the	 TCA	 cycle	 for	 energy	 production	 (Figure	 2).	
Additionally,	it	can	serve	as	a	source	of	citrate	for	de	novo	fatty	acid	synthesis	in	anabolic	
metabolism	and	cellular	growth	[73].	
	
Taken	 together,	 the	 cellular	 energy	 metabolism	 pathways	 comprehensively	 described	
here,	 are	 used	 by	 cells	 to	 meet	 their	 individual	 metabolic	 requirements	 for	 cellular	
survival,	development	and	functionality.	Specific	regulatory	mechanisms	regarding	energy	
metabolism	in	immune	cells	are	examined	in	the	subsequent	text.	
1.3.2 Regulation	of	Immune	Cells	by	Adapting	Energy	Metabolism	
As	 discussed	 in	 1.2,	 innate	 and	 adaptive	 immune	 cells	 are	 in	 constant	 contact	 and	
exchange	with	their	immediate	microenvironment.	They	are	part	of	complex	interactions	
e.g.	via	their	cell-specific	receptors	or	secreted	cytokines.	All	of	these	mechanisms	serve	
the	purpose	of	inter-cell	communication,	activation	and	support	once	pathogenic	agents	
or	abnormal	cells	are	detected.	Non-activated	or	resting	immune	cells	predominantly	rely	
on	OXPHOS	and	ETC	for	energy	production	since	they	do	not	depend	on	broad	anabolic	
processes.	 An	 activated	 immune	 cell	 requires	 an	 increased	 energy	 production	 with	
upregulated	metabolic	 pathways	 to	meet	 the	 extensive	pro-inflammatory	 signaling	 and	
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anabolic	processes.	Therefore,	upon	activation,	cells	switch	to	 increased	glycolysis	 rates	
for	 energy	 production,	 increased	 TCA	 cycle	 activity,	 glutaminolysis	 as	 well	 anabolic	
processes	 including	 the	 PPP.	 These	 mechanisms	 of	 increased	 energy	 pathways	 in	
activated	cells	are	observed	in	adaptive	immune	cells	 like	T	cell	and	B	cells	as	well	as	 in	
innate	 immune	 cells	 like	macrophages	 or	 NK	 cells	 [63],[76].	 Depending	 on	 the	 kind	 of	
energy	metabolism	the	cell	relies	on,	it	is	able	to	perform	specific	functions.	Without	the	
switch	 to	 an	 elevated	 energy	 metabolism,	 an	 immune	 cell	 could	 not	 implement	 pro-
inflammatory	signaling.	
Figure	4	 shows	a	brief	overview	of	 resting	and	active	 state	T	cell	 characteristics.	T	 cells	
that	 are	 in	 a	 more	 resting	 state	 include	 naïve	 T	 cells,	 memory	 T	 cells	 and	 resting	
regulatory	T	cells.	These	cell	populations	are	in	a	metabolically	latent	state	and	switch	to	
increased	 immunometabolism	 once	 they	 become	 activated	 [88].	 This	 increase	 in	
metabolic	 function	 is	 crucial	 for	 CD4+	 helper	 T	 cell,	 CD8+	 effector	 T	 cell	 and	 activated	
regulatory	 T	 cell	 function	 [73],[74]	 and	 allows	 memory	 T	 cells	 to	 undergo	 clonal	
expansion.	 Along	 with	 elevated	 immunometabolism,	 particularly	 glycolytic	 activity,	
intracellular	and	extracellular	pH	levels	increase	due	to	elevated	lactate	and	CO2	secretion	
from	 the	 cell.	 Furthermore,	 reactive	 oxygen	 species	 (ROS)	 increase	 indicating	
considerable	cellular	activity	and	stress.		Importantly,	in	healthy	individuals,	immune	cells	
are	able	to	modify	resting	and	active	states	depending	on	the	 immediate	requirements.	
After	antigen	clearance,	CD4+	helper	T	cells,	CD8+	effector	T	cells	and	 regulatory	T	cells	
are	able	to	return	to	their	resting	state.	This	leads	to	a	homeostasis	in	energy	metabolism	
that	 allows	 the	 appropriate	 function	 of	 immune	 response	 mechanisms	 and	 down-
regulation	of	pro-inflammatory	signaling	following	an	immune	attack.		
	
Figure	4:	Metabolism	drives	the	life	cycle	of	T	cells.	Overview	of	metabolic	states	in	activated	and	
resting	T	cells.	Resting	T	cells	are	more	prone	to	using	OXPHOS	and	FAS	for	meeting	their	energy	
demand.	ROS	 levels	are	not	elevated	and	pH	 is	not	decreased.	Naïve	T	 cells,	 resting	T	 regs	and	
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memory	T	cells	are	exemplarily	for	resting	T	cell	metabolism.	Their	overall	activity	is	lower	than	in	
activated	cells.	Cells	in	an	activated	metabolic	state	are	relying	more	on	glycolysis	and	FAO.	Their	
ROS	 as	 well	 as	 pH	 levels	 are	 increased	 -	 activated,	 proliferating,	 differentiating	 cells	 and	 cells	
undergoing	clonal	expansion	switch	to	this	active	state.	These	cells	include	effector	and	helper	T	
cells.	Their	overall	metabolic	sate	is	increased.	OXPHOS:	oxidative	phosphorylation,	FAS:	fatty	acid	
synthesis,	FAO:	fatty	acid	oxidation,	ROS:	reactive	oxygen	species,	T	reg:	regulatory	T	cells.	
The	maintenance	of	naïve,	effector,	regulatory	and	memory	T	cells	requires	cell-specific	
signaling.	Table	3	provides	a	detailed	overview	of	the	characteristic	metabolic	programs	
as	 well	 as	 the	 key	 metabolic	 regulators	 of	 CD4+	 T	 cell	 subtypes	 essential	 for	 the	
preservation	of	the	cell	type.	Key	metabolic	signaling	molecules	in	pro-inflammatory	T	cell	
activation	include	mTOR	(mammalian	target	of	rapamycin),	the	hormone	receptor	ERRα	
(estrogen	 receptor	α)	 and	 the	 transcription	 factor	HIF-1α	 (hypoxia-inducible	 factor-1α)	
(helper	 T	 cell	 subpopulations).	 AMPK	 (AMP-activated	 protein	 kinase)	 acts	 in	 immune-
suppressive	 and	 anti-inflammatory	 signaling	 pathways.	 These	metabolic	 regulators	 play	
central	 roles	 in	 immunometabolic	 cell	 signaling	 cascades	 and	 are	 essential	 in	 T	 cell	
homeostasis.	
Table	3:	CD4+	T	cell	subtypes	and	energy	metabolic	features.	Modified	based	on	
[39],[43],[47],[74].	
T	cell	type									 key	metabolic	regulator	 metabolic	program	
TN	 not	known	yet	 OXPHOS/glycolysis	
Th1	 mTORC1/ERRα	 glycolysis/FAS/AA	met.	
Th2		 mTORC2/ERRα	 glycolysis/FAS/AA	met.	
Th17		 mTORC1/ERRα/HIF-1α	 glycolysis/FAS/AA	met.	
T	regs		 AMPK	 OXPHOS/FAO	
TCM,	TEM,	TEMRA	 AMPK	and	others	 OXPHOS/FAO	
OXPHOS:	oxidative	phosphorylation,	FAS:	 fatty	acid	 synthesis,	FAO:	 fatty	acid	oxidation,	
AA	 met.:	 Amino	 Acid	 metabolism,	 Th:	 helper	 T	 cell,	 mTOR:	 mechanistic	 target	 of	
rapamycin,	ERR:	estrogen	receptor,	HIF-1α:	hypoxia-inducible	factor-1α,	FoxP3:	forkhead	
P3,	 AMPK:	 AMP-activated	 protein	 kinase,	 TN:	 naïve	 T	 cell,	 CM:	 central	 memory,	 EM:	
effector	memory,	 TEMAR:	 terminally	 differentiated	effector	memory	 cells	 re-expressing	
CD45RA.	
Just	 like	 CD4+	 T	 cell	 subsets,	 CD8+	 T	 cells	 rely	 on	 adaptations	 in	 energy	 metabolic	
pathways	and	show	comparable	metabolic	profiles.	Naïve	CD8+	T	cells	predominantly	use	
OXPHOS	and	glycolysis	to	meet	their	energy	demand	[89].	The	high	active	state	of	CD8+	
effector	 T	 cells	 demands	 elevated	 energetic	 requirements.	 Therefore,	 effector	 T	 cells	
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heavily	depend	on	glycolysis,	FAS	and	amino	acid	(AA)	metabolism	to	meet	their	energy	
demand.	 In	 contrast,	memory	CD8+	T	 cells	 require	 less	energy	and	depend	on	FAO	and	
OXPHOS	to	meet	their	energy	requirements	[90],[91].	Key	metabolic	regulators	in	CD8+	T	
cell	subsets	are	believed	to	be	similar	to	CD4+	T	cell	subsets,	but	have	yet	to	be	described	
in	detail	in	literature.	
Adaptations	in	energy	metabolism	of	B	cells	and	innate	immune	cells	have	been	reviewed	
extensively	 in	 [92]–[94].	 Comparable	 to	 the	 mechanisms	 observed	 in	 T	 cell	
subpopulations,	B	cells	and	innate	immune	cells	show	increased	glycolysis	and	FAS	in	pro-
inflammatory	cell	signaling	and	FAO	as	well	as	OXPHOS	in	latent	and	non-proliferative	cell	
populations.		
Taken	 together,	 immune	cells	are	 in	 constant	exchange	with	 their	metabolic	 regulatory	
systems	 in	 order	 to	 respond	 to	 the	 cellular	 requirements	 and	 defend	 the	 host	 against	
intruding	pathogenic	agents.	
To	date,	broad	research	has	shown	the	 interplay	between	metabolism	and	 immunity	 in	
healthy	individuals	and	research	is	evolving	in	analyzing	pathogenic	alterations	in	disease	
states.	Here,	autoimmune	diseases	like	MS	are	of	central	interest,	because	dysfunctional	
immune	activation	processes	may	show	direct	links	to	impaired	metabolic	signaling.		
Importantly,	 the	 interplay	of	physiological	and	psychological	 stress	 response	systems	as	
well	as	exhaustion	of	T	cells	due	to	prolonged	stimulation	and	activation	are	key	factors	
contributing	 to	 the	 pathology	 and	 symptoms	 of	 MS	 and	 have	 to	 be	 taken	 into	
consideration	when	discussing	the	essential	interplay	of	metabolism	in	MS	disease.		
1.3.3 HPA-axis	Stress	Response	Signaling		
One	 of	 the	 main	 stress	 response	 systems	 in	 the	 human	 body	 is	 the	 hypothalamus-
pituitary-adrenal	 (HPA)	 axis,	 which	 involves	 a	 cascade	 of	 mechanisms	 of	 hormone	
secretion	by	tissues	of	the	brain	and	kidney.		
The	 HPA	 axis	 is	 activated	 upon	 an	 encounter	 of	 an	 individual	 with	 a	 physiological	 or	
psychological	 stressor.	 It	 commences	 with	 the	 secretion	 of	 corticotropin-releasing	
hormone	 (CRH)	 by	 neuroendocrine	 neurons	 of	 the	 hypothalamus.	 Secondly,	 CRH	
stimulates	 adrenocorticotropic	 hormone	 (ACTH)	 secretion	 by	 the	 anterior	 lobe	 of	 the	
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pituitary	 gland.	 Lastly,	 ACTH	 acts	 on	 the	 adrenal	 cortex	 of	 the	 adrenal	 gland	 inducing	
glucocorticoid	 (GC)	 synthesis.	 The	 adrenal	 gland	 predominantly	 secrets	 the	GC	 cortisol,	
which,	 in	 a	 negative	 feedback	 loop,	 has	 the	 potential	 to	 act	 on	 the	 hypothalamus	 and	
pituitary	gland	preventing	CRH	and	ACTH	secretion.	For	clinical	analysis,	cortisol	levels	are	
mainly	measured	in	saliva	samples	from	individuals.	
GCs	 are	 one	 of	 the	 most	 potent	 hormones	 modulating	 pro-	 and	 anti-inflammatory	
processes	 in	 the	body	and	bind	 the	glucocorticoid	and	mineralocorticoid	 receptors.	The	
glucocorticoid	 receptor	 (GR)	 is	 found	 in	 the	 cytosol	 of	 various	 body	 cells	 including	
neurons	 and	 immune	 cells.	 In	 immune	 cells,	 GCs	 induce	 anti-inflammatory	 signaling	
pathways	 and	with	 that	 immunosuppression	 either	 by	 direct	 binding	 to	 proteins	 or	 by	
regulating	 gene	 expression	 of	 specific	 targets	 [95].	 One	 of	 the	 major	 mediators	 of	
immunosuppression	via	GCs	 is	 the	anti-inflammatory	protein	GC-induced	 leucine	 zipper	
(GILZ),	which	binds	 and	 inhibits	 one	of	 the	main	 pro-inflammatory	 signaling	molecules,	
NFκB	[96],[97].	The	comprehensive	mechanisms	by	which	GCs	induce	anti-inflammatory	
actions	in	cell	signaling	pathways	are	reviewed	extensively	by	Libert	and	Dejager	[98].		
In	 healthy	 individuals,	 the	 process	 of	 cortisol	 release	 and	 GC	 signaling	 allows	 the	
suppression	of	 immune	responses	 in	 favor	of	 the	activation	of	 the	sympathetic	nervous	
system	 and	 the	 physiological	 and	 psychological	 stress	 response.	 Once	 the	 stressor	 is	
absent,	cortisol	levels	decrease.	During	the	day,	cortisol	levels	peak	in	the	morning	before	
awakening	 and	 decrease	 over	 the	 course	 of	 the	 day	 with	 the	 lowest	 levels	 at	 night	
initiating	sleep.		
In	 autoimmune	 patients,	 alterations	 in	 HPA	 axis	 activity	 in	 combination	with	 increased	
disease	 levels	 have	 been	 shown	 alluding	 to	 a	 link	 between	 neuronal	 stress	 hormone	
signaling	and	immune	cell	function.	As	reviewed	by	Gold	et	al.,	hyperactivity	of	the	HPA	
axis	as	well	as	decreased	T	cell	sensitivity	to	GC	signaling	contributes	to	MS	disease	onset,	
development	and	progression	[99].	To	date,	GCs	have	been	shown	to	impact	helper	T	cell	
activation,	differentiation	and	proliferation,	which	are	key	processes	in	immune	response	
mechanisms	 and	metabolic	 functionality	 [100].	 Furthermore,	 the	prolonged	 stimulation	
and	activation	of	T	cells	is	associated	with	cellular	exhaustion	mechanisms,	which	can	be	
driven	forward	by	systemically	altered	stress	response	systems.		
The	 relevance	of	T	 cell	 exhaustion	 in	 the	 context	of	 immunometabolism	 is	discussed	 in	
the	subsequent	text.	
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1.3.4 T	cell	Exhaustion		
T	cell	exhaustion	describes	the	process	of	prolonged	cellular	stimulation	over	weeks	and	
months.	 It	coincides	with	the	expression	of	specific	 inhibitory	cell	 surface	receptors,	 for	
example	cytotoxic	T	lymphocyte	associated	protein	4	(CTLA-4),	T	cell	immunoglobulin	and	
mucin	 domain	 containing	 protein	 3	 (TIM-3),	 B	 and	 T	 lymphocyte	 attenuator	 (BTLA),	
lymphocyte	activation	gene	3	 (LAG-3)	or	programmed	cell	death-1	 (PD-1)	 [101],[102].	T	
cell	 exhaustion	 can	 be	 induced	 during	 or	 after	 chronic	 infections	 and	 cancer	 involving	
persistent	 and	 ongoing	 antigen	 exposure	 and	 overall	 inflammation.	 The	 state	 of	 T	 cell	
exhaustion	prevents	the	induction	of	an	optimal	immune	response	to	infection	or	tumor.	
However,	this	state	has	been	shown	to	be	reversible	and	immune	re-activation	possible,	if	
the	pathways	 involved	 in	T	cell	exhaustion	are	modulated	 (e.g.	via	PD-1)	 [103],[104].	 In	
their	2015	review,	Wherry	and	Kurachi	discuss	the	evolutionary	and	biological	significance	
of	the	state	of	T	cell	exhaustion	[105].	Exemplarily,	the	authors	point	out	that	exhausted	T	
cells	are	not	inert	and	have	been	shown	to	posses	specific	functions	like	the	containment	
of	 chronic	 infections,	 the	potential	of	driving	epitope	mutation	 in	 chronic	 infections,	or	
the	 prevention	 of	 tissue	 damage.	 Overall,	 from	 an	 evolutionary	 standpoint,	 a	 host-
pathogen	 balance	 is	 established	 in	 persisting	 infections	 allowing	 immune	 control	 and	
preventing	 uncontrolled	 pathogen	 replication.	 Importantly,	 inhibitory	 cell	 surface	
receptors	 are	 crucial	 regulators	 or	 auto-reactivity	 and	 are	 essential	 in	 preventing	
autoimmunity	[106].	
Immunometabolic	 signaling	 and	 stress	 response	 systems	 are	 key	 characteristics	
contributing	to	exhaustion	as	well	as	overall	altered	immune	cell	function	and	need	to	be	
considered	in	autoimmune	diseases	like	MS.		
1.4 Multiple	Sclerosis	and	Immunometabolism	
In	the	past	decades,	extensive	research	demonstrated	that	 immune	cells	of	MS	patients	
are	self-reactive	and	cause	dramatic	damage	in	the	body	over	long	periods	of	time	with	
phases	of	remission	and	relapses	 in	RRMS	patients.	As	described	previously,	the	precise	
causes	of	MS	and	factors	leading	to	relapses	in	RRMS	are	not	fully	understood	yet	(1.1.1),	
however,	 research	 results	 strongly	 suggest	 dysregulated	 pro-inflammatory	 immune	 cell	
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processes.	 Activated	 immune	 cells	 require	 altered	 metabolic	 pathways	 and	 signaling	
cascades	 and	 therefore	 have	 to	 be	 considered	 in	 MS	 disease	 development	 and	
progression.	
T	cells	have	successfully	become	one	of	the	main	targets	for	therapies	and	mechanisms	of	
action	of	prospective	drugs	continue	to	be	studied	extensively.	Immunometabolic	profiles	
of	 immune	cells	 from	MS	patients,	especially	of	T	 cell	 subtypes,	need	 to	be	 considered	
and	 the	 impact	of	energy	metabolism	recognized	as	a	potent	disease	 influencing	 factor	
and	potential	target	for	therapies	in	the	future.		
To	date,	immunometabolic	function	has	mostly	been	researched	in	the	murine	model	of	
MS,	the	experimental	autoimmune	encephalomyelitis	(EAE).	In	mice,	EAE	can	be	induced	
by	 immunization	 with	 myelin-specific	 antigen	 and	 adjuvants	 [107],[108].	 EAE	 presents	
with	 complex	 immunopathological	 and	 neuropathological	 conditions	 that	 have	 been	
shown	 to	 be	 comparable	 to	 the	 key	 pathological	 symptoms	 observed	 in	 MS,	 namely	
systemic	 inflammation	 and	 CNS	 neuronal	 demyelination	 [108].	 In	 the	 murine	 model,	
several	factors	benefiting	a	positive	course	of	disease	and	decline	of	symptoms	as	well	as	
complete	 reduction	 of	 EAE	 disease	 have	 been	 observed.	 For	 example,	 fasting	 (no	 food	
intake	for	up	to	16	hours)	and	ketogenic	diet	(strong	reduction	of	carbohydrates	in	diet)	
have	 proven	 to	 alleviate	 EAE	 symptoms,	 reduce	 pro-inflammatory	 cytokines	 as	well	 as	
antigen	presenting	and	Th1	and	Th17	T	cells,	while	inducing	an	increase	of	T	regs	[109].	
These	positive	effects	of	adaptations	in	diet	have	also	been	studied	in	murine	models	of	
other	autoimmune	diseases	like	Systemic	Lupus	Erythematosus	(SLE)	and	have	proven	to	
benefit	 the	 disease	 course	 [110].	 A	 comprehensive	 review	 describing	 the	 link	 between	
metabolism	 and	 immune	 function	 including	 cytokine	 and	 hormone	 effects	 by	 specific	
innate	and	adaptive	 immune	cells	was	 recently	published	by	Alwarawrah	et.	 al	 in	2018	
[111].	 The	 authors	 describe	 in	 detail	 that	 impaired	metabolic	 signaling	 interplays	 with	
immune	 function,	 is	 linked	 to	 autoimmunity	 and	 possesses	 potentials	 for	 therapy	 in	
autoimmune	 diseases.	 Furthermore,	 the	 positive	 effects	 of	 autophagy	 in	 inflammatory	
processes	 and	 auto-immunity	 have	 been	 described	 [112].	 Autophagy	 is	 defined	 as	 an	
evolutionary	 conserved	 process	 of	 cellular	 self-renewal	 by	 lysosomal	 degradation	 of	
macromolecules	 thereby	 eliminating	 waste	 products	 and	 maintaining	 the	 metabolic	
homeostasis	 [113]–[115].	 Proteins	 associated	 with	 autophagy	 processes	 orchestrate	
responses	to	nutrient	deprivation	as	well	as	pathogens.	First	studies	describe	the	positive	
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contributions	of	a	fasting	diet	to	cellular	autophagy	processes	and	anti-inflammation	with	
that	 indicating	 the	 potential	 for	 reestablishing	 impaired	 metabolic	 balance	 in	 immune	
cells	[116]–[119].	
To	date,	there	are	few	studies	on	the	mechanisms	of	immunometabolism	in	MS	disease	in	
humans.	 Impairments	 in	 mitochondrial	 respiration	 and	 glycolytic	 activity	 has	 been	
observed	in	PBMCs	from	MS	patients	[120].	In	2015,	De	Riccardis	and	colleagues	showed	
impairments	in	CD4+	T	cells	from	RRMS	patients	with	decreased	mitochondrial	respiration	
and	 increased	 glycolytic	 activity	 [121].	 These	 studies	 provide	 first	 insights	 into	 human	
immune	 cell	metabolism	 in	RRMS	patients	 and	allude	 to	overall	 impairments	 in	 energy	
metabolism.	
Along	with	energy	metabolic	pathways,	 the	HPA	axis	stress	response	system	has	shown	
strong	 interactions	with	 immune	cell	activation	and	pro-inflammatory	signaling.	Cortisol	
binds	 to	 the	 GR	 of	 immune	 cells	 and	 induces	 decreased	 pro-inflammatory	 signaling	
cascades.	Importantly,	in	immune	cells,	the	frequent	induction	of	the	GR	can	lead	to	the	
down-regulation	 of	 the	 receptor	 by	 the	 cell.	 Thereby,	 the	 cell	 possesses	 the	 ability	 to	
escape	 the	 induction	 of	 anti-inflammatory	 signaling	 via	 the	 HPA	 axis	 and	 cortisol	
hormone.	In	MS	patients,	alterations	in	HPA	axis	activity	have	been	shown,	including	the	
down-regulation	of	 the	GR	and	associated	proteins	 [122].	Alterations	 in	stress	 response	
systems	 and	 pro-inflammatory	 signaling	 in	 immune	 cells	 impact	 cellular	 energy	
metabolism	and	should	therefore	be	considered	in	autoimmunity.	
These	 first	 studies	 in	 murine	 models	 and	 MS	 patients	 strongly	 allude	 to	 overall	
impairments	in	immunometabolic	cell	signaling	and	energy	transduction	pathways.	They	
provide	firm	data	for	future	analyses	of	metabolic	dysfunctions	in	MS	disease.		
Particularly,	 mitochondrial	 function	 in	 T	 cells	 of	 MS	 patients	 in	 the	 context	 on	 pro-
inflammatory	cell	signaling	needs	to	be	studied	and	its	potential	for	therapeutic	targets.	
Here,	 inflammatory	 signaling,	 cellular	 exhaustion	 pathways	 and	 stress	 response	
mechanisms	including	CNS	hormone	signaling	strongly	impact	energy	pathways	and	need	
to	be	studied	collectively	when	analyzing	MS	disease	development	and	progression.		
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1.5 Aims	
The	aim	of	this	dissertation	was	the	investigation	of	human	immune	cell	subpopulations	
from	 RRMS	 patients	 linking	 energy	 metabolism	 pathways,	 mitochondrial	 function,	
inflammatory	signaling	and	stress	response	mechanisms.		
Energy	metabolism	profiles	of	CD4+	T	cells,	CD8+	T	cells	and	non-	CD4+/CD8+	T	cells	were	
compared	between	RRMS	patients	and	HC	participants.	Three	main	aims	were	defined,	as	
shown	graphically	in	Figure	5.		
	
Figure	 5:	 Model	 of	 Immunometabolic	 Signaling.	 The	 model	 includes	 three	 aims	 that	 were	
analyzed	as	part	of	this	dissertation.	Aim	1:	energy	metabolic	analyses	using	the	Seahorse	96eXF	
Analyzer	 and	 mitochondrial	 stress	 test	 kit.	 Aim	 2:	 gene	 expression	 mRNA	 analysis	 of	 CPT1a,	
GLUT1,	NFκB1,	NF-κB3,	TNFα,	GR,	GILZ.	Aim	3:	flow	cytometry	analyses	of	chemokine	receptors	
as	 well	 as	 PD-1	 and	 CPT1a.	 Molecules	 in	 red	 show	 glycolysis-inducing	 signaling,	 molecules	 in	
orange	 demonstrate	 an	 induction	 in	 mitochondrial	 respiration.	 AKT:	 protein	 kinase	 B,	 AMPK:	
AMP-activated	protein	kinase,	CPT1a:	Carnitine	palmitoyltransferase	I	isoform	a,	CCR:	chemokine	
receptor,	 CD:	 cluster	 of	 differentiation,	 ETC:	 electron	 transport	 chain,	 FA:	 fatty	 acid,	 GLUT1:	
glucose	transporter	1,	NF-κB:	nuclear	factor	'kappa-light-chain-enhancer'	of	activated	B-cells,	PD-
1:	 programmed	 cell	 death-1,	 TCA:	 Tri-citric	 acid,	 TCR:	 T	 cell	 receptor,	 TNF-α:	 tumor	 necrosis	
factor-α.	
First,	mitochondrial	respiration	and	glycolytic	function	in	these	three	subpopulations	was	
assessed	using	 the	 Seahorse	 XFe96	Analyzer	 providing	 information	 about	mitochondrial	
activity.	 Secondly,	 qRT-PCR	 gene	 expression	 analyses	 provided	 information	 about	 key	
regulators	 in	 cellular	 inflammatory,	metabolic	 and	 stress	 response	 signaling.	 Lastly,	 the	
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third	 aim,	 flow	 cytometry	 analyses	 provided	 data	 on	 the	 PBMC	 phenotype	 make-up	
(chemokine	 receptor	 analyses),	 extracellular	 PD-1	 T	 cell	 exhaustion	 surface	 marker	
analyses	as	well	as	intracellular	mitochondrial	membrane	protein	CPT1a	analyses.		
These	three	aims	link	mitochondrial	and	glycolytic	activity	to	gene	and	protein	expression	
of	 key	 energy,	 inflammatory	 and	 cortisol	 pathway	 genes	 in	 human	 immune	 cells.	 They	
provide	information	about	the	immunometabolic	networks	and	hormone	regulators	on	a	
protein	and	gene	expression	level	as	well	as	providing	information	about	the	interaction	
with	cellular	respiration.	
To	gain	biomaterial	 from	RRMS	patients	and	matched	HC	participants,	the	clinical	study	
Depression	 and	 Immune	 Function	 (DENIM)	was	 initiated	 and	 conducted	 as	 part	 of	 this	
dissertation.	 PBMCs	 were	 prepared	 for	 analyses	 and	 case	 report	 form	 assessments	
provided	information	about	RRMS	disease	parameters	as	well	as	additional	physiological	
and	psychological	 disease	 indications.	 Furthermore,	 saliva	 samples	 from	RRMS	patients	
and	 HC	 participants	were	 analyzed	 for	 cortisol	 levels	 providing	 information	 about	 HPA	
axis	activity	in	both	cohorts	and	linking	immunometabolism	to	CNS	hormone	signaling.	
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2 Materials	and	Methods	
2.1 							Clinical	Study	Depression	and	Immune	Function	(DENIM)	
2.1.1 	Background	and	Aim	of	the	Clinical	Study	DENIM	
As	 described	 in	 1.1,	 Multiple	 Sclerosis	 (MS)	 is	 a	 neurodegenerative	 disease	 strongly	
associated	with	auto-reactive	immune	cell	activation.	The	main	symptoms	of	MS	include	
motor	 deficits,	 cognitive	 impairments,	 decreased	 ability	 to	 focus	 and	 concentrate,	
depression	as	well	as	an	overall	inflammatory	phenotype.		
The	aim	of	the	clinical	study	Depression	and	Immune	Function	(DENIM)	was	to	gain	first	
insights	 into	 the	 underlying	 biological	 mechanisms	 of	 immune	 cell	 activation	 and	
neuropsychiatric	symptoms	in	patients	diagnosed	with	RRMS	with	and	without	comorbid	
major	 depressive	 disorder	 (MDD).	 The	 main	 interest	 was	 the	 analysis	 of	
immunometabolic	 mechanisms	 related	 to	 physiological	 as	 well	 as	 psychological	
symptoms.		
2.1.2 DENIM	Study	Organization	and	Set-up	
2.1.2.1 Study	Organization	
The	study	was	approved	by	the	ethics	committee	of	the	Charité	University	Medical	Center	
Berlin	 on	May	 21st	 2015	 (application	 number:	 EA1/096/15).	 Data	 protection	 of	 patient	
and	healthy	control	(HC)	participant	information	is	guaranteed	based	on	the	Charité	Data	
Protection	 Statement.	 The	 study	 is	 listed	 on	 www.clinicaltrials.gov	 with	 the	 ID:	
NCT02740296.		
All	MS	patients	were	assessed	at	the	Neuro	Cure	Clinical	Research	Center	(NCRC)	(head:	
Prof.	 Dr.	 med.	 Friedemann	 Paul)	 at	 the	 Charité	 Campus	 Mitte,	 Berlin.	 HC	 participants	
were	assessed	at	the	NCRC	as	well	as	at	the	Department	of	Psychiatry	and	Psychotherapy,	
work	 group	 Neuropsychiatry	 (head:	 Prof.	 Dr.	 Stefan	 Gold),	 at	 the	 Charité	 Campus	
Benjamin	Franklin,	Berlin.	
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2.1.2.2 Study	Visit	Set-up	
DENIM	is	a	cross	sectional	clinical	study	with	a	one-time	study	visit.	MS	patients	and	HC	
participants	 came	 into	 the	 clinic	 for	 the	 assessment,	 which	 included	 a	 blood	 draw,	
analysis	of	vital	parameters,	cognitive	tests,	demographic,	psychological	and	physiological	
health	 questionnaires	 and	 a	 structured	 clinical	 interview	 assessing	 the	 psychological	
health.	 Furthermore,	 all	 patients	 and	 participants	 took	 saliva	 samples	 in	 the	 two	 days	
following	the	study	visit.	The	visit	was	scheduled	between	8	am	and	10	am.	Patients	and	
participants	 came	 in	 for	 a	 fasting	 blood	draw	after	 not	 having	 eaten	 for	 12	 hours.	 The	
study	 was	 conducted	 in	 German	 and	 all	 questionnaires	 were	 in	 German.	 Patients	 and	
participants	were	all	native	German	speakers	or	had	language	levels	of	a	native	speaker.	
An	overview	of	all	 study	visit	assessments	 is	given	 in	Table	5	and	complete	case	 report	
form,	telephone	screening	sheets	and	salivary	sample	collection	sheets	in	Appendix.		
2.1.2.3 Inclusion	and	Exclusion	Criteria	
The	 study	 analyzed	 RRMS	 patients	 and	 carefully	 matched	 HC	 participants.	 Men	 and	
women	between	the	ages	of	18	and	55	were	included	in	the	study.	The	DENIM	study	was	
set-up	to	analyze	four	patient	cohorts:	1)	MS	patients	with	a	confirmed	diagnosis	of	RRMS	
and	no	current	or	past	history	of	MDD	(cohort	RRMS),	2)	MS	patients	with	a	confirmed	
diagnosis	 of	 RRMS	 and	 a	 current	 diagnosis	 of	 MDD	 (cohort	 RRMS+MDD),	 3)	 patients	
suffering	 from	MDD	 and	 no	 commodities	 of	 the	 immune	 system	 (cohort	MDD)	 and	 4)	
healthy	control	participants	(cohort	HC).	For	this	dissertation,	the	cohorts	RRMS	and	HC	
were	recruited	and	analyzed	and	information	given	here	are	related	to	these	two	cohorts.	
A	 full	 list	 of	 inclusion	 and	 exclusion	 criteria	 for	 MS	 patients	 and	 HC	 participants	 is	
provided	in	Table	4.	
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Table	 4:	 Inclusion	 and	 exclusion	 criteria	 of	 the	 clinical	 study	 Depression	 and	 Immune	
System	for	RRMS	patients	and	healthy	control	participants.	
Inclusion	criteria	 Exclusion	criteria	
• confirmed	 diagnosis	 of	 RRMS;	 no	
immune	modulatory	 therapy	 or	 stable	
immune	 modulatory	 therapy	 for	 at	
least	6	months		
• Infection	within	the	past	2	months	(e.g.	
the	 flu,	 a	 cold,	 a	 stomach	 virus	
infection)	
• Between	18	and	55	years	of	age	 • Pregnancy	
• BMI	≤	30	 • Epilepsy,	 Schizophrenia	 or	 other	
neurological	or	psychiatric	diseases	
• No	 steroid	 treatment	 for	 the	 past	 3	
months	
• Rheumatism,	 Lupus	 or	 any	 other	
immune	diseases	
• No	vaccination	in	the	past	3	months	 • Diabetes	
• Fasting	 blood	 draw	 after	 not	 having	
eaten	for	12	hours	
• HIV	or	Hepatitis	infection	
	 • Myocardial	 infarct	 or	 cardiovascular	
disease		
• Stroke	
• Head	injury	with	lasting	impairments	
• Treatment	 with	 any	 of	 these	 drugs:	
anti-psychotics,	 antidepressants,	
insulin,	anti-epileptic	medicines	
• Medicines,	 alcohol	 or	 drug	 abuse	
within	the	past	year	
• Participant	in	an	interventional	study	
HC:	 Healthy	 Control,	 RRMS:	 Relapsing	 Remitting	 Multiple	 Sclerosis,	 BMI:	 Body	 Mass	
Index,	HIV:	Human	Immunodeficiency	Virus.	
2.1.2.4 Telephone	Screening	for	Study	Eligibility		
An	 extensive	 telephone	 screening	 was	 conducted	 with	 every	 MS	 patient	 and	 HC	
participant	 in	order	to	verify	 inclusion	and	exclusion	criteria	for	the	study	(Table	4).	The	
MS	patients’	screenings	were	performed	by	the	same	interviewer	(Aline	Tänzer,	AT)	and	
HC	participants	screenings	by	AT	and	trained	staff.	Taken	together,	approximately	450	MS	
patients	and	300	HC	participants	were	contacted.	
2.1.2.5 Case	Report	Forms	–	Questionnaires,	Assessments,	Tests	
Case	 Report	 Forms	 (CRF)	 were	 conceptualized	 based	 on	 the	 study	 aims	 as	 well	 as	
inclusion	 and	 exclusion	 criteria	 (Table	 4).	 The	 assessments	 performed	 with	 the	 MS	
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patients	and	HC	participants	are	listed	in	Table	5.	Only	the	questionnaires	specific	for	the	
analyzed	cohorts	in	this	thesis	were	investigated.	HC	participants	did	not	perform	the	MS	
specific	 neurological	 tests	 Multiple	 Sclerosis	 Functional	 Composite	 (MSFC),	 Expanded	
Disability	Status	Scale	 (EDSS)	and	Hamburger	Lebensqualitätsfragebogen	 (HALEMS).	The	
CRFs	were	conceptualized	in	cooperation	with	the	NCRC.	Trained	personnel	performed	all	
cognitive	tests	and	clinical	assessments	(including	AT).	 
Table	5:	Clinical	assessments	of	RRMS	patients	and	HC	participants	in	a	study	site	visit	in	
the	clinical	study	Depression	and	Immune	Function.		
Cognitive	Tests:	
Multiple	Sclerosis	Functional	Composite	(MSFC	[214])a	
Expanded	Disability	Status	Scale	(EDSS	[135])a	
Oral	Symbol	Digit	Modality	Test	(oral	SDMT	[134])	
Demographical,	Psychological	and	Physiological	Questionnaires:	
Demography	questionnaire	
Beck’s	Anxiety	Index	(BAI	[133,	216])	
Beck’s	Depression	Index	II	(BDI-II	[132,	217])	
Fatigue	Scale	for	Motor	and	Cognitive	Function	(FSMC	[220])	
Fatigue	Severity	Scale	based	on	Krupp	(FSS	[221])	
Hamburger	Lebensqualitätsfragebogen	(HALEMS	[222])a	
Childhood	Trauma	Questionnaire	(CTQ	[223])	
Clinical	Interview	Assessment		
Mini	International	Neuropsychiatric	Interview	German	version	5.0.0	DSM-IV	(M.I.N.I.)	
[131]	additional	questions	from	the	Diagnostic	and	Statistical	Manual	of	Mental	
Disorders	Version	5	(DSM-V)	
Montgomery-Åsberg	Depression	Rating	Scale	(MADRS	[130])	
a	MSFC,	EDSS	and	HALEMS	were	not	assessed	with	or	by	HC	participants.	RRMS:	Relapsing	
Remitting	Multiple	Sclerosis,	HC:	Healthy	Control.	
2.1.2.6 Biological	Material	Collected	
For	 routine	 blood	 analyses,	 whole	 blood	 samples	 were	 analyzed	 by	 a	 routine	 blood	
diagnostic	 laboratory	 (Labor	 Berlin,	 Berlin).	 A	 summary	 of	 items	 analyzed	 is	 given	 in	
supplementary	 Table	 19.	 For	 research	 analyses,	 whole	 blood	 was	 prepared	 by	 trained	
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scientists	following	strict	standard	operating	procedures	(see	2.3.1.1	Cryo-preservation	of	
Peripheral	 Blood	 Mononuclear	 Cells	 ).	 Saliva	 samples	 for	 cortisol	 analyses	 were	
completed	by	the	MS	patients	and	HC	participants	independently	at	home	after	given	the	
appropriate	 instructions	 (see	 2.3.5	 ELISA	 Analyses	 of	 Salivary	 Cortisol	 Hormone	 and	
Appendix	for	CRF	salivary	collection	sheet).		
2.1.3 DENIM	Study	Recruitment	Period	and	Outcome	
The	DENIM	study	was	launched	with	the	first	patient	site	visit	on	November	24th	2015.	
The	study	ended	with	the	last	patient	out	on	June	1st	2017.		
2.1.3.1 Recruitment	Period	
During	 the	 recruitment	 time,	 a	 total	 of	 52	 study	 visits	 for	 RRMS	patients	 and	 50	 study	
visits	 of	HC	 participants	were	 performed.	 	Of	 these,	 14	 RRMS	patients	were	 ‘drop-out’	
patients,	 i.e.	 patients,	 who	 had	 to	 be	 excluded	 after	 the	 study	 visit,	 because	 the	 data	
showed	current	substance	abuse,	a	previous	MDD	diagnosis,	dysthymia	or	a	psychosis	–	
patient	information	that	had	not	been	revealed	during	the	telephone	screening.			
2.1.3.2 Sample	Analysis	
Generally,	 about	80	mL	of	 fresh	whole	blood	was	drawn	 from	each	MS	patient	and	HC	
participant	and	between	8x107	and	12x107	Peripheral	Blood	Mononuclear	Cells	(PBMCs)	
could	 be	 isolated.	 Aliquots	 of	 1x107	 cells/cryo	 tube	 were	 frozen	 and	 stored	 in	 liquid	
nitrogen.	Saliva	samples	of	MS	patients	and	HC	participants	were	prepared	and	stored	at		
-20°C	until	analysis.		
All	 CRF	 data	 were	 computerized	 and	 statistics	 were	 performed	 using	 SPSS	 (IBM).	
Furthermore,	 statistics	 and	 graphical	 figures	 were	 completed	 using	 GraphPad	 Prism	
(GraphPadSoftware	Inc.).		
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2.2 	Materials		
All	companies	listed	are	located	in	Germany,	except	if	noted	otherwise.	
2.2.1 Laboratory	Equipment	
A	list	of	all	laboratory	equipment	used	for	the	dissertation	is	given	in	Table	6.	
Table	6:	Laboratory	equipment.	
Autoclave	24	 Melag,	Berlin	
Centrifuge	Megafuge	2.0	R	 ThermoFisher,	Life	Technologies,	Berlin	
CO2-Incubator	Hera	cell	240	 ThermoFisher,	Life	Technologies,	Berlin	
Flow	Cytometer	FACS	Canto	II™	 Becton	Dickinson,	Heidelberg	
GeneAmp®	PCR	Systems	9700	 Applied	Biosystems,	ThermoFisher,	Life	
Technologies,	Berlin	
Invers-Microscope	Axiovert	10	 Zeiss,	Jena	
NanoDrop™2000c	
Spectralphotometer	
ThermoFisher,	Life	Technologies,	Berlin	
Non-CO2	Incubator	Biometra	APT	
Line	
Binder,	Tuttlingen	
pH-Meter	766	Calimatic	 Knick,	Berlin	
Pipettes	 Eppendorf,	Hamburg		
Quadro	MACS	Seperator	 MACS,	Miltenyi	Biotech,	Bergisch	Gladbach	
Sterile	Laboratory	Bench	Hera	Safe	 ThermoFisher,	Life	Technologies,	Berlin	
Step	One	Plus	Real	Time	PCR	
Systems	
Applied	Biosystems,	ThermoFisher,	Life	
Technologies,	Berlin	
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2.2.2 Glass	and	Plastic	Equipment	
A	list	of	all	glass	and	plastic	ware	used	for	the	dissertation	is	provided	in	Table	7.	
Table	7:	Glass	and	plastic	equipment.	
Cell	Culture	Flask	275	mL	 Sarstedt,	Nürmbrecht	
Cell	Culture	Plate	6-well	 Greiner	bio-one,	Frickenhausen	
Cell	Cryo	1°C	freezing	container,	Mr.	Frosty™	 Nalgene®,	Roskilde,	Denkmark	
Cell	Strainer	35	µm	FACS	tubes	 ThermoFisher,	Life	Technologies,	Berlin	
Cryo	Tubes	 ThermoFisher,	Life	Technologies,	Berlin	
Eppendorf	Reaction	TZZSubes	(1.5	&	2	mL)	 Sarstedt,	Nürmbrecht	
Flow	Cytometry	tubes	 Sarstedt,	Nümbrecht	
Glass	Pipettes	 Sarstedt,	Nürmbrecht	
MACS	LS	Colums	 MACS,	Miltenyi	Biotech,	Bergisch	
Gladbach	
MicroAmp®	Fast	Optical	96-Well	Reaction	
Plate	
ThermoFisher,	Life	Technologies,	Berlin	
Neubauer	Counting	Chamber																						
(0.1-0.0025	mm2)	
Hecht-Assistent,	Sondheim	
Pasteur	Glass	Pipettes	1	mL	 ThermoFisher,	Life	Technologies,	Berlin	
Salivetten	 Sarstedt,	Nümbrecht	
Seahorse	Calibration	Plate	 Agilent,	Waldbronn	
Seahorse	Cell	Culture	Plate		 Agilent,	Waldbronn	
Single	Use	Pipettes	(5	mL,	10	mL,	25	mL)	 Becton	Dickinson,	Heidelberg	
Sterile	Filter	(0.22	µm)	 Millipore,	Schwalbach	
Syringe	30	mL	 Becton	Dickinson,	Heidelberg	
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2.2.3 Reagents	and	Chemicals	
All	chemicals	and	reagents	used	are	listed	in	Table	8.		
Table	8:	Reagents,	chemicals	and	analysis	kits.	
Anti-Mouse	Ig,	κ/Negative	Control	
Compensation	Particles	Set		
Becton	Dickinson,	Heidelberg,	Germany	
a-CD28	 eBioscience,	ThermoFisher,	Berlin	
Biocoll	 Merck,	Biochrom,	Darmstadt,	Germany	
Bovine	Serum	Albumin	 Serva,	Heidelberg	
Cortisol	Detection	Kit	 IBL,	Hamburg	
DMSO	 § AppliChem	GmbH,	Darmstadt	
FCCP	 Agilent,	Waldbronn	
FCS	S0115/1318D	 Merck,	Biochrom,	Darmstadt,	Germany		
Glucose	 Sigma,	Eisenhofen	
L-Glutamine	 ThermoFisher,	Life	Technologies,	Berlin	
MACS	BSA	stock	solution	 Miltenyi,	Bergisch	Gladbach	
Auto	MACS	Rinsing	Solution	 MACS,	Miltenyi	Biotech,	Bergisch	
Gladbach	
MACS	BSA	Stock	Solution	 MACS,	Miltenyi	Biotech,	Bergisch	
Gladbach	
Oligomycin	 Agilent,	Waldbronn	
OKT,	a-CD3	clone	 eBioscience,	ThermoFisher,	Berlin	
4%	Paraformaldehyde	solution	in	1x	PBS	 Santa	Cruz	Biotechnology,	Heidelberg	
1x	PBS	 Gibco,	Life	Techonogies,	Berlin,	Germany	
Perm/Wash,	Cytofix/Cytoperm	 Becton	Dickinson,	Heidelberg	
Rotenone	antimycin	A	 Agilent,	Waldbronn	
RPMI	1640	Medium,	GlutaMAX™	
Supplement	
GIBCO,	Life	Technologies,	Berlin,	Germany	
Seahorse	XF	Base	Medium	 Agilent,	Waldbronn	
Sodium	Azide	 Sigma,	Eisenhofen	
Sodium	Pyruvate	 ThermoFisher,	Life	Technologies,	Berlin	
Trypan	Blue	 Sigma,	Eisenhofen		
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2.2.4 Cell	Culture	Media	
Cell	culture	medium	 Seahorse	mitochondrial	stress	test	medium	
RPMI	1640	Medium,	GlutaMAX™	
supplement:	
Seahorse	XF	Base	Medium	
110.4	g/mol	Sodium	Pyruvate	
10	%	FCS	 10	mM	Glucose	
	 2	mM	L-	Glutamine	
	 	
Cell	freezing	medium	 	
RPMI	1640	Medium,	GlutaMAX™	
supplement:	
	
25	%	FCS	 	
10	%	DMSO	 	
	
2.2.5 Materials	for	RNA	isolation	and	cDNA	Synthesis	
Materials	and	kits	used	for	ribonucleic	acid	(RNA)	isolation	and	complementary	deoxy-
ribonucleic	acid	(cDNA)	synthesis	are	listed	in	Table	9.	
Table	9:	RNA	isolation	and	cDNA	synthesis	kits	and	reagents.	
RNAlater	 ThermoFisher,	Life	Technologies,	Berlin	
RNeasy	Plus	Universal	Mini	Kit	 Qiagen,	Hilden	
cDNA	synthesis	kit	 ThermoFisher,	Life	Technologies,	Berlin	
	
2.2.6 Materials	and	Reagents	for	qRT-PCR	Analyses	
All	materials	and	reagents	for	quantitative	real	time-polymerase	chain	reaction	(qRT-PCR)	
analyses	were	supplied	by	ThermoFisher	Scientific,	Life	Technologies,	Berlin	(Table	10).	
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Table	10:	qRT-PCR	materials	and	reagents.	a	
TaqMan	Gene	Expression	Kit																																																		
TaqMan	Gene	Expression	Master	Mix																																		
TaqMan	Gene	Probe	 									Gene	Name	 Taq	Man	ID	
GLUT1	 SLC2A1		 Hs00892681_m1	
TNF	alpha	g1	 Tumor	Necrosis	Factor		 Hs01113624_g1	
CPT1a	 CPT1a	 Hs00912671_m1	
NFκB1	 Nuclear	Factor	kappa	B	subunit	1	 Hs00765730_m1	
NFκB3	p65	subunit	 RELA	proto-oncogene,	NFκB-subunit	 Hs00153294_m1	
GR	 NR3C1	 Hs00353740_m1	
GILZ	 TSC22	domain	family	member	3	 Hs00608272_m1	
TBP	 TATA	Box	Binding	Protein	 Hs00427620_m1	
Importin	8	 IPO8	 Hs00183533_m1	
a	all	supplied	by	ThermoFisher,	Life	Technologies,	Berlin.	
The	CPT1a	gene	probe	binds	 five	different	 reference	sequences	 [123]	 including	the	one	
detected	by	the	flow	cytometry	CPT1a	antibody.	For	NFκB	expression	analysis,	two	subunits	
were	 chosen	 due	 to	 the	 complexity	 of	 the	 functional	 protein.	NFκB3	 (subunit	 p65)	 most	
commonly	forms	the	functional	dimer	of	the	final	protein	along	with	NFκB	1	(subunit	p50).	
2.2.7 Buffer	and	Stock	Solutions	for	Magnetically	Activated	Cell	Sorting	and	Flow	
Cytometry	Analyses	
	
	
	
	
	
	
MACS	buffer	
5	%	MACS	BSA	Stock	Solution	
in	Auto	MACS	Rinsing	Solution	
Flow	cytometry	buffer	
1	x		PBS	
0.5	%	BSA	
0.02	%	Sodium	Azide	
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2.2.8 Magnetically	Activated	Cell	Sorting	and	Flow	Cytometry	Antibodies	
A	 full	 list	 of	 antibodies	 used	 for	 magnetically	 activated	 cell	 sorting	 (MACS)	 and	 flow	
cytometry	analyses	is	provided	in	Table	11	and	Table	12	respectively.	
Table	 11:	 List	 of	 antibodies	 used	 for	Magnetically	 Activated	 Cell	 Sorting	 (MACS)	 and	
flow	cytometry.	
MACS	antibodies	 	
antigen	 linked	to	 						clone	 concentration	 company	
CD4	 	Micro	beads	 							n/a	 									1:5	 Miltenyi,	Biotech	
GmbH,	Bergisch	
Gladbach	CD8	 	Micro	beads	 							n/a	 									1:5	
Flow	cytometry	analysis	antibodies	
antigen	 linked	to	 clone	 concen
tration	
company	
CPT1a	 AlexaFluor®488	 8F6AE9	 1:100	 Abcam,	Cambridge,	UK	
IgG2b	 AlexaFluor®488	 7E10G10	 1:100	 Abcam,	Cambridge,	UK	
CD279	(PD-1)	 PE	 EH12.2H7	 1:40	 Biotechne,	Wiesbaden	
CD127	(IL-7Rα)	 APC	 A019D5	 1:50	 Biolegend,	London,	UK	
CD16	 APC	 3G8	 1:500	 Biolegend,	London,	UK	
CD194	(CCR4)	 APC	 L291H4	 1:25	 Biolegend,	London,	UK	
CD197	(CCR7)		 APC	 G043H7	 1:20	 Biolegend,	London,	UK	
CD14	 Brilliant	Violet	421™	 HCD14	 1:500	 Biolegend,	London,	UK	
CD183	(CXCR3)	 Brilliant	Violet	421™	 G025H7	 1:100	 Biolegend,	London,	UK	
CD25	(IL-2Rα)	 Brilliant	Violet	421™	 M-A251	 1:100	 Biolegend,	London,	UK	
CD3	 Brilliant	Violet	421™	 UCHT1	 1:200	 Biolegend,	London,	UK	
CD3	 Brilliant	Violet	510™	 UCHT1	 1:25	 Biolegend,	London,	UK	
CD8a	 Brilliant	Violet	510™	 RPA-T8	 1:25	 Biolegend,	London,	UK	
CD196	(CCR6)	 PE/Cy7	 G034E3	 1:50	 Biolegend,	London,	UK	
CD20	 PE/Cy7	 2H7	 1:500	 Biolegend,	London,	UK	
CD45RA	 PE/Cy7	 HI100	 1:200	 Biolegend,	London,	UK	
CD4	 PerCP/Cy5.5	 PRA-T4	 1:50	 Biolegend,	London,	UK	
CD56	(NCAM)	 PerCP/Cy5.5	 HCD56	 1:200	 Biolegend,	London,	UK	
Live/dead	
marker	
ZombieNIR™	Fixable	
Viability	Kit	
	n/a	 1:	1000	 Biolegend,	London,	UK	
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Table	12:	Four	antibody	panels	for	cell	phenotyping,	PD-1	and	CPT1a	analysis.	
Panel	1:	memory	T	cell	subtypes	
fluorochrome	 conjugate	
Alexa	Fluor	488	 CPT1a		
PE		 PD-1	
PerCP-Cy5.5	 CD4	
PE-Cy7	 CD45RA	
APC		 CCR7	
Zombie	NIR™	 Live/dead	differentiation	
BV421™	 CD3	
BV510™	 CD8	
Panel	2:	effector	T	cell	subtypes	
fluorochrome	 conjugate	
Alexa	Fluor	488	 CPT1a		
PE		 PD-1	
PerCP-Cy5.5	 CD4	
PE-Cy7	 CCR6	
APC		 CCR4	
Zombie	NIR™	 Live/dead	differentiation	
BV421™	 CXCR3	
BV510™	 CD8	
Panel	3:	regulatory	T	cells		
fluorochrome	 conjugate	
Alexa	Fluor	488	 CPT1a		
PE		 PD-1	
PerCP-Cy5.5	 CD4	
PE-Cy7	 CD45RA	
APC		 CD127	
Zombie	NIR™	 Live/dead	differentiation	
BV421™	 CD25	
BV510™	 CD3	
Panel	4:	B	cells,	NK	cells,	monocytes		
fluorochrome	 conjugate	
Alexa	Fluor	488	 CPT1a		
PE		 PD-1	
PerCP-Cy5.5	 CD56	
PE-Cy7	 CD20	
APC		 CD16	
Zombie	NIR™	 Live/dead	differentiation	
BV421™	 CD14	
BV510™	 CD3	
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2.2.9 Software	used	for	analyses	
Table	13	lists	all	software	used	for	data	analyses	and	corresponding	company	names.	
Table	13:	Software.	
software	 company	
FACSDiva	version	6.1.2		 Becton	Dickinson,	Heidelberg,	Germany	
FlowJo®	10.3	 FlowJo,	LLC,	Ashland,	OR,	USA	
GraphPad	Prism	7	 GraphPadSoftware	Inc.,	La	Jolla,	CA,	USA	
Microsoft	Office	2016	 Microsoft,	Berlin,	Germany	
SPSS	23	 IBM	Inc.,	Berlin,	Germany	
Step	One	Plus™	 ThermoFisher,	Life	Technologies,	Berlin,	Germany	
Wave	Desktop	2.3	 Agilent,	Waldbronn,	Germany	
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2.3 	Methods	
2.3.1 Cellular	Biology		
2.3.1.1 Cryo-preservation	of	Peripheral	Blood	Mononuclear	Cells	(PBMC)	
Peripheral	Blood	Mononuclear	Cells	(PBMCs)	were	separated	from	about	80	mL	of	fresh	
whole	 blood	 by	 density	 gradient	 centrifugation	 (Biocoll	 Separating	 Solution,	 Biochrom	
GmbH).	The	time	between	blood	draw	and	PBMC	isolation	did	not	exceed	30	minutes	for	
all	MS	patients	and	HC	participants.	
To	obtain	isolated	PBMCs,	whole	blood	was	diluted	1:2	with	1xPBS	(phosphate	buffered	
saline)	 (room	 temperature	 (RT))	 and	 carefully	 layered	 on	 top	 of	 15	 mL	 of	 Biocoll	
Separating	Solution	(Merck,	Biochrom)	(RT).	This	preparation	was	centrifuged	for	30	min	
(RT)	at	300xg	with	the	centrifuge	break	off.	The	PBMC	monolayer	was	distracted	from	the	
separated	blood	contents	and	washed	 two	 times	 in	1xPBS	 (4°C).	PBMCs	were	added	 to	
RPMI	1640	GlutaMAX™	medium	(GIBCO,	Life	Technologies)	supplemented	with	25%	FCS	
(Merck,	Biochrome)	and	10%	DMSO	(AppliChem	GmbH).	Aliquots	of	1x107	cells/cryo	tube	
were	 slowly	 frozen	 to	 -80°C	 at	 10°C	 per	 hour	 intervals	 in	 a	 Mr.	 Frosty	 container	
(Nalgene®).	After	20-30	hours,	 the	 frozen	aliquots	were	 transferred	 into	 liquid	nitrogen	
for	long	time	storage.	
2.3.1.2 Thawing	of	PBMCs	
PBMCs	 in	cryo	tubes	were	taken	out	of	the	 liquid	nitrogen	container	and	placed	on	 ice.	
Cells	were	thawed	quickly	to	37°C	and	subsequently	resuspended	in	45	mL	of	37°C	RPMI	
medium	with	 GlutaMAX™	 supplemented	with	 10%	 FCS	 and	 centrifuged	 at	 300xg	 for	 5	
minutes.	 The	 supernatant	was	 taken	off	 and	 the	 cells	were	washed	 in	 1x	 PBS	 (RT)	 and	
centrifuged	at	300xg	for	5	minutes.	The	supernatant	was	taken	off	again	and	cells	were	
prepared	according	to	protocols.	
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2.3.1.3 MACS	Positive	Selection	
CD4+	and	CD8+	T	cells	 from	MS	patients	and	HC	participants	were	purified	 from	PBMCs	
using	magnetic	bead	positive	selection	(Miltenyi).	All	steps	were	performed	with	reagents	
and	the	centrifuge	at	4°C.	
PBMCs	were	thawed	according	to	protocol	(see	2.3.1.2).	After	the	last	washing	step,	the	
supernatant	 was	 taken	 off	 and	 80	 µL	 of	 MACS	 buffer	 and	 20	 µL	 CD4	 positive	 T	 cell	
selection	MACS	antibody	(Miltenyi)	were	added	per	5x106	cells.	The	cell	suspension	was	
incubated	at	4°C	 in	 the	dark	 for	15	minutes	and	subsequently	washed	with	5	mL	MACS	
buffer	(300xg,	5	min.).	The	supernatant	was	taken	off	and	the	cells	were	resuspended	in	3	
mL	MACS	buffer.	An	LS	column	(Miltenyi)	was	placed	into	the	Quadro	MACS	magnet	and	
rinsed	three	times	with	3	mL	MACS	rinsing	buffer	(Miltenyi).	Subsequently,	the	3	mL	cell	
suspension	 was	 applied	 onto	 the	 column.	 Here,	 the	 magnetically	 labeled	 CD4+	 T	 cells	
were	 retained	 inside	 the	 column	 and	 the	 non-labeled	 cells	 (negative	 fraction)	 were	
washed	 out	 into	 a	 15	 mL	 falcon	 tube.	 To	 retrieve	 the	 magnetically	 labeled	 cells,	 the	
column	was	placed	outside	the	magnet	 into	a	new	15	mL	falcon	tube	and	rinsed	with	5	
mL	MACS	buffer.	The	cells	were	centrifuged	at	300xg	for	5	min.	and	the	supernatant	was	
taken	 off.	 Following	 the	 CD4+	 T	 cell	 selection,	 CD8+	 T	 cells	 were	 separated	 from	 the	
negative	fraction	using	the	same	protocol	and	the	CD8	positive	selection	MACS	antibody	
(both	Miltenyi).		
Subsequently,	 three	 fractions	were	 obtained:	 CD4+	 T	 cells,	 CD8+	 T	 cells	 and	 a	 negative	
fraction	 containing	 PBMCs	 lacking	 the	 separated	 CD4+	 and	 CD8+	 T	 cells	 -	 the	 “non-
CD4+/CD8+	T	cell”	fraction.	The	non-CD4+/CD8+	T	cell	fraction	mainly	compromises	B	cells,	
NK	cells	and	monocytes.	After	the	MACS	separation,	all	fractions	were	taken	up	in	RPMI	
medium	with	GlutaMAX™	supplemented	with	10%	FCS.	
2.3.1.4 Cell	Culture	of	Sorted	PBMC	subtypes	
Following	MACS	separation	(see	2.3.1.3),	the	three	populations,	CD4+	T	cells,	CD8+	T	cells	
and	non-CD4+/CD8+	T	cells,	were	seeded	at	a	density	of	2x106	cells/well	in	a	six	well	plate	
in	RPMI	medium	with	GlutaMAX™	and	10%	FCS.	The	cells	were	incubated	for	2	h	in	a	5%	
CO2	incubator	at	37°C.		
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2.3.2 In	vitro	Metabolic	Analyses	using	the	Seahorse	XFe96	Analyzer	
2.3.2.1 Establishing	the	Mitochondrial	Stress	Test	Analysis	Protocol		
In	 order	 to	 contribute	 valid	 data,	 the	 Mitochondrial	 Stress	 Test	 Analyses	 using	 the	
Seahorse	 XFe	 96	 analyzer	 had	 to	 be	 established	 for	 human	 immune	 cell	 bioenergetic	
analyses.	According	to	the	manufacturer’s	instructions	(Agilent),	the	following	tests	were	
performed:	 titration	 of	 optimal	 FCCP,	 oligomycin	 and	 rotenone	 with	 antimycin	 A	
concentrations	as	well	as	the	required	cell	number	per	well.	The	following	concentrations	
were	determined	as	optimal	based	on	the	pre-analyses	assays:	FCCP:	2	µM,	oligomycin	1	
µM,	 rotenone	 with	 antimycine	 A:	 0.5	 µM.	 The	 cryopreserved	 PBMCs	 from	 a	 healthy	
donor	 were	 thawed	 10	 days	 after	 blood	 draw	 for	 the	 assay	 analysis	 (see	 2.3.1	 for	
methods).	Cell	density	 tests	 revealed	4x105	 cells/well	 giving	optimal	OCR	values	 (Figure	
6).	Data	was	analyzed	using	the	manufacturer’s	provided	Mito	Stress	Test	Kit	Generator	
V2.	Due	to	 limited	PBMC	material	 from	MS	patients	and	HC	participants,	no	more	 than	
4x105	cells/well	could	be	used.	
	
	
	
Figure	 6:	 Seahorse	 XFe	 96	 Analyzer	 assay	 test	 analyses	 for	 cell	 density	 determination	 shows	
increases	 in	 OCR	 with	 increasing	 PBMC	 numbers.	 The	 graphs	 show	 Peripheral	 Blood	
Mononuclear	Cells	(PBMCs)	from	a	healthy	donor.	The	cells	were	cryo	preserved	after	blood	draw	
and	thawed	after	10	days	for	Seahorse	Mitochondrial	Stress	Test	Kit	assay	analysis.	The	data	was	
generated	in	real-time	under	basal	conditions,	in	response	to	oligomycin,	FCCP	and	Rotenone	and	
Antimycin	 A	 using	 a	 Seahorse	 XFe	 96	 Analyzer	 (Agilent).	 Three	 different	 cell	 densities	 were	
analyzed:	 2x105	 cells/well,	 3x105	 cells/well	 and	 4x105	 cells/well.	 Mean	 and	 SEM	 calculated	 per	
condition	 for	 each	 time	 point.	 OCR:	 oxygen	 consumption	 rate,	 FCCP:	 Carbonyl	 cyanide-4-
(trifluoromethoxy)phenylhydrazone.									
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In	this	thesis,	the	main	aim	was	to	analyze	CD4+	and	CD8+	T	cells.	CD4+	and	CD8+	T	cells	
are	 non-adherent,	 therefore,	 it	 was	 tested	 whether	 the	 cells	 are	 detaching	 from	 the	
culture	plate	during	mixing	times	in	the	Seahorse	analyzer.	This	would	lead	to	inaccurate	
readouts,	because	energy	consumption	of	detaching	cells	 floating	 in	the	medium	would	
not	 be	 measured.	 Cellular	 adherence	 was	 examined	 using	 poly-D-lysine	 (PDL)	 in	 the	
Seahorse	cell	culture	plates	according	to	the	manufacturer’s	instructions	(Agilent).	PBMCs	
from	a	healthy	donor	were	thawed	and	CD4+	and	CD8+	T	cells	were	purified	using	MACS.		
Furthermore,	a	non-CD4+/CD8+	T	cell	fraction	lacking	CD4+	and	CD8+	T	cells	was	obtained	
(see	2.3.1.3	MACS	Positive	Selection).		The	three	cell	populations	were	incubated	at	37°C	
in	a	5%	CO2	incubator	for	2	h	at	2x106	cells/well	in	a	six	well	plate	(see	for	2.3.1	methods).	
Subsequently,	the	cells	were	washed	with	Seahorse	mitochondrial	stress	test	medium	(5	
min.	 at	 300xg)	 and	 seeded	 at	 4x105	 cells/well	 into	 the	 according	 Seahorse	 cell	 culture	
plates	previously	coated	with	PDL	or	non-coated.		
No	differences	in	bioenergetic	readouts	were	observed	between	PDL	treated	versus	PDL	
non-treated	Seahorse	cell	culture	plates	(at	least	5	wells/assay	condition	were	analyzed)	
(Figure	7).	 	Therefore,	using	PDL	to	attach	T	cells	 to	the	Seahorse	cell	culture	plate	was	
not	 necessary	 for	 T	 cell	 analyses.	 Furthermore,	 with	 respect	 to	 possible	 activation	 of	
immune	cells	by	PDL,	it	was	moreover	of	advantage	not	to	use	PDL	in	order	to	get	valid	
assay	results.	
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Figure	 7:	 Seahorse	 XFe	 96	 Analyzer	 metabolic	 assay	 cellular	 adherence	 testing	 shows	 no	
difference	 in	 OCR	 measurements	 with	 or	 without	 PDL	 plate	 coating.	 The	 graphs	 shows	
magnetically	purified	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	 (PBMCs	 lacking	CD4+	
and	 CD8+	 T	 cells)	 from	 a	 healthy	 donor	 incubated	 and	measured	with	 or	without	 previous	 PDL	
plate	coating.	Cryopreserved	PBMCs	were	thawed	after	90	days	for	Seahorse	Mitochondrial	Stress	
Test	Kit	assay	analysis.	The	data	was	generated	in	real-time	under	basal	conditions,	in	response	to	
oligomycin,	FCCP	and	Rotenone	and	Antimycin	A	using	a	Seahorse	XFe	96	Analyzer	(Agilent).	Cell	
density:	4x105	cells/well.	Mean	and	SEM	calculated	per	condition	for	each	time	point.	PDL:	Poly-
D-Lysine,	 OCR:	 oxygen	 consumption	 rate,	 FCCP:	 Carbonyl	 cyanide-4-
(trifluoromethoxy)phenylhydrazone.									
	
Furthermore,	previous	 studies	of	Keane	et	al.	 [124]	 showed	 that	human	PBMCs	display	
decreasing	 bioenergetics	 over	 time	 in	 cryo-preservation.	 Keane	 and	 colleagues	 showed	
that	after	50	days	of	storage,	bioenergetic	levels	stabilized	and	did	not	decrease	further.	
To	 ensure	 equal	 treatment	 and	 exclusion	 of	 bioenergetic	 effects	 caused	 by	 freezing	
duration	 to	 the	 highest	 extent	 possible,	 it	 was	 decided	 that	 all	 MS	 patients’	 and	 HC	
participants’	PBMC	samples	were	analyzed	no	earlier	 than	50	days	after	 liquid	nitrogen	
storage.	Additionally,	it	was	ensured	that	there	was	no	correlation	between	MS	patients’	
and	HC	participants’	PBMC	freezing	duration	and	metabolic,	genetic	or	FACS	analyses.		
Finally,	 to	 test	 PBMC	 activation	 and	 compare	 it	 to	 freshly	 thawed	 PBMCs	 (all	 from	 the	
same	healthy	donor),	α-CD3	and	α-CD28	stimulation	assays	were	performed.		
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Hence,	after	thawing	(see	2.3.1),	2x106	PBMCs/well	were	seeded	into	a	six	well	plate	and	
stimulated	 with	 1	 mg/mL	α-CD3	 (clone	 OKT)	 and	 1	 µg/mL	α-CD28	 (both	 eBioscience,	
ThermoFisher)	for	2	h,	22	h	or	left	unstimulated.	These	three	conditions	were	compared	
to	freshly	thawed	PBMCs.	It	was	observed,	that	freshly	thawed	and	analyzed	PBMCs	had	
higher	metabolic	 rates	 compared	 to	 PBMCs	 that	 were	 stimulated	 for	 2	 h,	 22	 h	 or	 not	
stimulated	at	all	during	the	22	h	incubation	(see	Figure	8).		
	
	
Figure	8:	Seahorse	XFe	96	Analyzer	metabolic	assay	PBMC	stimulation	testing	with	α -CD3	and	
α -CD28.	The	graphs	show	PBMCs	from	a	healthy	donor.	Cryopreserved	PBMCs	were	thawed	after	
225	 days	 for	 assay	 analysis.	 Four	 assay	 conditions	 were	 analyzed:	 PBMCs	 incubated	 for	 22	 h	
without	stimulation,	PBMCs	stimulated	with	α-CD3	and	α-CD28	for	22	h,	PBMCs	stimulated	with	
α-CD3	and	α-CD28	for	2	h	and	freshly	thawed	PBMCs	without	a	stimulation.	Assay	used:	Seahorse	
Mitochondrial	Stress	Test	Kit	assay.	Cell	density:	4x105	cells/well.	The	data	was	generated	in	real-
time	 under	 basal	 conditions,	 in	 response	 to	 oligomycin,	 FCCP	 and	 Rotenone	 and	 Antimycin	 A	
using	a	Seahorse	XFe	96	Analyzer	(Agilent).	Mean	and	SEM	calculated	per	condition	for	each	time	
point.	PBMC:	Peripheral	Blood	Mononuclear	Cell,	OCR:	oxygen	consumption	rate,	FCCP:	Carbonyl	
cyanide-4-(trifluoromethoxy)phenylhydrazone.									
	
The	final	Seahorse	XFe	96	Analyzer	protocol	was	established	from	all	extensive	pre-assay	
experiments	and	analyses	(described	in	detail	in	2.3.2).	
	
Analyzing	samples	from	a	cross-sectional	clinical	study	recruiting	MS	patients	and	closely	
matched	HC	participants	 simultaneously	 at	 two	different	medical	 centers	within	 a	 time	
frame	 of	 two	 years,	 the	 laboratory	 analyses	 and	 study	 organization	 and	 management	
were	controlled	for	and	planned	as	best	as	possible.		
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2.3.2.2 Metabolic	Analyses	of	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	
Using	the	Seahorse	Mitochondrial	Stress	Test	Kit	assay,	CD4+	T	cells,	CD8+	T	cells	and	non-
CD4+/CD8+	T	cells	 from	MS	patients	and	matched	HC	participants	were	analyzed	 in	the	
Seahorse	XFe	96	analyzer.	An	MS	patient	and	the	accordingly	matched	HC	participant	pair	
was	analyzed	on	the	same	Seahorse	cell	culture	plate	to	ensure	comparability	and	avoid	
inter-assay	 variance.	 Based	 on	 the	 manufacturer’s	 recommendations,	 samples	 were	
analyzed	in	at	least	triplicates	and	the	mean	was	calculated	to	ensure	data	accuracy	and	
omit	inter-well	differences.	All	samples	were	frozen	for	at	least	50	days	prior	to	thawing.	
After	PBMC	purification,	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	were	rested	
for	 two	 hours.	 Subsequently,	 the	 cells	 were	 harvested	 and	 washed	 with	 Seahorse	
Mitochondrial	Stress	Test	Kit	medium	(300xg,	5	min.).	The	cells	were	seeded	at	a	density	
of	 4x105	 cells	 per	 well	 into	 a	 Seahorse	 cell	 culture	 plate	 and	 incubated	 wrapped	 in	 a	
plastic	bag	at	37	°C	in	a	non-CO2	incubator	for	30	minutes.	The	sensor	cartridge	(Agilent	
Technologies)	 was	 incubated	 for	 4	 h	 with	 calibration	 buffer	 (Agilent	 Technologies)	
wrapped	in	a	plastic	bag	at	37	°C	in	a	non-CO2	incubator.	Prior	to	putting	the	calibration	
plate	into	the	Seahorse	analyzer,	the	appropriate	ports	were	filled	with	reagents:	20	µL	of	
2	µM	FCCP	in	port	A,	22	µL	of	1	µM	oligomycin	in	port	B,	25	µL	of	0.5	µM	rotenone	with	
antimycin	A	in	port	C	and	27	µL	of	Seahorse	Mitochondrial	Stress	Test	Kit	medium	in	port	
D	 (all	 Agilent	 Technologies).	 All	 reagents	 were	 prepared	 with	 Seahorse	 Mitochondrial	
Stress	Test	Kit	medium.	To	prevent	vaporization	of	the	reagents	in	the	ports,	the	sensor	
cartridge	 was	 immediately	 placed	 into	 the	 analyzer	 for	 a	 15	min.	 calibration,	 which	 is	
required	by	the	machine	and	follows	the	company’s	instructions.	Finally,	the	cell	culture	
plate	 was	 added	 to	 the	 Seahorse	 analyzer	 and	 the	 analysis	 started	 using	 the	 protocol	
provided	in	Table	14.		
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Table	14:	Seahorse	XFe	96	analyzer	mitochondrial	stress	test	kit	analysis	protocol.	
equilibration	12	minutes	
baseline	readings	(loop	3	times)	
mix	3	min	–	wait	–	3	min	measure		
inject	port	A	oligomycin	(loop	3	times):	
mix	3	min	–	wait	–	3	min	measure	
inject	Port	B	FCCP	(loop	3	times):	
mix	3	min	–	wait	–	3	min	measure	
inject	Port	C	rotenone	and	antimycin	A	(loop	3	times):	
mix	3	min	–	wait	–	3	min	measure	
program	ends.	
	
2.3.2.3 Evaluation	of	MS	Patient	and	HC	Participant	Samples	
The	Seahorse	XFe	96	Analyzer	measures	 the	changes	 in	oxygen	consumption	rate	 (OCR,	
pmols/min)	 and	 extracellular	 acidification	 rate	 (ECAR,	mpH/min)	 in	 the	medium	 under	
real-time	 conditions.	 Therefore,	 direct	 conclusions	 about	 mitochondrial	 aerobic	
respiration	 (OCR)	 and	 the	 changes	 in	 pH	 in	 the	 medium	 (ECAR)	 can	 be	 drawn.	 The	
acidification	rate	is	the	result	of	changes	in	pH	mainly	due	to	cellular	 lactate	production	
and	CO2	release	from	the	cells.		The	cells	were	analyzed	in	real-time	under	four	different	
conditions:	1)	basal	respiration	without	any	reagents	in	the	Seahorse	Medium,	respiration	
in	 response	 to	 2)	 oligomycin,	 3)	 FCCP	 and	 4)	 rotenone	 and	 antimycin	 A.	 The	 values	
measured	by	the	Seahorse	XFe	96	Analyzer	were	analyzed	using	the	Wave	software	and	
Seahorse	 XFe	 96	 Mito	 Stress	 Test	 Generator	 V2	 (both	 Agilent,	 Waldbronn).	 OCR	
(pmoles/min.)	values	for	basal	respiration	(BR),	spare	respiratory	capacity	(SRC),	maximal	
respiration	 (MR),	 proton	 leakage,	 ATP	 production	 and	 non-mitochondrial	 respiration	
(NMR)	were	obtained.	The	equations	the	Seahorse	XFe	96	Mito	Stress	Test	Generator	V2	
(Agilent,	Waldbronn)	used	to	determine	each	parameter	are	listed	in	Table	15.		
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Table	 15:	 Seahorse	 Analyzer	 Parameter	 Calculations	 for	 OCR	 and	 ECAR	 using	 the	
mitochondrial	stress	test	kit.	(table	adapted	from	[125])	
parameter	value	 equation	
Non-mitochondrial	
oxygen	consumption	
Minimum	rate	measurement	after	rotenone/antimycin	A	
injection	
Basal	respiration	 (last	rate	measurement	before	first	injection)-(NMR)	
Maximal	respiration	 (maximum	rate	measurement	after	FCCP	injection)-(NMR)	
H+	(proton)	leak	 (minimum	rate	measurement	after	oligomycin	injection)-(NMR)	
ATP	production	 (last	rate	measurement	before	oligomycin	injection)-(minimum	
rate	measurement	after	oligomycin	injection)	
Spare	respiratory	
capacity	
(MR)-(BR)	
Basal	ECAR	 last	rate	measurement	before	first	injection	
Maximal	ECAR	 maximum	rate	measurement	after	oligomycin	injection	
NMR:	Non-mitochondrial	respiration,	BR:	basal	respiration,	MR:	maximal	respiration,	PL:	
proton	 leak,	 ATP:	 adenosine	 triphosphate,	 SRC:	 spare	 respiratory	 capacity,	 ECAR:	
Extracellular	Acidification	Rate.	
	
Using	 the	 mitochondrial	 stress	 test	 assay	 for	 the	 Seahorse	 XFe	 96	 analyzer,	 basal	
extracellular	acidification	rate	(ECAR)	and	maximal	ECAR	after	oligomycin	injection	can	be	
evaluated	 (Table	 15).	 Changes	 in	mpH/min.	 after	 FCCP	 injection	 include	 changes	 in	 the	
medium	resulting	from	mitochondrial	respiration	and	other	bioenergetic	pathways	in	the	
cells	(e.g.	TCA	cycle,	pentose	phosphate	pathway),	which	influence	the	pH	of	the	medium.	
Therefore,	 only	 basal	 ECAR	 (last	 rate	 measurement	 before	 oligomycin	 injection)	 and	
maximal	ECAR	 (highest	value	after	oligomycin	 injection)	were	analyzed.	These	values	 in	
pH	changes	in	the	medium	provide	data	for	basal	cellular	glycolysis	rates	in	unstimulated	
cells	and	maximal	glycolysis	rates	during	mitochondrial	ETC	complex	V	inhibition.		
Due	 to	 differing	 outcomes	 in	 cell	 number	 from	 MS	 patients	 after	 density	 gradient	
centrifugation	 PBMC	 isolation	 and	 because	 of	 differences	 in	 cell	 viability	 potentially	
caused	by	MS	medication,	24	MS	patient-HC	participant	pairs	out	of	the	31	pairs	included	
in	the	study	analyses	(Table	16)	could	be	analyzed.		
The	 real-time	measurement	 of	 cell	 viability	 can	 cause	 readouts	 that	 can’t	 be	 used	 for	
analyses,	mainly	due	 to	cell	 viability	during	 the	assay	 run	or	possible	air	bubbles	 in	 the	
well	 interfering	with	 the	 Seahorse	 Analyzer	 system.	 If,	 under	 the	 assay	 conditions,	 cell	
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viability	 suffered	 or,	 by	 definition,	 CD8+	 T	 cell	 purification	 yielded	 lower	 outcome	 and	
could	not	be	analyzed,	the	data	was	excluded	resulting	in	the	differing	numbers	of	pairs	
analyzed	 (n-numbers).	 However,	 at	 least	 three	wells	 per	 cell	 population	were	 used	 for	
analyses	 in	 order	 to	 ensure	 data	 and	 statistical	 accuracy	 as	 well	 as	 to	 omit	 inter-well	
differences.	If	less	than	three	wells	were	analyzable,	the	data	was	excluded.	For	three	or	
more	 wells	 per	 cell	 population,	 the	 mean	 was	 calculated	 and	 used	 for	 data	 analyses.	
Exemplarily:	 for	MS	patients’	CD8+	T	cells	on	average	5.5	wells	 (mean,	SD	2.3)	could	be	
used	for	analyses.	For	HC	participants’	CD8+	T	cells	on	average	5.6	wells	 (mean,	SD	2.2)	
were	 used	 for	 analyses.	 There	 was	 no	 significant	 difference	 in	 the	 number	 of	 wells	
analyzed	 from	MS	 patients	 and	HC	 participants	 for	 CD4+	 T	 cells,	 CD8+	 T	 cells	 and	 non-
CD4+/CD8+	T	cells	(all	p≥0.5).	
2.3.3 Flow	Cytometry	Analyses	
2.3.3.1 Intracellular	and	Extracellular	Staining	
PBMCs	 from	 an	MS	 patient	 and	 correspondingly	 matched	 HC	 participant	 were	 always	
analyzed	in	parallel	 in	the	flow	cytometer.	The	cryo	preserved	PBMC	vials	used	were	all	
prepared	from	the	one	blood	draw	at	the	study	visit	(2.3.1),	which	ensures	comparability	
of	 the	results	between	the	different	experiments.	The	antibodies	are	 listed	 in	Table	11,	
the	corresponding	antibody	panels	used	are	listed	in		
Table	 12	 and	 Figure	 15	 give	 an	 overview	 of	 the	 final	 cell	 phenotypes	 analyzed.	 The	
antibody	 panels	 are	 based	 on	 a	 publication	 by	 Maecker	 et	 al.	 2012	 [126]	 and	 were	
modified	to	incorporate	CPT1a	and	PD-1	analyses.	
For	 flow	cytometry	antibody	staining,	one	cryo	 tube	per	MS	patient	and	HC	participant	
with	1x107	cells	was	thawed.	The	cells	were	aliquoted	in	four	5	mL	flow	cytometry	tubes	
for	 each	 panel.	 The	 tubes	 were	 incubated	 in	 the	 dark	 at	 RT	 for	 15	 minutes	 with	 the	
live/dead	marker	Zombie	NIR	 in	50	µL	1xPBS.	For	staining	panel	1	(Table	12),	the	CCR7-
APC	 antibody	was	 also	 added	 to	 the	 solution.	 Subsequently,	 50	 µL	 of	 the	 extracellular	
antibody	mix	of	each	panel	 (Table	12)	were	added	 for	an	additional	15	min.	 incubation	
(RT,	in	the	dark).	The	cells	were	then	washed	in	1	mL	FACS	buffer	(300xg,	5	min.).		
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For	 intracellular	 staining,	 100	 µL	 cytofix/cytoperm	 (Becton	 Dickinson)	 were	 added	 and	
cells	 were	 incubated	 for	 15	 min.	 (RT,	 in	 the	 dark).	 The	 cells	 were	 washed	 in	 1	 mL	
perm/wash	(Becton	Dickinson)	(300xg,	5	min.).	Anti-CPT1a-AlexaFluor®488	was	diluted	in	
100	 µL	 perm/wash	 and	 incubated	with	 the	 cells	 for	 30	minutes	 at	 RT	 in	 the	 dark.	 For	
isotype	control	analyses,	the	corresponding	isotype	was	used.	The	cells	were	washed	in	1	
mL	 perm/wash	 (300xg,	 5	 min.).	 300	 µL	 FASC	 buffer	 was	 added	 and	 the	 cells	 were	
analyzed	within	2	hours.		
2.3.3.2 Titration	of	Antibodies		
Antibodies	used	for	all	four	multi-color	antibody	panels	in	flow	cytometry	analyses	(Table	
11)	were	titrated	to	their	optimal	concentration	(Intracellular	and	Extracellular	Staining).	
2.3.3.3 Gating	Strategy	
Flow	cytometry	gates	were	 set	and	cell	populations	determined	based	on	 the	antibody	
panels	 used	 (Table	 12).	 Figure	 9	 through	 Figure	 13	display	 the	 gating	 strategy	 for	 each	
antibody	 panel.	 Figure	 15	 summarizes	 the	 final	 cell	 phenotypes	 based	 on	 the	 antibody	
panels	used.		
	
Figure	9:	Gating	strategy	for	panel	1	of	phenotyping	analyses	to	determine	memory	subtypes	in	
CD4+	and	CD8+	T	cells.	Flow	cytometry	analyses	of	cryopreserved	PBMCs	from	MS	patients	and	HC	
participants.	 Lymphocytes	 were	 identified	 based	 on	 size	 using	 forward	 scatter	 (FSC)	 and	 side	
scatter	(SSC).	Doublets	were	excluded	based	on	FSC-H	(height)	and	FSC-A	(area)	followed	by	dead	
cell	exclusion.	T	cells	and	non-T	cells	were	discriminated	based	on	CD3	surface	expression.	Further	
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determination	 of	 T	 cells	 was	 distinguished	 by	 CD4	 and	 CD8	 surface	 expression.	 T	 cell	 memory	
subsets	were	discriminated	based	on	CCR7	and	CD45RA	surface	expression:	TCM:	CCR7+	CD45RA-,	
naïve:	CCR7+	CD45RA+,	TEM:	CCR7-	CD45RA-,	TEMRA:	CCR7-	CD45RA+.	TCM:	central	memory	T	cell,	
TEM:	 effector	 memory	 T	 cell,	 TEMRA:	 terminally	 differentiated	 effector	 memory	 cells	 re-	
expressing	CD45RA.			
	
Figure	10:	Gating	strategy	for	panel	2	of	phenotyping	analyses	to	determine	CD4+	helper	T	cells	
and	CD8+	T	cell	subtypes.	Flow	cytometry	analyses	of	cryopreserved	PBMCs	from	MS	patients	and	
HC	 participants.	 Cells	 were	 gated	 on	 single	 cell	 live	 lymphocytes	 as	 shown	 in	 Figure	 9:	
lymphocytes	 were	 identified	 based	 on	 size	 using	 forward	 scatter	 (FSC)	 and	 side	 scatter	 (SSC).	
Doublets	were	excluded	based	on	FSC-H	(height)	and	FSC-A	(area)	followed	by	dead	cell	exclusion.	
T	 cells	 and	 non-T	 cells	 were	 discriminated	 based	 on	 CD3	 surface	 expression.	 Further	
determination	of	T	cells	was	distinguished	by	CD4	and	CD8	surface	expression.	CD4+	helper	T	cell	
subsets	were	discriminated	based	on	the	differential	expression	of	CCR4,	CCR6	and	CXCR3.	Th1:	
CCR6-	CXCR3+,	Th1/Th17:	CCR6+	CXCR3+,	Th2:	CCR6-	CXCR3-	CCR4+,	Th0:	CCR6-	CXCR3-	CCR4-,	Th17:	
CCR6-	 CXCR3-	 CCR4+.	 The	expression	of	CCR4,	CCR6	and	CXCR3	was	 further	 analyzed	on	CD8+	 T	
cells.	CCR:	CC	chemokine	receptor,	CXCR3:	CXC	chemokine	receptor	3.	
	
CD4+	CD25-	CD127+	conventional	T	cells	were	discriminated	from	T	regs	by	a	boolean	gate	
including	all	CD4+	T	cells	but	CD25+	and	CD127low	(IL7-Rα)	T	regs	(Figure	11).	In	addition	to	
defining	cell	populations	using	CD127,	the	median	fluorescent	intensities	(MFI)	of	IL7-Rα	
and	IL2-Rα	were	analyzed	in	conventional	T	cells	of	MS	patients	and	HC	participants.	
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Figure	11:	Gating	strategy	for	panel	3	of	phenotyping	analyses	to	determine	regulatory	T	cells	in	
CD4+	 T	 cells.	 Flow	 cytometry	 analyses	 of	 cryopreserved	 PBMCs	 from	 MS	 patients	 and	 HC	
participants.	Cells	were	gated	on	single	cell	 live	 lymphocytes	as	shown	 in	Figure	9:	 lymphocytes	
were	 identified	based	on	 size	using	 forward	 scatter	 (FSC)	and	 side	 scatter	 (SSC).	Doublets	were	
excluded	based	on	 FSC-H	 (height)	 and	 FSC-A	 (area)	 followed	by	dead	 cell	 exclusion.	 T	 cells	 and	
non-T	cells	were	discriminated	based	on	CD3	surface	expression.	helper	T	cells	were	distinguished	
by	 CD4	 surface	 expression.	 T	 regs	 were	 then	 discriminated	 based	 on	 CD25/CD127low	 surface	
expression	and	further	divided	into	naïve	and	memory	T	regs	based	on	CD45RA	expression.	CD4+	
CD25-	CD127+	conventional	T	cells	were	defined	by	a	boolean	gate	including	all	CD4+	T	cells	but	T	
regs.	T	reg:	regulatory	T	cell.	
	
Figure	12:	Gating	strategy	for	panel	4	of	phenotyping	analyses	to	determine	B	cells	and	NK	cells.	
Flow	 cytometry	 analyses	 of	 cryopreserved	 PBMCs	 from	MS	 patients	 and	 HC	 participants.	 Cells	
were	 gated	 on	 single	 cell	 live	 lymphocytes	 as	 shown	 in	 Figure	 9:	 Lymphocytes	 were	 identified	
based	on	size	using	forward	scatter	(FSC)	and	side	scatter	(SSC).	Doublets	were	excluded	based	on	
FSC-H	 (height)	 and	 FSC-A	 (area)	 followed	 by	 dead	 cell	 exclusion.	 T	 cells	 and	 non-T	 cells	 were	
discriminated	based	on	CD3	surface	expression.	CD3-	non-T	 cells	were	 further	discriminated	 for	
CD20,	CD56	and	CD16	expression.	B	cells:	CD20+,	cytotoxic	NK	cells:	CD16+	CD56-,	regulatory	NK	
cells:	CD16int./-	CD56+.	NK	cell:	natural	killer	cell.	
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Figure	 13:	 Gating	 strategy	 for	 panel	 4	 of	 phenotyping	 analyses	 to	 determine	 monocyte	
subpopulations.	 Flow	 cytometry	 analyses	 of	 cryopreserved	 PBMCs	 from	 MS	 patients	 and	 HC	
participants.	 Monocytes	 were	 identified	 based	 on	 forward	 scatter	 (FSC)	 and	 side	 scatter	 (SSC)	
properties.	Doublets	were	excluded	based	on	FSC-H	 (height)	and	FSC-A	 (area)	 followed	by	dead	
cell	 exclusion.	 T	 cells	 and	 non-T	 cells	 were	 discriminated	 based	 on	 CD3	 surface	 expression.	
Contaminating	B	cells	and	NK	cells	were	excluded	based	on	CD20	and	CD56	expression.	Monocyte	
subsets	 were	 identified	 by	 the	 differential	 expression	 of	 CD14	 and	 CD16:	 CD14+	 CD16++	 non-
classical	monocytes,	CD14++	CD16+	intermediate	monocytes,	CD14++	CD16-	classical	monocytes.	NK	
cell:	natural	killer	cell.	
Figure	14	shows	a	representative	PD-1	staining	and	a	CPT1a	antibody	staining	compared	
to	 its	 isotype	 control.	 CD4+	 naïve	 T	 cells	 (full	 gating	 shown	 in	 Figure	 9)	 were	 set	 as	 a	
negative	 reference	 (Figure	 14	 B)	 to	 determine	 PD-1	 positive	 T	 cell	 populations.	 An	
exemplary	 histogram	 is	 shown	 with	 CD4+	 effector	 memory	 T	 cells.	 For	 analysis,	 the	
median	fluorescent	intensity	(MFI)	of	the	PD-1	negative	reference	population	of	interest	
was	subtracted	from	the	MFI	of	the	positive	population	of	interest.		
For	the	analysis	of	CPT1a,	which	is	generally	expressed	in	all	cells,	the	MFI	was	compared	
between	the	study	groups.	Figure	14	C	shows	an	applicable	CPT1a	isotype	control	tested	
in	 order	 to	 demonstrate	 the	 CPT1a	 antibody	 specificity.	 Here,	 CD4+	 effector	memory	 T	
cells	are	again	exemplarily	shown.	The	CPT1a	AlexaFluor®488	antibody	 (clone	7E10G10,	
Abcam)	binds	to	the	C-terminal	region	(aa	489-773)	of	CPT1a	at	the	outer	mitochondrial	
membrane	[127].	
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Figure	14:	Expression	of	PD-1	and	CPT1a	in	CD4+	T	cell	subpopulations.	Flow	cytometry	analyses	
of	cryopreserved	PBMCs	from	MS	patients	and	HC	participants.	Cells	were	gated	on	single	cell	live	
lymphocytes	 as	 shown	 in	 Figure	 9:	 lymphocytes	 were	 identified	 based	 on	 size	 using	 forward	
scatter	 (FSC)	and	side	scatter	 (SSC)	properties.	Doublets	were	excluded	based	on	FSC-H	(height)	
and	FSC-A	(area)	followed	by	dead	cell	exclusion.	T	cells	and	non-T	cells	were	discriminated	based	
on	CD3	 surface	expression.	 Further	determination	of	 T	 cells	was	distinguished	by	CD4	and	CD8	
surface	expression.	CD4+	memory	T	cell	populations	are	shown	here.	 (A)	memory	T	cell	 subsets	
were	discriminated	based	on	CCR7	and	CD45RA	surface	expression:	TCM:	CCR7+	CD45RA-,	naïve:	
CCR7+	CD45RA+,	TEM:	CCR7-	CD45RA-,	TEMRA:	CCR7-	CD45RA+.	(B)	MFI	in	CD4+	naïve	T	cells	(blue)	
as	PD-1	negative	control	applied	to	all	MS	and	HC	T	cell	subsets	analyzed	and	a	representative	PD-
1	positive	staining:	CD4+	TEM	cells	(red).	(C)	MFI	of	CD4+	TEM	CPT1a	(red)	and	its	isotype	control	
(green).	 TEM:	 effector	 memory	 T	 cells,	 TN:	 naïve	 T	 cell,	 TCM:	 central	 memory	 T	 cell,	 TEMRA:	
terminally	 differentiated	 effector	 memory	 cells	 re-	 expressing	 CD45RA,	 CCR7:	 CC	 chemokine	
receptor	7.	
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Figure	15:	Overview	of	PBMC	phenotyping	based	on	flow	cytometry	gating	in	MS	patients	and	
HC	participants.	The	lymphocyte	gate	(top	box)	and	monocytes	gate	(bottom	right	box)	is	set	on	
whole	PBMCs	differentiated	by	cell	size	and	width	(FSC/SSC),	 live	dead	cells,	single	cells	and	the	
respective	 surface	 receptors	 to	 determine	 cell	 phenotypes.	 The	 figure	 illustrates	 the	 surface	
receptors	 used	 to	 differentiate	 cell	 populations.	 CCR:	 CC	 chemokine	 receptor,	 CXCR3:	 CXC	
chemokine	 receptor	 3,	 CM:	 central	 memory,	 EM:	 effector	 memory,	 TEMRA:	 terminally	
differentiated	effector	memory	cells	re-	expressing	CD45RA,	NK	cell:	natural	killer	cell,	cyt	NK	cell:	
cytotoxic	NK	cell,	reg	NK	cell:	regulatory	NK	cell.	
2.3.4 Gene	Expression	Analyses	
2.3.4.1 Preparation	and	Conservation	of	RNA		
In	order	to	obtain	RNA	samples	from	CD4+	and	CD8+	T	cells	as	well	as	non-CD4+/CD8+	T	
cells	 from	 MS	 patients	 and	 healthy	 control	 participants,	 aliquots	 of	 these	 three	 cell	
fractions	were	taken	after	the	two	hour	resting	period	following	the	magnetic	cell	sorting	
(see	 2.3.1.3	 and	 2.3.1.4).	 The	 cells	 were	 centrifuged	 at	 300xg	 for	 5	 minutes	 and	 the	
supernatant	was	 taken	off.	80µL	of	RNAlater®	 (Life	Technologies)	was	added	to	 the	cell	
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pellets	and	resuspended.	The	cells	in	RNAlater®	solution	were	stored	at	4°C	for	1-3	days	
and	frozen	at	-80°C	until	analysis.	 	
2.3.4.2 RNA	Isolation	and	cDNA	Synthesis	
RNA	isolation	(Qiagen	RNeasy®	Plus	Mini	Kit)	and	cDNA	synthesis	(RevertAid	H	Minus	First	
Strand	 cDNA	 Synthesis	 Kit,	 ThermoFisher	 Scientific)	 were	 performed	 following	 the	
manufacturer’s	instructions.	RNA	measurements	were	performed	on	a	NanoDrop™2000c	
Spectralphotometer	(ThermoFisher,	Life	Technologies).	For	each	cell	fraction	from	an	MS	
patient	 and	 matched	 healthy	 control	 participant,	 the	 same	 quantity	 of	 RNA	 was	
transcribed	into	cDNA.	cDNA	synthesis	was	performed	on	a	GeneAmp®	PCR	Systems	9700	
(Applied	Biosystems,	ThermoFisher,	Life	Technologies).	RNA	isolation	and	cDNA	synthesis	
were	performed	on	the	same	day.	The	cDNA	was	stored	at	-80°C	until	qRT-PCR	analysis.	
2.3.4.3 qRT-PCR	Analyses	
Gene	 expression	 analyses	 from	 matched	 MS	 patients	 and	 HC	 participants	 were	
performed	on	the	same	qRT-PCR	plate	to	ensure	data	comparability.	For	all	MS	patients	
and	HC	participants,	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	were	analyzed.	
TaqMan	Gene	expression	probes	and	Master	Mix	(both	LifeTechnologies)	were	used	for	
qRT-PCR	 analysis	 on	 a	 Step	 One	 Plus	 Real	 Time	 PCR	 System	 (Applied	 Biosystems,	
ThermoFisher,	Life	Technologies).	A	full	list	of	all	reagents	is	provided	in	Table	9	and	Table	
10.		
Per	one	reaction,	the	following	compounds	were	used:	10	µL	TaqMan	Master	Mix,	8	µL	
DEPC	water	(Life	Technologies),	1	µL	Taq	Man	probe	and	1	µL	cDNA.	The	samples	were	
analyzed	 in	 triplicates	 with	 two	 housekeeping	 genes	 (TATA	 Box	 Binding	 Protein	 and	
Importin	8)	analyzed	for	reference.	Following	2	minutes	at	50	°C	and	10	minutes	at	95°C,	
40	cycles	were	performed	as	follows:	15	seconds	at	95°C,	1	minute	at	60°C.	Finally,	4°C	to	
stop	 the	 reaction.	 The	 individual	 gene	 transcript	 levels	 were	 assessed	 relative	 to	 the	
housekeeping	genes	following	ΔΔCT	values.	Differences	of	more	than	0.5	in	ΔΔCT	values	
within	the	triplicates	were	excluded.	
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2.3.5 ELISA	Analyses	of	Salivary	Cortisol	Hormone		
MS	patients	and	HC	participants	collected	two	morning	(after	waking	up)	and	two	evening	
(at	9	pm)	saliva	samples	on	the	two	days	following	the	study	visit.	30	minutes	before	the	
samples	were	taken,	the	patients	and	healthy	controls	were	asked	not	to:	exercise,	chew	
gum,	drink	anything	but	water,	eat	and	brush	their	teeth.		
Cortisol	levels	in	saliva	of	MS	patients	and	HC	participants	were	determined	using	the	IBL	
Cortisol	 detection	 ELISA	 kit	 (IBL)	 according	 the	manufacturer’s	 instructions.	MS	 patient	
and	HC	participant	sample	pairs	were	analyzed	on	the	same	plate.	
2.3.6 Statistical	Analyses	
Data	 was	 analyzed	 using	 paired-sample	 statistics	 based	 on	 recommendations	 for	 a	
matched	case-control	study	design	[128].	Analyses	were	performed	using	SPSS	version	23	
(IBM	Inc.)	and	GraphPad	Prism	version	7	(GraphPadSoftware	Inc.).	FACS	Diva	version	6.1.2	
(BD)	and	FlowJo®	version	10.3	(FlowJo	Inc.)	was	used	to	conduct	flow	cytometry	analyses,	
Wave	Desktop	2.3	(Agilent)	was	used	to	conduct	Seahorse	analyses	(software	overview	in	
Table	13).	 	To	compare	groups	and	test	for	statistical	significance,	paired	nonparametric	
Wilcoxon	signed	rank	test	was	used	presenting	median	values	with	 interquartile	ranges,	
unless	otherwise	specified.	The	Wilcoxon	 test	does	not	 require	a	normal	distribution	of	
data.	A	two-tailed	p≤0.05;	p≤0.01	and	p≤0.001	was	considered	significant	and	a	p	value	≤	
0.10	was	considered	a	trend.	To	test	for	bivariate	correlation	analyses,	Spearman’s	rank	
correlation	 test	 was	 used.	 This	 test	 also	 does	 not	 require	 normal	 distribution	 of	 data.				
The	Spearman’s	rank	correlation	coefficient	rS	indicates	the	power	and	direction	(positive	
or	negative	correlation)	of	linear	statistical	association,	providing	values	between	-1	and	
+1.	The	p-value	 shows	whether	 rS	 significantly	differs	 from	0.	Here,	a	p-value	of	p≤0.05	
was	considered	significant	and	a	p	value	of	≤0.10	was	considered	a	trend.	
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3 Results	
Multiple	Sclerosis	is	a	neurodegenerative	disease	affecting	the	central	nervous	system	as	
well	as	the	immune	system.	Immune	cells	are	dependent	on	energy	resources	and	it	has	
been	shown	that	energy	metabolism	greatly	affects	the	general	 immune	cell	phenotype	
including	 the	 state	 of	 activation,	 senescence,	 differentiation,	 memory	 development	 or	
proliferation	 [129].	 	 Immune	 cells	 respond	 to	 external	 environmental	 factors	 in	 their	
immediate	 microenvironment	 and	 induce	 energy	 metabolic	 shifts	 from	 inside	 the	 cell.	
The	 immune	 system	 of	 patients	 diagnosed	 with	 RRMS	 is	 continuously	 triggered	 and	
repeatedly	activated.	This	chronic	immune	activation	may	induce	shifts	in	normal	immune	
cell	 energy	 metabolism.	 Therefore,	 it	 was	 the	 aim	 of	 this	 thesis	 to	 analyze	
immunometabolic	dysfunctions	and	underlying	molecular	mechanisms	in	immune	cells	of	
RRMS	patients.		
3.1 MS	Patient	and	Healthy	Participant	Cohort	Characteristics	
MS	patients	and	HC	participants	were	 recruited	as	part	on	 the	Depression	and	 Immune	
System	(DENIM)	study	 (see	2.1	 for	 full	 information	regarding	recruitment	and	Appendix	
for	 full	 Case	Report	 Form).	Main	 characteristics	of	MS	patients	 and	HC	participants	 are	
displayed	 in	Table	16.	Patients	and	controls	were	 thoroughly	matched	 for	 sex,	age	 (±	5	
years),	BMI	(±	2	kg/m2)	and	current	smoking	status.	Due	to	careful	matching	of	patients	
and	 controls,	 there	 are	 no	 differences	 in	 sex,	 age	 (p=0.43),	 BMI	 (p=0.45)	 or	 smoking	
status.	The	cohort	consists	primarily	of	female	(77.4%)	non-smokers	(96.8%).		
Psychiatric	and	cardiovascular	diseases	have	been	associated	with	a	general	 increase	 in	
inflammation	the	body	and	were	therefore	excluded	in	this	study	to	avert	 influences	on	
results.	Other	immunological	diseases	were	also	exclusion	criteria.		
The	following	questionnaires	were	used	for	the	assessment	of	major	depressive	disorder	
(MDD)	and	anxiety	disorder:	Montgomery-Åsperg	Depression	Rating	Scale	(MADRS)	[130],	
Mini	International	Neuropsychiatric	Interview	German	version	5.0.0	DSM-IV	(MINI)	[131],	
Beck’s	Depression	Inventory-II	(BDI-II)	[132,	217]	and	Beck’s	Anxiety	Inventory	(BAI)	[133,	
216].	 Depression	 scores	 of	 MS	 patients	 and	 HC	 participants	 were	 rated	 in	 a	 clinical	
interview	 using	 the	 MINI	 and	 MADRS.	 The	 patients	 and	 participants	 included	 in	 the	
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cohorts	 did	 not	 meet	 MDD	 criteria	 (Table	 16).	 The	 BDI-II	 and	 BAI	 are	 self-rated	
questionnaires.	MS	patients	showed	significantly	higher	BDI-II	 (p<0.01)	and	BAI	(p=0.02)	
scores	 compared	 to	HC	participants.	However,	 in	both	groups,	 the	 scores	did	not	meet	
depression	 or	 anxiety	 disorder	 criteria.	 Cognitive	 ability	 testing	 using	 the	 Single	 Digit	
Modality	 Scale	 (SDMT)	 [134]	 did	 not	 reveal	 differences	 between	 MS	 patients	 and	 HC	
participants	 (p=0.13).	 The	 Expanded	 Disability	 Status	 Scale	 (EDSS)	 [135]	 testing	 was	
performed	with	MS	patients	 to	 rate	 the	patient’s	disability	status	 ranging	 from	0	to	10.	
The	MS	patient	cohort	had	a	median	EDSS	of	2	with	results	ranging	from	0	to	4.5	within	
the	cohort.		
Blood	pressure	measurements	revealed	normal	ranges	 in	both	cohorts	and	 levels	 for	C-
reactive	protein	(CRP)	did	not	indicate	inflammation	(Table	16).		
In	conclusion,	MS	patients	and	HC	participants	did	not	show	any	concomitant	psychiatric	
disorders	 or	 indicators	 for	 pro-inflammation	 induced	 by	 concomitant	 cardiovascular	
diseases.		
Table	16:	MS	patients’	and	healthy	control	participants’	cohort	characteristics.		
	 RRMS	(n=31)	 HC	(n=31)	 P*	
Age,	years	 38	(34-48)	 40	(30-49)	 0.43	
BMI,	kg/m2	 23.3	(21.3-25.6)	 23.7	(22.4-25.8)	 0.45	
Blood	pressure	systolic,	mmHg	 120	(112-131)	 123	(106-126)	 0.25	
Blood	pressure	diastolic,	mmHg	 78	(67-87)	 78	(69-86)	 0.91	
CRP,	mg/L	 0.55	(0.4-1.6)	 0.9	(0.4-1.5)	 0.45	
%	Females	(n)	 77.4	(24)	 77.4	(24)	 0.99	
%	Current	non-smokers	(n)	 96.8	(30)	 96.8	(30)	 0.99	
Duration	of	disease,	years		 6.15	(2.7-10.9)	 n/a	 n/a	
EDSS	 2	(0.5-2.5)	 n/a	 n/a	
SDMT	 0.5	(0-1)	 0	(-0.5-0.5)	 0.13	
MADRS	 2	(1-3)	 1	(0-2)	 0.12	
BDI-II	 4	(1-7)	 0	(0-2)	 0.01	
BAI	 3	(1-9)	 2	(0-5)	 0.02	
31	MS	 patients	 and	 31	matched	 HC	 participants	 were	 analyzed.	 CRP	was	 analyzed	 for	
n=30	pairs.	24	MS	patients	added	 information	 for	MS	disease	duration.	30	MS	patients	
completed	 the	SDMT.	Relapsing	Remitting	Multiple	Sclerosis,	HC:	Healthy	Control,	BMI:	
Body	Mass	Index,	CRP:	C-reactive	protein,	EDSS:	Expanded	Disability	Status	Scale,	MADRS:	
Montgomery-Åsperg	Depression	Rating	Scale,	BDI-II:	Beck’s	Depression	Inventory-II,	BAI:	
Beck’s	 Anxiety	 Inventory.	 n/a:	 not	 applicable,	 SDMT:	 Single	 Digit	 Modalities	 Scale.	
*Wilcoxon	signed-rank	test.	medians	with	interquartile	ranges	(in	brackets)	are	displayed.		
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As	 described	 in	 2.1,	 all	 MS	 patients	 recruited	 for	 the	 study	 were	 in	 remission	 and	 on	
stable	immunomodulatory	therapy	(all	inclusion	criteria	listed	in	Table	4).	The	aim	was	to	
omit	any	effects	related	to	non-stable	and	non-immunomodulatory	medication	as	well	as	
comorbidities	 in	 laboratory	 results.	 Table	 17	 provides	 an	 overview	 of	 all	
immunomodulatory	medications	and	the	corresponding	commercial	names	taken	by	the	
MS	patients	(n=31).	Four	MS	patients	did	not	take	immunomodulatory	medication.	
Table	17:	Immunomodulatory	medications	taken	by	MS	patients.	
medication	 commercial	name	(number	of	patients)	
		Interferon	beta	1a	 Avonex	(2),	Rebif	22	(2),	Rebif	44	(1)	
		Interferon	beta	1b	 Extavir	(2)	
		Teriflunomide	 Aubagio	(4)	
		Glatiramer	Acetate	 Copaxone	20	mg	(2),	Copaxone	40	mg	(4)	
		Fingolimod	 Gilenya	(2)	
		Alemtuzumab	 Lemtrada	(1)	
		Dimethyl	fumarate	 Tecfidera	(7)	
		No	medication																(4)	
	
Five	 patients	 on	 additional	 medications	 were	 included	 due	 to	 the	 year-long	 stable	
medication.	 Amongst	 them,	 four	 patients	 taking	 L-Tyroxin	 or	 Thyronajod	 (thyroiditis	
medication)	for	more	than	three	years	and	one	patient	taking	Simvastatin	(blood	pressure	
medication)	for	ten	years.	
Patients	 and	HC	 participants	were	 asked	 during	 the	 clinical	 assessment	whether	 family	
members	 are	 diagnosed	 with	 MS.	 Three	 female	 MS	 patients	 reported:	 two	 cousins	
(maternal	and	paternal	sides),	great-grandmother	paternal	side	and	twin	sister.	One	male	
patient	 reported	 that	 his	 mother	 was	 diagnosed	 with	 MS.	 One	 female	 HC	 participant	
reported	that	her	sister	was	diagnosed	with	MS.	
In	conclusion,	overall,	the	MS	patient	cohort	was	free	of	immunological,	cardiovascular	or	
psychiatric	diseases	and	medications	other	than	the	ones	taken	for	MS	treatment	 (with	
the	 exception	 of	 stable	 thyroid	 and	 blood	 pressure	 medication,	 as	 stated).	 Therefore,	
biological	effects	measured	in	laboratory	analyses	were	controlled	for	as	best	as	possible.	
Differential	blood	analyses	showed	decreased	absolute	numbers	of	lymphocytes	in	the	
MS	patient	cohort	(p=0.01).	No	difference	in	monocytes	was	measured	(Figure	16).	
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Basophils	were	decreased	in	the	MS	patient	cohort	(p≤0.01,	Figure	35	supplements).	
Group	differences	in	other	cell	populations	were	not	observed	(see	Table	19	in	
supplements	for	a	complete	list	of	all	populations	analyzed).	
	
Figure	 16:	Within	 group	 comparisons	 of	 differential	 blood	 parameters	 in	MS	 patients	
and	HC	participants.	Whole	blood	was	analyzed	 in	a	certified	 routine	 laboratory:	 Labor	
Berlin,	Berlin,	Germany.	Blood	was	drawn	after	a	12	hour	fasting	period	and	analyzed	on	
the	same	day.	lymphocytes:	n=30	pairs.	monocytes:	n=30	pairs.	Wilcoxon	signed-rank	test	
with	medians	with	 interquartile	 ranges	are	displayed.	HC:	healthy	control,	MS:	multiple	
sclerosis.	
	
A	 trend	 towards	 decreased	 high	 density	 lipoprotein	 (HDL)	 levels	 in	 MS	 patients	 was	
observed	(p=0.08).	Low	density	lipoprotein	(LDL)	levels	as	well	as	CRP	levels	did	not	vary	
between	groups	(Figure	17).	
	
Figure	17:	Within	group	comparisons	of	differential	blood	parameters	HDL,	LDL	and	CRP	
in	 MS	 patients	 and	 HC	 participants.	 Whole	 blood	 was	 analyzed	 in	 a	 certified	 routine	
laboratory:	Labor	Berlin,	Berlin,	Germany.	Blood	was	drawn	after	a	12	hour	fasting	period	
and	 analyzed	 on	 the	 same	 day.	 HDL:	 n=31	 pairs.	 LDL:	 n=31	 pairs.	 CRP:	 n=30	 pairs.	
Wilcoxon	 signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	 HDL:	 high	
density	 lipoprotein,	 LDL:	 low	 density	 lipoprotein,	 CRP:	 C-reactive	 Protein,	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
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3.2 In	vitro	Analysis	of	Immune	Cell	Energy	Metabolism	using	the	
Seahorse	XFe96	Analyzer	
To	 analyze	 and	 compare	 immunometabolic	 profiles	 in	 specific	 PBMC	 subpopulations,	
their	mitochondrial	 and	 glycolytic	 respiration	were	 assessed.	 Purified	 and	unstimulated	
CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	(defined	as	the	cell	fraction	after	CD4+	
T	cell	and	CD8+	T	cell	purification)	from	MS	patients	and	HC	participants	were	analyzed	in	
real-time	using	the	Seahorse	XFe	96	Analyzer	(Agilent,	Waldbronn).		
3.2.1 Metabolic	Assay	Verification	
To	 ensure	 metabolic	 assay	 validity	 and	 test	 data	 compared	 to	 available	 literature	 on	
human	 immune	 cell	 energy	 metabolism,	 within	 group	 comparisons	 of	 the	 real-time	
energy	states	of	immune	cells	from	the	healthy	participant	cohort	were	performed.		
Figure	18	shows	the	kinetic	profile	of	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	
from	 HC	 participants.	 Differences	 in	 oxygen	 consumption	 rate	 (OCR)	 are	 displayed,	
focusing	on	basal	respiration	(BR)	and	maximal	respiration	(MR)	as	exemplary	measures.	
In	union	with	literature	on	immune	cell	metabolism,	there	were	no	significant	differences	
in	BR	between	resting	unstimulated	CD4+	T	cells	and	CD8+	T	cells	(n=24	pairs,	p=0.97)	as	
well	as	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	(n=23	pairs,	p=0.13).	CD4+	T	cells	showed	
significantly	 lower	 basal	 OCR	 values	 compared	 to	 non-CD4+/CD8+	 T	 cells	 (n=24	 pairs,	
p≤0.001).	 Analyzing	MR,	 there	was	 a	 trend	 between	CD4+	 T	 cells	 and	 non-CD4+/CD8+	 T	
cells	(n=24	pairs,	p=0.06)	and	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	(n=23	pairs,	p=0.07).	
There	was	no	significant	difference	in	maximal	OCR	between	CD4+	T	cells	and	CD8+	T	cells	
(n=24	pairs,	p=0.49).		
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Figure	18:	Within	group	 comparisons	 in	 the	HC	participant	 cohort	 showed	adapted	metabolic	
profiles	 in	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells.	The	data	was	generated	in	real-
time	 with	 unstimulated	 cells	 under	 basal	 conditions,	 in	 response	 to	 oligomycin,	 FCCP	 and	
Rotenone	and	Antimycin	A	using	a	Seahorse	XFe	96	Analyzer	(Agilent).	(A)	kinetic	profile	of	OCR	
values	of	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells.	BR	and	MR	are	exemplarily	colored	
for	 non-CD4+/CD8+	 T	 cells.	 BR	 measured	 at	 third	 time	 point	 before	 oligomycin	 injection,	 MR	
measured	 after	 FCCP	 injection.	 (B)	BR:	 CD4+	 T	 cells:CD8+	 T	 cells	 (n=24	 pairs),	 CD4+	 T	 cells:non-
CD4+/CD8+	T	 cells	 (n=23	pairs),	CD8+	T	 cells:non-CD4+/CD8+	T	 cells	 (n=23	pairs).	 (C)	MR:	CD4+	T	
cells:CD8+	T	cells	 (n=24	pairs),	CD4+	T	cells:non-CD4+/CD8+	T	cells	 (n=24	pairs),	CD8+	T	cells:non-
CD4+/CD8+	T	cells	(n=23	pairs).	(A)	Mean	and	SEM	calculated	per	condition	for	each	time	point.	(B,	
C)	Wilcoxon	 signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed	 for	 BR	 and	MR.	
OCR:	 oxygen	 consumption	 rate,	 BR:	 basal	 respiration,	MR:	maximal	 respiration,	 FCCP:	 Carbonyl	
cyanide-4-(trifluoromethoxy)phenylhydrazone,	HC:	healthy	control,	MS:	multiple	sclerosis.				
	
In	 summary,	 using	 the	 Seahorse	 XFe	 96	 Analyzer,	 current	 literature	 data	 could	 be	
confirmed	 and	 provided	 valid	 results	 for	 measuring	 immunometabolic	 states	 of	
unstimulated	human	CD4+	 T	 cells,	 CD8+	 T	 cells	 and	non-CD4+/CD8+	 T	 cells	 from	healthy	
individuals.		
Subsequently,	between	group	analyses	of	the	MS	patient	and	HC	participant	cohort	were	
performed	assessing	alterations	in	immunometabolism	in	MS	disease.	
3.2.2 Mitochondrial	Energy	Metabolism	Profile	of	Purified	CD4+	T	cells	
CD4+	 T	 cells	 have	 been	 shown	 to	 play	 a	major	 role	 in	MS	 pathogenesis	 and	 area	main	
target	 in	current	treatment.	Therefore,	 it	was	of	great	 interest	to	analyze	mitochondrial	
respiration	 in	 this	cell	population	and	generate	an	 immunometabolic	profile	 in	order	 to	
further	investigate	the	role	in	MS	disease.	
Following	 MACS	 purification,	 CD4+	 T	 cells	 from	MS	 patients	 and	 HC	 participants	 were	
analyzed	 in	 the	 Seahorse	 XFe	 96	 Analyzer.	 CD4+	 T	 cells	 from	 MS	 patients	 showed	
significantly	 lower	BR	 (p≤0.001),	MR	 (p≤0.01),	 spare	 respiratory	 capacity	 (SRC)	 (p≤0.01)	
and	 ATP	 production	 (p≤0.01)	 compared	 to	 HC	 participants	 (n=21	 to	 23	 pairs).	 Non-
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mitochondrial	respiration	(NMR)	(p=0.22)	and	proton	leakage	(PL)	(p=0.13)	did	not	show	
significant	differences	between	both	groups	(Figure	19).		
	
Figure	 19:	 Impaired	metabolic	 profile	 of	 CD4+	 T	 cells	 in	MS	 patients	 compared	 to	HC	
participants.	The	data	was	generated	in	real-time	under	basal	conditions,	in	response	to	
oligomycin,	 FCCP	 and	 Rotenone	 and	 Antimycin	 A	 using	 a	 Seahorse	 XFe	 96	 Analyzer	
(Agilent).	(A)	Kinetic	profile	of	OCR	values	of	CD4+	T	cells.	Colored	displays	are	exemplarily	
shown	 for	HC.	 (B)	BR	n=23	pairs.	 (C)	MR	n=22	pairs.	 (D)	 SRC	n=23	pairs.	 (E)	NMR	n=20	
pairs.	 (F)	 ATP	 production	 n=23	 pairs.	 (G)	 PL	 n=23	 pairs,	 p=0.13.	 (A)	 Mean	 and	 SEM	
calculated	per	group	for	each	time	point.	(B-G)	Wilcoxon	signed-rank	test,	medians	with	
interquartile	ranges	are	displayed.	OCR:	oxygen	consumption	rate,	BR:	basal	respiration,	
MR:	 maximal	 respiration,	 SRC:	 spare	 respiratory	 capacity,	 NMR:	 non-mitochondrial	
respiration,	ATP:	Adenosine	triphosphate,	PL:	proton	leakage,	FCCP:	Carbonyl	cyanide-4-
(trifluoromethoxy)phenylhydrazone,	HC:	healthy	control,	MS:	multiple	sclerosis.	
	
3.2.3 Mitochondrial	Energy	Metabolism	Profile	of	Purified	CD8+	T	cells		
Complementary	 to	 CD4+	 T	 cells,	 CD8+	 T	 cells	 have	 been	 found	 to	 be	modulated	 in	MS	
pathology	 and	 are	 targeted	 in	 current	 MS	 medication.	 The	 aim	 was	 to	 generate	 a	
mitochondrial	 respiration	 profile	 of	 CD8+	 T	 cells	 from	 MS	 patients	 providing	 greater	
insights	 into	 autoimmune	 mechanisms	 in	 MS	 disease	 and	 the	 contributions	 of	 energy	
metabolism	of	both	T	cell	subpopulations.			
CD8+	 T	 cells	 were	 purified	 and	 prepared	 for	 Seahorse	 XFe	 96	 Analyzer	 measurements.	
CD8+	T	 cells	 from	MS	patients	did	not	 show	significant	differences	 in	BR,	MR,	SRC,	ATP	
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production,	NMR	and	PL	 (all	p≥0.26)	compared	to	matched	HC	participants	 (n=21	to	23	
pairs)	(Figure	20).			
	
Figure	20:	Metabolic	profile	of	mitochondrial	respiratory	capacity	dos	not	differ	in	CD8+	
T	cells	from	MS	patients	compared	to		HC	participants.	The	data	was	generated	in	real-
time	 under	 basal	 conditions,	 in	 response	 to	 oligomycin,	 FCCP	 and	 Rotenone	 and	
Antimycin	A	using	a	Seahorse	XFe	96	Analyzer	(Agilent).	(A)	Kinetic	profile	of	OCR	values	
of	CD8+	T	cells.	Colored	displays	are	exemplarily	shown	for	HC.	(B)	BR	n=23	pairs.	(C)	MR	
n=23	pairs.	(D)	SRC	n=23	pairs.	(E)	NMR	n=21	pairs.	(F)	ATP	production	n=23	pairs.	(G)	PL	
n=23	pairs.	(A)	Mean	and	SEM	calculated	per	group	for	each	time	point.	(B-G)	Wilcoxon	
signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	 OCR:	 oxygen	
consumption	rate,	BR:	basal	respiration,	MR:	maximal	respiration,	SRC:	spare	respiratory	
capacity,	NMR:	non-mitochondrial	 respiration,	ATP:	Adenosine	 triphosphate,	PL:	proton	
leakage,	 FCCP:	 Carbonyl	 cyanide-4-(trifluoromethoxy)phenylhydrazone,	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
3.2.4 Mitochondrial	Energy	Metabolism	Profile	of	non-CD4+/CD8+	T	cells		
In	 addition	 to	 CD4+	 and	CD8+	 T	 cells,	 other	 immune	 cells	 including	B	 cells	 and	NK	 cells	
have	been	shown	to	contribute	to	MS	disease	relapse	and	progression.	Therefore,	it	was	
the	aim	to	analyze	mitochondrial	respiration	in	the	non-CD4+/CD8+	T	cell	fraction	from	MS	
patients	as	well	as	HC	participants	and	generate	an	immunometabolic	profile	that	can	be	
compared	to	the	ones	from	the	CD4+	and	CD8+	T	cell	subpopulations.	The	non-CD4+/CD8+	
T	cell	fraction	mainly	constitutes	monocytes,	B	cells	as	well	as	NK	cells	and	the	analyses	
Results	
75	
	
provide	first	insights	into	the	energy	profile	of	these	blood	cell	populations	in	MS	patients	
compared	to	HC	participants.	
Non-CD4+/CD8+	T	cells	 from	MS	patients	did	not	show	significant	differences	 in	BR,	MR,	
SRC,	ATP	production	and	NMR	(all	p≥0.10)	compared	to	matched	HC	participants	(n=21	to	
24	pairs)	(Figure	21).		Proton	leakage	showed	a	trend	towards	an	increase	in	MS	patient’s	
non-CD4+/CD8+	T	cells	(p=0.10).	
	
Figure	 21:	 Metabolic	 profile	 of	 mitochondrial	 respiratory	 capacity	 does	 not	 differ	 in	 non-
CD4+/CD8+	 T	 cells	 from	MS	 patients	 compared	 to	 HC	 participants.	 The	 data	was	 generated	 in	
real-time	under	basal	conditions,	in	response	to	oligomycin,	FCCP	and	Rotenone	and	Antimycin	A	
using	a	Seahorse	XFe	96	Analyzer	 (Agilent).	(A)	Kinetic	profile	of	OCR	values	of	non-CD4+/CD8+	T	
cells.	Colored	displays	are	exemplarily	 shown	 for	HC.	 	 (B)	BR	n=24	pairs.	 (C)	MR	n=24	pairs.	 (D)	
SRC	n=24	pairs.	(E)	NMR	n=23	pairs.	(F)	ATP	production	n=24	pairs.	(G)	PL	n=24	pairs.	 (A)	Mean	
and	SEM	calculated	per	group	for	each	time	point.	(B-G)	Wilcoxon	signed-rank	test,	medians	with	
interquartile	 ranges	 are	 displayed.	 OCR:	 oxygen	 consumption	 rate,	 BR:	 basal	 respiration,	 MR:	
maximal	 respiration,	 SRC:	 spare	 respiratory	 capacity,	 NMR:	 non-mitochondrial	 respiration,	 ATP:	
Adenosine	 triphosphate,	 PL:	 proton	 leakage,	 FCCP:	 Carbonyl	 cyanide-4-
(trifluoromethoxy)phenylhydrazone,	HC:	healthy	control,	MS:	multiple	sclerosis.															
	
In	conclusion,	 the	results	allude	to	an	overall	 impaired	mitochondrial	 immunometabolic	
profile	in	CD4+	T	cells	in	the	MS	patient	cohort.	This	was	not	observed	in	CD8+	T	cells	and	
non-CD4+/CD8+	T	cells.	
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3.2.5 Glycolytic	Activity	of	Purified	Immune	Cells	
In	addition	to	examining	mitochondrial	respiration,	between	group	analyses	of	glycolytic	
activity	in	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	was	performed	for	the	MS	
patient	and	HC	participant	cohorts.	Mitochondrial	energy	metabolism	data	of	 the	 three	
cell	 fractions	 was	 complemented	 with	 data	 on	 glycolytic	 immunometabolism,	 thereby	
testing	for	compensatory	energy	pathways	and	cellular	activation	status.		
Figure	22	 summarizes	 the	kinetic	profiles	as	well	 as	basal	 (measurement	 three	on	 time	
axis)	and	maximal	Extracellular	Acidification	Rate	 (ECAR)	 (highest	value	after	oligomycin	
injection	 on	 time	 axis)	 for	 all	 three	 cell	 populations.	 For	 comparability	 purposes	 with	
previously	 shown	 OCR	 graphs,	 all	 time	 points	 are	 displayed	 in	 the	 kinetic	 profile.	
However,	 time	 points	 following	 FCCP	 injection	 were	 excluded	 from	 the	 analysis	 of	
glycolytic	activity,	because	the	data	compromise	additional	metabolic	pathway	activities	
including	 glutaminolysis	 and	 the	 pentose	 phosphate	 pathway.	 Activities	 of	 these	
pathways	also	affect	changes	in	pH	in	the	medium	measured	by	the	Seahorse	analyzer.		
CD4+	T	cells	from	MS	patients	showed	decreased	basal	ECAR	compared	to	HC	participants	
(n=24	pairs,	p≤0.001).	There	was	no	significant	difference	in	baseline	ECAR	in	CD8+	T	cells	
(n=23	pairs,	p=0.32).	Non-CD4+/CD8+	T	cells	showed	a	trend	toward	 increased	glycolytic	
activity	in	MS	patients	(n=25	pairs,	p=0.06).	Maximal	ECAR	after	oligomycin	injection	was	
significantly	decreased	 in	CD4+	T	cells	 from	MS	patients	 (n=24	pairs,	p=0.01),	but	not	 in	
CD8+	T	cells	(n=23	pairs,	p=0.19)	and	non-CD4+/CD8+	T	cells	(n=24	pairs,	p=0.37).		
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Figure	22:	Changes	 in	Extracellular	Acidification	Rates,	between	group	analyses	of	MS	
patient’s	and	HC	participant’s	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells.	The	
data	was	generated	in	real-time	under	basal	conditions,	in	response	to	oligomycin,	FCCP	
and	Rotenone	and	Antimycin	A	using	a	Seahorse	XFe	96	Analyzer	(Agilent).	Kinetic	profile	
of	ECAR	values	of	CD4+	T	cells	(A),	CD8+	T	cells	(D)	and	non-	CD4+/CD8+	T	cells	(G).	Basal	
ECAR	in	(B)	CD4+	T	cells	n=24	pairs.	(E)	CD8+	T	cells	n=23	pairs	and	(H)	non-CD4+/CD8+	T	
cells	n=25	pairs.	Maximal	ECAR	after	oligomycin	injection	in	(C)	CD4+	T	cells	n=24	pairs,	(F)	
CD8+	T	cells	n=23	pairs	and	(I)	non-CD4+/CD8+	T	cells	n=20	pairs.	(A,	D,	G)	Mean	with	SEM	
calculated	 for	each	 time	point.	 (B,	C,	E,	F,	H,	 I)	Wilcoxon	signed-rank	 test	with	medians	
with	interquartile	ranges	are	displayed.	ECAR:	extracellular	Acidification	Rate,	HC:	healthy	
control,	MS:	multiple	sclerosis.	
3.2.6 Metabolic	Phenotype	of	Purified	Immune	Cells		
The	 previous	 figures	 showed	mitochondrial	 and	 glycolytic	 activity	 of	 purified	 CD4+	 and	
CD8+	T	cells	as	well	as	non-CD4+/CD8+	T	cells.	To	summarize	and	illustrate	the	changes	in	
OCR	and	ECAR	 from	basal	 levels	 (third	value	on	 time	axis	 in	previous	kinetic	graphs)	 to	
maximal	 levels	 (for	 OCR	 after	 FCCP	 injection,	 for	 ECAR	 after	 oligomycin	 injection	 on	
previous	kinetic	graphs)	 for	each	cell	population,	energy	graphs	were	generated.	Figure	
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23	summarizes	the	data	on	cellular	 immunometabolism	in	CD4+	T	cells,	CD8+	T	cells	and	
non-CD4+/CD8+	T	cells	comparing	the	MS	patient	and	HC	participant	cohorts.		
CD4+	T	cells	from	MS	patients	not	only	showed	decreased	basal	and	maximal	OCR	values,	
but	 also	 displayed	 lower	 basal	 and	 maximal	 ECAR	 rates	 compared	 to	 HC	 participants	
(Figure	23	A).	This	alludes	to	an	overall	dysfunction	in	cellular	energy	metabolism	within	
the	CD4+	T	cell	population	in	MS	patients.	CD8+	T	cells	did	not	show	impairments	in	OCR	
and	ECAR	comparing	the	MS	patient	and	HC	participant	cohorts	 (Figure	23	B).	The	non-
CD4+/CD8+	T	cell	fraction	did	not	show	alterations	in	OCR	values	between	both	groups.	In	
the	MS	 patient	 cohort,	 non-CD4+/CD8+	 T	 cells	 showed	 a	 trend	 toward	 increased	 basal	
ECAR	 values	 compared	 to	 HC	 participants,	 potentially	 alluding	 to	 elevated	 glycolytic	
activity	in	this	cell	population	(Figure	23	C).	
	
	
Figure	23:	Energy	graphs	OCR	vs.	ECAR	in	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	
cells	in	MS	patients	and	HC	participants.	The	data	was	generated	in	real-time	under	basal	
conditions,	 in	 response	 to	oligomycin	 (maximal	 ECAR)	 and	FCCP	 (maximal	OCR)	using	 a	
Seahorse	XFe	96	Analyzer	(Agilent).	(A)	CD4+	T	cells	MS	(n=23):	basal	OCR:	10.5	(1.8),	basal	
ECAR:	7.7	(0.6),	max.	OCR:	49.5	(7.3),	max.	ECAR:	13.4	(0.8).	CD4+	T	cells	HC:	basal	OCR:	
16.3	(1.5),	basal	ECAR:	10.8	(0.9),	max.	OCR:	86.3	(17.2),	max.	ECAR:	16.6	(1.3).	(B)	CD8+	T	
cells	MS	 (n=23):	 basal	 OCR:	 16.8	 (2.5),	 basal	 ECAR:	 11.3	 (1.5),	max.	 OCR:	 101.2	 (24.7),	
max.	ECAR:	19.6	(2.8).	CD8+	T	cells	HC:	basal	OCR:	17.5	(2.9),	basal	ECAR:	12.6	(1.8),	max.	
OCR:	87.2	(18.1),	max.	ECAR:	22.9	(3.2).	(C)	non-CD4+/CD8+	T	cells	MS	(n=24):	basal	OCR:	
24.3	 (2.9),	 basal	 ECAR:	 54.0	 (5.1),	max.	 OCR:	 139.1	 (24.2),	max.	 ECAR:	 61.3	 (7.4).	 non-
CD4+/CD8+	 T	 cells	 HC:	 basal	 OCR:	 20.9	 (2.0),	 basal	 ECAR:	 44.6	 (3.6),	 max.	 OCR:	 117.0	
(17.0),	max.	ECAR:	54.7	(4.3).	Means	with	SEM	(in	brackets)	calculated.	For	some	points,	
the	error	bars	would	be	shorter	than	the	height	of	the	symbol,	therefore,	in	these	cases	
the	 error	 bars	 were	 excluded.	 OCR:	 Oxygen	 Consumption	 Rate,	 ECAR:	 extracellular	
Acidification	Rate,	max.:	maximal,	HC:	healthy	control,	MS:	multiple	sclerosis.	
	
In	summary,	comprehensive	immunometabolic	profiles	of	enriched	CD4+	and	CD8+	T	cells	
as	well	as	non-	CD4+/CD8+	T	cells	were	generated	for	the	MS	patient	and	HC	participant	
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cohorts.	Two	main	cellular	energy	pathways	were	analyzed,	mitochondrial	respiration	as	
well	 as	 glycolytic	 respiration,	 providing	 central	 insights	 into	 immunometabolism	 in	MS	
disease.	
To	further	investigate	the	complexity	of	immune	cell	subpopulations	and	gain	insight	into	
specific	 cell	 signaling,	 flow	 cytometry	 analyses	 of	 MS	 patient’s	 and	 HC	 participant’s	
PBMCs	were	performed.		
3.3 	Flow	Cytometry	Analyses		
Metabolic	analyses	showed	 impaired	energy	profiles	 in	 immune	cells	 from	MS	patients.	
Predominantly,	enriched	CD4+	T	cells	 from	MS	patients	displayed	an	overall	decrease	 in	
mitochondrial	 and	 glycolytic	 activity.	 To	 investigate	 the	 phenotype	 of	 specific	 cell	
subpopulations,	 PBMCs	 were	 analyzed	 by	 flow	 cytometry.	 Complementing	 the	
phenotypic	 characterization	 of	 the	 PBMCs,	 the	 analysis	 of	 a	 potential	 impairment	 in	
mitochondrial	respiration	as	well	as	T	cell	exhaustion	was	of	great	interest.	Therefore,	the	
mitochondrial	 membrane	 protein	 CPT1a,	 essential	 in	 fatty	 acid	 transfer	 into	
mitochondria,	and	the	cellular	exhaustion	marker	PD-1,	upregulated	in	ongoing	immune	
cell	 activation,	 were	 assessed.	 Phenotypic	 characterization	 as	 well	 as	 CPT1a	 and	 PD-1	
target	analyses	provide	more	detailed	 information	about	 the	underlying	mechanisms	of	
modulations	in	immunometabolism.	
3.3.1 Phenotypic	Characterization	of	Immune	Cell	Subpopulations		
The	 phenotype	 of	 PBMCs	 from	 MS	 patients	 and	 their	 correspondingly	 matched	 HC	
participants	was	analyzed	pairwise	in	flow	cytometry.	Antibody	staining	panels	are	listed	
in	Table	12.	There	were	no	significant	differences	 in	the	relative	number	of	CD4+	T	cells	
(p=0.59),	 CD8+	 T	 cells	 (p=0.24),	 regulatory	 T	 cells	 (T	 regs)	 (p=0.86)	 as	 well	 as	 classical	
(p=0.68),	 intermediate	 (p=0.56)	 and	 non-classical	 (p=0.54)	 monocytes	 between	 MS	
patients	and	HC	participants	(n=29	pairs)	(Figure	24).		
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Figure	24:	 T	 cell	 and	monocyte	 subpopulations	 show	no	differences	 in	 frequency	between	MS	
patients	and	HC	participants.	Between	group	analyses	of	MS	patients	and	HC	participants,	n=29	
pairs.	T	cells	are	%	of	live	T	cells	in	CD3+	T	cell	population,	monocytes	are	%	of	live	monocytes	in	
FSC/SSC	monocyte	gate.	CD4+	T	cells	p=0.59,	CD8+	T	cells,	Tregs,	CD14+	CD16-	classical	monocytes,	
CD14+	 CD16+	 intermediate	 monocytes	 and	 CD14+	 CD16+high	 non-classical	 monocytes.	 Wilcoxon	
signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	 ,	 HC:	 healthy	 control,	 MS:	
multiple	sclerosis.	
	
CD4+	 central	 memory	 (CM),	 effector	 memory	 (EM),	 terminally	 differentiated	 effector	
memory	cells	re-	expressing	CD45RA	(TEMRA)	and	naïve	T	cells	(TN)	do	not	show	significant	
differences	in	%	of	CD4+	T	cells	between	MS	patients	and	HC	participants	(all	p≥0.52,	n=28	
pairs)	 (appendix	Figure	36).	CD8+	TCM	show	a	trend	towards	being	decreased	within	the	
CD8+	T	cell	population	 in	MS	patients	compared	to	HC	participants	(p=0.06,	n=28	pairs).	
TEM,	TEMRA	and	TN	CD8+	T	cells	do	not	show	significant	differences	in	%	of	CD8+	T	cells	(all	
p≥0.32,	n=28	pairs)	(appendix	Figure	36).	
Comparing	 and	 analyzing	 frequencies	 of	 T	 cell	 subtypes	 based	 on	 the	 expression	 of	
chemokine	 receptors,	 MS	 patients	 show	 a	 decreased	 frequency	 of	 CD8+	 CCR6+	 T	 cells	
compared	 to	 HC	 participants	 (n=29	 pairs,	 p=0.03,	 appendix	 Figure	 37).	 Additional	
chemokine	receptor	expressing	CD4+	helper	and	CD8+	effector	T	cell	subpopulations	did	
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not	 show	 statistically	 significant	 differences	 in	 frequencies	 between	 both	 cohorts	 (all	
p≥0.31,	appendix	Figure	37).	
Analyzing	 non	 T	 cell	 populations,	 an	 increased	 amount	 of	 B	 cells	 was	 detected	 in	 MS	
patients’	PBMCs	(n=29	pairs,	p≤0.01,	appendix	Figure	38).		Furthermore,	the	frequency	of	
cytotoxic	 NK	 cells	 was	 significantly	 decreased	 (p≤0.001)	 and	 regulatory	 NK	 cells	 were	
significantly	increased	in	MS	patients	(p≤0.001,	appendix	Figure	39).		
In	conclusion,	no	major	differences	in	frequencies	of	CD4+	and	CD8+	T	cell	subpopulations	
or	 monocyte	 subsets	 were	 detected	 comparing	 the	 MS	 patient’s	 and	 HC	 participant’s	
cohorts.	Alterations	of	B	cell	and	NK	cell	populations	could	be	shown	in	MS	patients.	
3.3.2 CPT1a	Expression	in	Immune	Cell	Subpopulations	
Complementing	phenotypic	analyses,	intracellular	CPT1a	protein	staining	was	performed	
in	all	cell	subtypes	to	further	investigate	metabolic	functioning.	
To	 confirm	 the	 specificity	 of	 the	 CPT1a	 antibody,	 its	 isotype	 control	 was	 used	 to	 stain	
PBMCs	from	an	MS	patient-HC	participant	pair.	Figure	25	displays	exemplary	histograms	
in	 major	 T	 cell	 subpopulations	 comparing	 the	 CPT1a	 antibody	 and	 isotype	 control	
staining.	The	isotype	control	stainings	did	not	show	detectable	background	fluorescence,	
which	 could	 allude	 to	 non-specific	 FC-receptor	 binding	 or	 protein	 interactions.	 These	
results	are	representative	for	other	PBMC	subpopulations.		
	
Figure	25:	Flow	cytometry	isotype	control	staining	for	CPT1a	coupled	AlexaFluor®488	antibody	
in	CD4+	and	CD8+	T	cells.		Histogram	show	stainings	of	PBMC	subpopulations	from	an	MS	patient-
HC	 participant	 pair	 using	 the	 CPT1a	 antibody	 (AlexaFluor®488,	 clone	 8F6AE9,	 Abcam)	 and	 its	
isotype	 control	 (mouse	 IgG2b	 AlexaFluor®488,	 clone	 7E10G10,	 Abcam).	 CPT1a:	 Carnitine	
palmitoyltransferase	I	isoform,	HC:	healthy	control,	MS:	multiple	sclerosis.	
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Total	 CD4+	 T	 cells	 and	 CD4+	 helper	 T	 cell	 populations,	 Th0,	 Th1,	 Th2,	 Th17	 and	 Th1/17	
cells,	 showed	 increased	 CPT1a	 median	 fluorescent	 intensity	 (MFI)	 in	 MS	 patients	
compared	to	HC	participants	(all	p≤0.02,	n=29	pairs)	(Figure	26	A,	C).	A	representative	MS	
patient-HC	participant	histogram	is	shown	for	each	cell	population	(Figure	26	B,	D).	
	
	
Figure	 26:	 CD4+	 T	 cells	 and	 CD4+	 helper	 T	 cell	 subpopulations	 show	 increased	 MFI	 of	 CPT1a	
analyzed	by	flow	cytometry.	 (A,C)	Between	group	analyses	for	MS	patients	and	HC	participants	
are	shown,	n=29	pairs.	(B,	D)	Histograms	show	CPT1a	expression	in	a	representative	MS	patient-
HC	 participant	 pair	 in	 the	 corresponding	 cell	 subsets.	Wilcoxon	 signed-rank	 test,	medians	with	
interquartile	 ranges	 are	 displayed.	 CPT1a:	 Carnitine	 palmitoyltransferase	 I	isoform,	 Th:	 T	 helper	
cell,	MFI:	Median	Fluorescent	Intensity,	HC:	healthy	control,	MS:	multiple	sclerosis.	
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There	 were	 no	 differences	 in	 CPT1a	 MFI	 measured	 in	 naïve,	 EM,	 CM	 or	 TEMRA	
subpopulations	 in	CD4+	as	well	as	 in	CD8+	T	cells	between	MS	patients	and	matched	HC	
participants	(all	p≥0.15,	n=28	pairs)	(appendix	Figure	40).	 
CD4+	T	regs	and	the	subpopulation	of	naïve	T	regs	showed	 increased	CPT1a	MFIs	 in	MS	
patients	 (p≤0.023,	n=29	pairs).	Memory	T	regs	showed	a	trend	toward	 increased	CPT1a	
MFI	 in	MS	patients	 (p=0.066,	n=29	pairs)	 (Figure	27	A).	A	representative	MS	patient-HC	
participant	histogram	is	shown	for	each	subpopulation	(Figure	27	B).	
	
Figure	27:	CD4+	regulatory	T	cell	subpopulations	show	increased	CPT1a	MFIs	as	analyzed	by	flow	
cytometry.	 (A)	 Between	 group	 analyses	 for	 MS	 patients	 and	 HC	 participants	 are	 shown.	 n=29	
pairs.	(B)	Histograms	show	CPT1a	expression	in	the	corresponding	cell	subsets	of	a	representative	
MS	patient-HC	participant	pair.	Wilcoxon	signed-rank	test,	medians	with	interquartile	ranges	are	
displayed.	CPT1a:	Carnitine	palmitoyltransferase	 I	isoform,	T	 reg:	 regulatory	T	 cell,	MFI:	Median	
Fluorescent	Intensity,	HC:	healthy	control,	MS:	multiple	sclerosis.	
When	analyzing	CD8+	T	cell	subpopulations,	 it	was	shown	that	total	CD8+	T	cells	did	not	
differ	in	CPT1a	MFI	(p=0.59,	n=29	pairs),	while	the	subsets	of	CCR4+	T	cells,	CCR6+	T	cells	
and	CXCR3+	T	cells	showed	increased	CPT1a	MFIs	in	MS	patients	(all	p≤0.02,	n=29	pairs)	
(Figure	28	A).	This	concludes	that	there	may	be	CD8+	T	cell	sub-populations	that	did	not	
differ	 in	or	displayed	decreased	CPT1a	MFI	between	the	MS	patient	and	HC	participant	
groups.	 It	 may	 most	 likely	 be	 that	 these	 cells	 are	 non-chemokine	 receptor	 expressing	
cells.	 Histograms	 from	 representative	 case-control	 pairs	 are	 shown	 for	 each	 cell	
population	(Figure	28	B).	
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Figure	28:	CD8+	T	 cell	 subpopulations	 showed	 increased	MFI	 for	CPT1a	 in	 flow	cytometry.	 (A)	
Between	group	analyses	for	MS	patients	and	HC	participants	are	shown.	n=29	pairs.	CD8+	T	cells.	
CD8+	CCR4+	Tcells.	CD8+	CCR6+	T	cells.	CD8+	CXCR3+	T	cells.	(B)	Corresponding	histograms	show	a	
presentative	MS	patient-HC	participant	pair	MFI	of	CPT1a	vs.	cell	count	for	each	cell	population.	
Wilcoxon	signed-rank	 test,	medians	with	 interquartile	 ranges	are	displayed.	CCR:	CC	chemokine	
receptor,	 CXCR3:	 CXC	 chemokine	 receptor	 3,	 MFI:	 Median	 Fluorescent	 Intensity,	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
Furthermore,	CPT1a	MFI	was	analyzed	 in	B	 cells,	NK	 cell	 subpopulations	and	monocyte	
subpopulations.	 MS	 patients	 showed	 increased	 CPT1a	 MFI	 in	 cytotoxic	 NK	 cells	 (n=29	
pairs,	p≤0.05)	and	a	trend	of	increased	CPT1a	in	regulatory	NK	cells	(n=29	pairs,	p=0.057).	
B	cell	and	monocyte	subpopulations	did	not	differ	compared	to	the	HC	cohort	(appendix	
Figure	41	A).	
In	 conclusion,	 CD4+	 helper	 T	 cells,	 T	 regs,	 naïve	 T	 regs	 as	 well	 as	 CD8+	 T	 cell	
subpopulations	and	cytotoxic	NK	cells	showed	increased	levels	of	CPT1a	in	the	MS	patient	
cohort	compared	to	the	HC	participant	cohort.		
These	 results	 suggest	 a	 dysfunction	 in	mitochondrial	 energy	 regulation	 in	MS	 patient’s	
immune	cell	subtypes,	predominantly	in	CD4+	T	cell	subpopulations	and	therefore	add	to	
the	 results	 obtained	 in	 the	 Seahorse	 analyses	 with	 a	 decrease	 in	 mitochondrial	 and	
glycolytic	activity	observed	in	CD4+	T	cells.	
3.3.3 PD-1	Expression	in	Immune	Cell	Subpopulations	
To	investigate	whether	PBMCs	from	MS	patients	indicate	cellular	exhaustion	phenotypes,	
cell	 surface	PD-1	 (programmed	cell	death-1)	 levels	were	measured.	Overall,	 there	were	
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no	significant	differences	in	PD-1	expression	measured	in	any	T	cell	population.	Figure	29	
shows	PD-1	MFIs	for	CD4+	T	cells	(p>0.1,	n=29	pairs)	and	CD8+	T	cells	(p>0.1,	n=29	pairs).	
	
Figure	29:	PD-1	expression	levels	in	CD4+	and	CD8+	T	cells	from	MS	patients	and	HC	participants.	
Within	group	analyses	of	MS	patients	and	HC	participants	 (n=29	pairs).	CD4+	T	cells	and	CD8+	T	
cells.	 Wilcoxon	 signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
PD-1	expression	analyses	in	CD4+	and	CD8+	T	cell	subpopulations	(naïve,	memory,	effector	
and	helper	 T	 cells	 as	well	 as	 T	 regs)	did	not	 show	changed	patterns	 comparing	 the	MS	
patient	and	HC	participant	cohorts.		
Taken	together,	the	results	indicate	that	PD-1	expression	patterns	are	not	altered	in	T	cell	
subpopulations	 from	 MS	 patients	 compared	 to	 HC	 participants	 and	 therefore	 do	 not	
indicate	a	PD-1-mediated	cellular	exhaustion	phenotype.		
3.3.4 IL7-Rα 	and	IL2-Rα 	expression	in	conventional	T	cells		
IL7-Rα	 (CD127)	 and	 IL2-Rα	 (CD25)	 play	 essential	 roles	 in	 CD4+	 T	 cell	 development	 and	
homeostasis.	 In	this	study,	the	markers	were	primarily	used	to	discriminate	T	regs	from	
CD4+	 CD25-	 CD127+	 conventional	 T	 cells.	 In	 addition	 to	 using	 IL7-Rα	 and	 IL2-Rα	 for	
phenotyping,	 the	 MFI	 was	 analyzed	 in	 CD4+	 CD25-	 CD127+	 conventional	 T	 cells,	 which	
provided	 information	 about	mature	 CD4+	 T	 cell	maintenance,	 activation,	 survival	 and	 T	
cell	receptor	signaling	excluding	T	regs.	The	results	showed	a	trend	toward	decreased	IL7-
Rα	and	no	changes	in	IL2-Rα	expression	in	CD4+	CD25-	CD127+	conventional	T	cells	of	MS	
patients	compared	to	HC	participants	(Figure	30).	The	histogram	shows	a	representative	
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MS	patients	and	HC	participant	pair	 for	 IL7-Rα	 (Figure	30	A).	 IL7-Rα	 (n=29	pairs,	p≤0.1)	
and	IL2-Rα	(n=28	pairs,	p=0.844)	(Figure	30	B	and	C).	
	
Figure	30:	Conventional	CD4+	T	cells	show	a	trend	towards	decreased	IL7-Rα 	and	no	changes	in	
IL2-Rα 	expression	in	MS	patients	compared	to	HC	participants.		(A)	The	histogram	shows	IL7-Rα	
(CD127)	expression	in	conventional	T	cells	from	a	representative	MS	patient-HC	participant	pair.	
Between	group	analyses	of	MFI	in	conventional	T	cells	of	MS	patients	and	HC	participants,	IL7-Rα	
n=29	pairs,	p=0.066	 (B)	and	 IL2-Rα	n=28	pairs,	p=0.844	 (C).	Wilcoxon	signed-rank	 test,	medians	
with	 interquartile	 ranges	 are	 displayed.	 Conventional	 T	 cells	 are	 defined	 as	 all	 CD4+	 T	 cells	
excluding	CD25+	CD127+	T	regs.	T	regs:	regulatory	T	cells,	conventional	T	cells:	CD4+	CD25-	CD127+	
conventional	T	cells,	HC:	healthy	control,	MS:	multiple	sclerosis.	
3.4 mRNA	Gene	Expression	in	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	
T	cells		
Complementing	the	metabolic	analyses	with	the	Seahorse	analyzer	and	the	phenotypic,	
CPT1a	and	PD-1	protein	level	analyses	by	flow	cytometry,	gene	expression	was	measured	
in	MS	patient’s	and	HC	participant’s	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	
(defined	 as	 all	 PBMCs	 except	 for	 CD4+	 and	 CD8+	 T	 cells).	 In	 mRNA	 gene	 expression	
analyses,	mechanisms	 like	 post-translational	 protein	modifications	 can	 be	 omitted	 and	
direct	gene	transcription	measured.			
Linking	 pro-inflammatory	 signaling	 pathways	 along	 with	 energy	 metabolism	 activation	
pathways	 were	 the	 main	 interest.	 Therefore,	 genes	 encoding	 key	 cellular	 signaling	
proteins	that	integrate	metabolism	and	inflammation	were	chosen	for	analysis	and	mRNA	
expression	 levels	 were	 measured.	 The	 genes	 of	 interest	 were	 tumor	 necrosis	 factor-α	
(TNF-α),	glucose	transporter	1	(GLUT1),	Carnitine	palmitoyltransferase	I	isoform	(CPT1a),	
nuclear	factor	'kappa-light-chain-enhancer'	of	activated	B-cells	(NFκB)	1	and	NFκB3.	
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Additionally,	 to	further	 investigate	the	 impact	and	relevance	of	stress	response	systems	
on	 immune	 cells	 in	 MS	 disease	 and	 to	 accompany	 data	 from	 circadian	 hypothalamic-
pituitary-adrenal	(HPA)	axis	activity	measured	by	salivary	cortisol,	mRNA	expression	levels	
of	 the	glucocorticoid	 receptor	 (GR)	 and	 the	glucocorticoid-induced	 leucine	 zipper	 (GILZ)	
were	measured	in	all	three	cell	fractions.		
3.4.1 mRNA	Analysis	of	Pro-Inflammatory	and	Energy	Metabolism	Genes	TNF-a,	
NFκB1,	NFκB3,	GLUT1	and	CPT1a	
Pair-wise	within	group	analyses	of	TNF-α,	GLUT1,	CPT1a,	NFκB1	and	NFκB3	mRNA	gene	
expression	 levels	 between	 the	 MS	 patient	 cohort	 and	 HC	 participant	 cohort	 were	
performed.	 There	 were	 no	 significant	 differences	 in	 mRNA	 expression	 levels	 of	 the	
analyzed	genes	in	CD4+	T	cells	(n=26	pairs,	p>0.1)	and	CD8+	T	cells	(n=26	pairs,	p>0.1).	In	
non-CD4+/CD8+	T	 cells,	TNF-α	 levels	were	elevated	 in	MS	patients	 (n=25	pairs,	 p≤0.05)	
and	 there	was	 a	 trend	 toward	 increased	 CPT1a	 expression	 levels	 in	MS	 patients	 (n=25	
pairs,	 p≤0.1),	 while	 the	 other	 genes	 did	 not	 show	 differing	 expression	 patterns	 (n=23	
pairs,	all	p>0.1)	(Figure	31).		
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Figure	 31:	 Analysis	 mRNA	 gene	 expression	 in	 CD4+	 T	 cells,	 CD8+	 T	 cells	 and	 non-
CD4+/CD8+	T	cells	from	MS	patients	and	HC	participants.	Expression	analyses	for	GLUT1,	
NFκB1,	NFκB3,	 TNFα	and	 CPT1a	 are	 shown.	 	The	 ratio	 between	 NFκB1	and	 NFκB3	was	
determined	 for	NFκB	expression.	 CD4+	 T	 cells:	 n=26	pairs,	 p>0.1	 for	 all	 genes	 analyzed.	
CD8+	T	cells:	n=26	pairs,	p>0.1	for	all	genes	analyzed.	non-CD4+/CD8+	T	cells:	n=25	pairs,	
p>0.1	 if	 not	 depicted.	 Gene	 transcript	 levels	 were	 assessed	 relative	 to	 housekeeping	
genes	 IPO8	 and	 TBP	 following	 ΔΔCT.	 Wilcoxon	 signed-rank	 test	 with	 medians	 with	
interquartile	ranges	are	displayed.	CPT1a:	Carnitine	palmitoyltransferase	I	isoform	a,	TNF-
α:	 Tumor	 Necrosis	 Factor-α,	 NF-κB:	 nuclear	 factor	 'kappa-light-chain-enhancer'	 of	
activated	B-cells,	GLUT1:	Glucose	Transporter	1,	IPO8:	Importin	8,	TBP:	TATA	Box	Binding	
Protein,	HC:	healthy	control,	MS:	multiple	sclerosis.	
3.4.2 mRNA	Analysis	of	Glucocorticoid	Receptor	(GR)	and	Glucocorticoid-induced	
Leucine	Zipper	(GILZ)		
GR	 and	 GILZ	 gene	 expression	 were	 analyzed	 in	 CD4+	 T	 cells,	 CD8+	 T	 cells	 and	 non-
CD4+/CD8+	 T	 cells	 from	 MS	 patients	 and	 HC	 participants.	 Significant	 differences	 were	
observed	 in	GILZ	mRNA	expression	 levels	 in	CD4+	T	cells	with	higher	gene	expression	 in	
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MS	patients	(n=27	pairs,	p≤0.05)	and	 in	GR	mRNA	expression	 levels	 in	CD8+	T	cells	with	
lower	 gene	 expression	 in	 MS	 patients	 (n=27	 pairs,	 p≤0.01).	 In	 non-CD4+/CD8+	 T	 cells,	
there	were	no	group	differences	in	GR	or	GILZ	gene	expression	(Figure	32).		
	
Figure	32:	Analysis	GR	and	GILZ	mRNA	gene	expression	in	CD4+	T	cells,	CD8+	T	cells	and	
non-CD4+/CD8+	 T	 cells	 from	MS	 patients	 and	 HC	 participants.	 CD4+	 T	 cells:	GR	 n=26	
pairs,	GILZ	n=27	pairs.	CD8+	T	cells:	GR	and	GILZ	n=26	pairs.	non-CD4+/CD8+	T	cells:	GR	and	
GILZ	 n=24	 pairs.	 Gene	 transcript	 levels	 were	 assessed	 relative	 to	 housekeeping	 genes	
IPO8	and	TBP	following	ΔΔCT.	Wilcoxon	signed-rank	test	with	medians	with	interquartile	
ranges	 are	 displayed.	 GR:	 Glucocorticoid	 Receptor,	GILZ:	 Glucocorticoid-induced	 Leucine	
Zipper,	IPO8:	Importin	8,	TBP:	TATA	Box	Binding	Protein,	HC:	healthy	control,	MS:	multiple	
sclerosis.	
3.5 Cortisol	Levels	in	Saliva	Samples		
To	 analyze	 circadian	 hypothalamic-pituitary-adrenal	 (HPA)	 axis	 activity,	 salivary	 cortisol	
levels	were	measured	at	four	time	points	on	the	two	consecutive	days	following	the	study	
site	visit	(morning	and	evening).	25	MS	patient-HC	participant	pairs	were	analyzed	(Figure	
33).	There	were	no	significant	differences	between	the	two	groups	at	morning	or	evening	
measures	 (p>0.1).	A	significant	difference	was	measured	between	morning	and	evening	
samples	across	both	groups	showing	increased	cortisol	levels	after	awakening	(p<0.001).		
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Figure	 33:	No	difference	 in	morning	and	 evening	 salivary	 cortisol	 levels	 between	MS	patients	
and	HC	participants.	On	two	consecutive	days,	two	morning	(after	awakening,	time	point	1	and	3)	
and	two	evening	(at	9pm,	time	point	2	and	4)	saliva	samples	were	analyzed.	n=25	pairs.	Day	one,	
morning:	 p=0.10,	 evening:	 p>0.99.	 Day	 two,	 morning:	 p=0.24,	 evening:	 p=0.96.	 A	 significant	
difference	in	cortisol	levels	was	measured	between	morning	and	evening	cortisol	levels	(p<0.001)	
for	both	groups.	2x4	repeated	measures	Anova,	95%	confidence	interval.	HC:	healthy	control,	MS:	
multiple	sclerosis.	
3.6 	Clinical	Data	Correlation	Analyses	
Correlation	 analyses	 were	 performed	 in	 order	 to	 observe	 associations	 between	 case	
report	form	(CRF)	data	and	metabolic	and	flow	cytometry	results.	From	CRF	data,	the	MS	
progression	 index	was	 chosen	 for	 correlation	 analyses.	 	 It	 is	 calculated	 by	 dividing	 the	
Expanded	Disease	Status	Scale	(EDSS)	score	by	disease	duration	 	 (the	time	between	the	
clinical	 MS	 diagnosis	 and	 date	 of	 the	 study	 visit)	 [136].	 The	 EDSS	 allows	 the	 rating	 of	
disease	progression	on	a	scale	 from	0	 to	10	and	 thereby	defines	 the	patient’s	disability	
status	 based	 on	 the	 physical	 functional	 assessment.	 The	 disease	 duration	 takes	 into	
account	 for	 how	 long	 the	 patients	 have	 been	 diagnosed	 with	MS.	 	 Therefore,	 the	MS	
progression	 index	not	only	provides	 information	about	MS	duration,	but	also	takes	 into	
account	the	patient’s	disability	status.		
To	 recollect	 briefly,	 in	 this	 study,	 the	median	 EDSS	 score	was	 2	 (with	 the	 interquartile	
range	 (IQR)	 of	 0.5-2.5)	 and	 the	median	 disease	 duration	 was	 6.15	 years	 (IQR	 2.7-10.9	
years)	(Table	16).		
Spearman’s	rho	correlation	analyses	between	MS	progression	 index	and	flow	cytometry	
CPT1a	levels	in	CD4+	T	cells	revealed	a	trend	for	a	negative	correlation	with	lower	CPT1a	
levels	 in	 MS	 patients	 with	 higher	 disability	 scores	 (rS=-0.40,	 p=0.06)	 (Figure	 34	 A).	
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Correlation	 analyses	 of	 CPT1a	 in	 CD8+	 T	 cells	 and	 MS	 progression	 index	 revealed	 a	
negative	correlation	(rS=-0.52,	p=0.01)	(Figure	34	B).	Similar	to	CD4+	T	cells,	in	CD8+	T	cells,	
CPT1a	decreases	with	increasing	progression	index.		
Correlation	 analyses	 between	 MS	 progression	 index	 and	 Seahorse	 XFe	 96	 metabolic	
analyzer	 basal	 respiration	 data	 were	 performed	 for	 CD4+	 and	 CD8+	 T	 cell	 subtypes	
(rS=0.13,	 p=0.61	 and	 rS=-0.30,	 p=0.92	 respectively).	 These	 analyses	 did	 not	 reveal	
correlations	(Figure	34	C	and	D).		
	
Figure	34:	Correlation	analyses	between	MS	disease	progression	index	and	metabolic	and	flow	
cytometric	data	in	CD4+	and	CD8+	T	cells.	For	each	patient,	the	MS	disease	progression	index	was	
calculated	by	dividing	the	EDSS	score	by	the	time	since	clinical	MS	diagnosis	and	study	visit,	the	
disease	duration.	Correlation	of	MS	disease	progression	index	with	CPT1a	flow	cytometry	data	in	
(A)	 CD4+	 and	 (B)	 CD8+	 T	 cells.	 n=23.	 Basal	 respiration	 data	 from	 Seahorse	 XFe	 96	 analyzer	
metabolic	assay	analyses	were	correlated	with	the	MS	disease	progression	index	in	(C)	CD4+	and	
(D)	 CD8+	 T	 cells.	 n=18.	 rS=	 Spearman	 correlation	 coefficient.	 EDSS:	 Expanded	 Disability	 Status	
Scale,	 CPT1a:	 Carnitine	 palmitoyltransferase	 I	 isoform	 a,	 HC:	 healthy	 control,	 MS:	 multiple	
sclerosis.	
Taken	 together,	 the	data	 shows	a	negative	 correlation	between	CPT1a	and	 the	disease	
progression	 index	 in	T	cell	 subtypes	of	 the	MS	patient	cohort.	For	metabolic	analysis	of	
basal	respiration,	an	association	between	T	cell	subtypes	and	disease	progression	was	not	
found.		
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4 Discussion	
4.1 The	DENIM	Study	Provides	a	Robust	MS	Patient	and	HC	Participant	
Cohort	
Providing	 a	 solid	MS	 patient	 and	 HC	 participant	 background	with	 respect	 to	 biological	
samples	 (PBMCs	and	saliva)	as	well	as	case	report	 form	data	 is	 the	basis	 for	pre-clinical	
analyses	 and	 utterly	 crucial	 in	 the	 evaluation	 and	 interpretation	 of	 the	 extensive	
laboratory	data.	
The	strengths	of	the	DENIM	study	include	the	meticulously	matched	RRMS	patients	and	
HC	participants	with	respect	to	age	(≤55	years),	sex,	BMI	(≤30	kg/m2)	and	smoking	status.	
Physical	and	psychological	comorbidities	were	excluded.	These	criteria	are	known	to	be	
associated	with	strong	inflammatory	effects	and	it	is	therefore	essential	to	consider	them	
in	patient	and	HC	participant	analyses.		Data	from	62	MS	patients	and	HC	participants	was	
analyzed	 providing	 a	 relatively	 large	 cohort	 of	 human	 clinical	 and	 corresponding	 pre-
clinical	 data.	 Patients	 and	 participants	 had	 no	 significant	 physical	 or	 psychological	
comorbidities	 and	 medications	 other	 than	 immunomodulatory	 therapy.	 Furthermore,	
also	 critical	 for	 the	 extensive	metabolic	 analyses,	 all	 patients	 and	 participants	 had	 not	
eaten	 for	 12	 hours	 prior	 to	 the	 blood	 draw	 and	 PBMCs	 were	 processed	 within	 thirty	
minutes.	 These	 clinical	 study	 criteria	 provide	 a	 strong	 foundation	 for	 the	 pre-clinical	
analyses	and	have	not	been	presented	in	previous	studies	related	to	metabolism	and	MS	
research	in	human	immune	cells.		
In	the	past	three	years,	first	studies	analyzed	immune	cell	metabolism	in	RRMS	patients.	
In	2017,	La	Rocca	and	colleagues	published	data	comparing	PBMCs	from	RRMS	patients	
without	 treatment,	with	 INF-β1a	treatment	and	healthy	controls	 [120].	While	 the	study	
provided	critical	metabolic	data,	the	patients	and	control	participants	were	not	matched	
and	not	fasting	for	a	time	period	prior	to	the	study	visit	whole	blood	draw.	De	Riccardis	
and	 colleagues	provided	data	on	 immunometabolism	 in	 a	 cohort	 of	 treatment-free	MS	
patients	in	2015	[121].	RRMS	patients	and	HC	participants	were	matched	for	age,	but	not	
for	other	parameters	or	 analyzed	 in	pairs.	 The	 subsequent	 text	will	 discuss	 the	 specific	
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results	 of	 these	 studies	with	 respect	 to	 the	data	provided	 in	 the	DENIM	 study	 in	more	
detail.	
Taken	 together,	 while	 analyzing	 first	 human	 RRMS	 patients,	 data	 on	 patients	matched	
one	on	one	to	HC	participants	with	respect	to	key	metabolic	influences	like	BMI,	age,	sex	
and	smoking	status	as	well	as	fasting	blood	draw	is	missing.	Furthermore,	the	studies	did	
not	consider	physiological	and	psychological	diseases,	which	are	key	influencing	factors	in	
MS	disease	(namely	major	depressive	disorder)	and	have	been	shown	to	contribute	to	the	
inflammatory	profile	of	immune	cells.	
The	 DENIM	 study	 considers	 key	 systemic	 modulators	 of	 inflammation	 and	 examines	
patients	 and	 HC	 participants	 in	within	 group	 pairwise	 analyses.	 It	 is	 important	 to	 note	
again	 that	 the	 aim	 of	 the	 study	 was	 to	 examine	 patients	 in	 remission	 and	 the	 results	
obtained	 help	 to	 understand	 this	 phase	 of	 RRMS	 disease	 and	 to	 elucidate	 potential	
influences	on	relapse	rates	and	disease	progression.	
	
4.2 Detection	of	Comparable	Phenotyping	Profiles	of	Major	T	cell	
Subpopulations	in	MS	Patients	and	HC	Participants	
It	 is	 known	 that	 inflammation	 in	 disease	 states	 leads	 to	 a	 shift	 in	 the	 immune	 cell	
repertoire	 in	 human.	 Depending	 on	 the	 intruding	 pathogen,	 e.g.	 extra-	 or	 intracellular	
bacteria,	viruses	or	worms,	specific	immune	cell	subtypes	are	activated	and	proliferation	
processes	 induced	to	 fight	the	 infection.	 In	autoimmune	diseases	 like	MS,	analyzing	the	
specific	immune	cell	phenotype	plays	a	central	role	to	better	understand	the	disease	and	
the	 cellular	 and	 humoral	 factors	 contributing	 to	 the	 activation	 of	 the	 immune	 system	
against	 self-structures.	 These	 analyses	 can	 help	 to	 allude	 to	 disease	 causing	 factors,	
development	and	progression	as	well	as	potentially	hint	to	new	therapeutic	targets.	
In	 the	 current	 study,	 a	 comprehensive	 PBMC	 immune	 cell	 phenotyping	was	 performed	
with	 both	 cohorts	 to	 compare	 phenotype	 alterations	 in	 MS	 disease	 versus	 healthy	
individuals.	Additionally,	intracellular	and	cell	surface	molecules	were	analyzed	to	include	
metabolic	 and	 T	 cell	 exhaustion	 markers.	 Routine	 whole	 blood	 analyses	 showed	
decreased	 absolute	 numbers	 of	 lymphocytes	 in	MS	 patients	 while	 relative	 numbers	 of	
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lymphocytes	 measured	 by	 flow	 cytometry	 did	 not	 show	 differences	 between	 both	
cohorts.	Hence,	although	MS	patients	show	decreased	absolute	numbers	of	lymphocytes,	
the	 distribution	 of	 T	 cell	 subpopulations	 is	 not	 altered	 in	 the	 MS	 patient	 cohort.	
Comparable	levels	of	major	CD4+	T	cell	subpopulations	including	Tregs	were	detected	in	
MS	patients	and	HC	participants.	Solely	CD8+	CCR6+	effector	T	cells	showed	alterations	of	
the	phenotypic	make	up	with	a	decreased	 frequency	 in	MS	patients.	 Finally,	memory	T	
cell	subpopulations	did	not	show	alterations	between	MS	patients	and	HC	participants.	
In	RRMS,	 shifts	 in	 the	 immune	cell	 repertoire	have	been	described.	Studies	 could	 show	
increasing	populations	of	activated	CD4+	T	cell	subpopulations	as	well	as	CD8+	effector	T	
cells	in	patients	in	active	disease	phases	[137]–[139].	These	cell	populations	were	shown	
to	become	re-activated	once	they	cross	the	BBB	and	 infiltrate	the	CNS.	Within	the	CNS,	
they	 migrate	 to	 inflammatory	 sites,	 induce	 the	 formation	 of	 lesions	 and	 with	 that	
neuronal	 demyelination.	 Therefore,	 immunomodulatory	 drugs	 approved	 for	 RRMS	
treatment	 are	 effective	 in	 preventing	 disease	 progression	 by	 targeting	 different	
mechanisms	 of	 actions	 of	 T	 cells	 and	 other	 immune	 cells.	 Briefly,	 the	 mechanisms	 of	
action	 include:	 the	 prevention	 of	 T	 cell	 activation	 and	 division,	 the	 inhibition	 of	 pro-
inflammatory	 cytokine	 secretion,	 the	 trapping	 of	 T	 cells	 in	 lymph	 nodes	 and	with	 that	
prevention	of	their	migration	into	the	CNS,	inhibition	of	B	cell	function	and	the	induction	
of	Tregs	[2],[140]–[142].		
To	 date,	 it	 could	 be	 shown	 that	 the	 frequency	 of	 Tregs	 in	 PBMCs	 from	RRMS	 patients	
does	 not	 seem	 to	 be	 altered,	 but	 may	 be	 accompanied	 by	 a	 decreased	 suppressive	
capacity	 [143],[144].	 A	 study	 by	 Feger	 et	 al.	 revealed	 increased	 CD4+	 CD25+	 Treg	
frequencies	in	the	CSF	of	MS	patients	with	neuroinflammation	and	no	differences	of	Treg	
frequency	in	MS	patient’s	PBMCs	[143].	These	findings	were	accompanied	by	a	reduced	
immunosuppressive	 capacity	 of	 Tregs.	 The	 authors	 suggest	 that	 peripheral	 Tregs	 are	
recruited	 from	 the	 blood	 to	 the	 CNS	 of	MS	 patients	 with	 ongoing	 neuroinflammation.	
They	further	discuss	their	findings	by	stating	that	Tregs	enrichment	in	the	cerebral	spinal	
fluid	(CSF)	of	the	CNS	may	not	be	sufficient	to	fight	neuroinflammation.	These	results	are	
accompanied	 by	 studies	 demonstrating	 functional	 impairments	 of	 Tregs,	 specifically	
impaired	immunosuppressive	capacities	[145],[146].	Here,	Treg	quality	is	imperative	over	
quantity.	The	studies	demonstrate	that	the	specific	roles	of	Tregs	in	MS	disease	and	the	
mechanisms	of	action	of	this	cell	population	leave	opportunities	for	more	detailed	cellular	
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signaling	analyses	in	active	and	remission	disease	phases	as	well	as	peripheral	blood	and	
CSF	 analyses.	 Furthermore,	 the	 interaction	 with	 other	 immune	 cell	 populations	 with	
regard	to	cell	activation	and	cytokine	secretion	should	be	considered.		
Data	 on	 phenotypic	 alterations	 in	 CD4+	 T	 cell	 subpopulations	 indicate	 that	 it	 may	 not	
merely	 be	 the	 quantity	 of	 cells	 or	 the	 phenotypic	 make	 up	 leading	 to	 MS	 disease	
development	 and	 progression,	 but	 cell	 specific	 dysfunctions	 including	 potential	
alterations	 in	 immunometabolic	 signaling,	 which	 may	 contribute	 to	 auto-reactive	
processes	observed	in	MS	disease.	
While	the	precise	functions	of	CD8+	effector	T	cell	subpopulations	are	still	 the	center	of	
research,	 CD8+	 CCR6+	 T	 cells	 have	 been	 shown	 to	 be	 essential	 in	 Th17-mediated	 pro-
inflammatory	 immune	 responses	 [50].	 A	 decreased	population	of	 CD8+	 CCR6+	 T	 cells	 in	
PBMCs	of	MS	patients	may	indicate	the	transmigration	of	these	cells	from	the	peripheral	
blood	 to	 potential	 inflammatory	 sites.	 However,	 the	 observed	 decrease	 of	 this	 cell	
population	 in	the	current	study	requires	future	detailed	analyses	 in	order	to	conclude	a	
potential	 link	 to	 MS	 disease	 progression.	 Studies	 by	 other	 research	 groups	 have	 not	
described	this	effect	in	MS	disease	to	date.	
Due	 to	 the	high	proliferative	 capacities	of	memory	T	 cell	 subsets	and	 their	potential	of	
pro-inflammatory	cytokine	secretion	upon	a	secondary	antigen	encounter,	the	influence	
of	memory	T	cells	on	MS	disease	has	been	examined.	In	the	current	study,	alterations	in	
memory	T	cell	 subsets	of	MS	patients	could	not	be	detected.	Previous	studies	analyzed	
CD4+	 memory	 T	 cell	 phenotypes	 in	 MS	 patients	 and	 the	 effect	 of	 different	
immunomodulatory	medications:	decreases	in	TCM	cells	in	patients	treated	with	INF-β	or	
glatiramer	acetate	[147],	increases	in	TCM	cells	in	patients	treated	with	fingolimod	[148],	
decreases	 of	 TCM	 and	 TEM	 cells	 in	 patients	 treated	 with	 dimethyl	 fumerate	 [149]	 and	
unchanged	TCM	and	TEM	cell	populations	in	patients	on	natalizumab	treatment	[150].	The	
current	study	 included	patients	with	different	kinds	of	 immunomodulatory	medications,	
which	may	be	causative	of	the	observed	CD4+	memory	T	cell	subset	phenotypes	in	the	MS	
patient	 cohort.	 A	 study	 by	 Haegele	 et	 al.	 analyzed	 16	 RRMS	 patients	 and	 compared	
peripheral	blood-derived	and	CSF-derived	memory	CD4+	and	CD8+	T	 cell	 subsets	 to	age	
and	 sex-matched	healthy	 controls	 [151].	 Patients	were	 in	 active	 disease	 states	 or	 after	
relapse	and	free	of	immunomodulatory	therapy.	The	authors	detected	increased	CD8+	TEM	
T	 cell	 populations	 in	 peripheral	 blood	 of	 patients	 compared	 to	 healthy	 individuals	 and	
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discuss	 their	 finding	by	potential	 systemic	 immune	activation	and	 increased	MS	disease	
activity.	Furthermore,	Haegele	and	colleagues	observed	a	reduction	in	CD8+	TEM	T	cells	in	
the	 CSF	 of	 MS	 patients	 compared	 to	 the	 patient’s	 corresponding	 peripheral	 blood	
samples.	The	authors	state	that	this	may	be	due	to	CD8+	TEM	T	cells	infiltrating	brain	tissue	
and	 inducing	 inflammatory	 responses	 [151].	 Alterations	 in	 CD4+	memory	 T	 cell	 subsets	
were	 not	 described.	 The	 DENIM	 study	 analyzed	 peripheral	 blood	 samples	 from	 MS	
patients	on	different	immunomodulatory	therapies	providing	data	on	remission	phase	MS	
patient	memory	cell	phenotype	analyses	compared	to	carefully	matched	HC	participants.	
Future	CSF	sample	analyses	may	provide	more	detailed	information	about	alterations	in	
memory	 T	 cell	 subsets	 in	 MS	 remission	 phase	 and	 their	 impact	 on	 CNS	 infiltration.	
However,	 considering	 the	 importance	 of	 immunometabolism,	 patient	 and	 control	
matching	should	be	considered.	
Taken	 together,	 the	 phenotypic	 analyses	 of	 the	 CD4+	 and	 CD8+	 T	 cell	 subpopulations	
showed	 little	 or	 no	 changes	 in	 the	MS	 patient	 cohort	 compared	 to	 the	 HC	 participant	
cohort.	Therefore,	qualitative	analyses	may	hint	to	potential	dysfunctions	in	MS	patient’s	
immune	 cell	 subpopulations.	 The	 results	 of	 immunometabolic	 analyses	 of	 T	 cell	
subpopulations	are	subsequently	discussed.	
	
4.3 Decreased	Immunometabolic	Potential	is	specific	to	CD4+	T	cells	from	
MS	Patients	
To	date,	it	is	commonly	known	that	immune	cells	adapt	their	metabolic	function	based	on	
their	 immediate	requirements,	however,	 little	 is	known	about	 immunometabolic	effects	
in	MS	patients.	Novel	 detection	 and	 analyses	 technologies	 developed	 in	 the	past	 years	
are	allowing	detailed	measurements	of	cellular	metabolism	and	the	definition	of	specific	
pathways	involved	within	very	short	periods	of	time.	These	technologies	help	to	allude	to	
underlying	cellular	dysfunctions	and	eventually	establish	targets	for	new	therapies.	
In	the	current	study,	for	the	first	time,	the	immunometabolic	profile	of	sorted	CD4+	and	
CD8+	 T	 cells	 from	RRMS	patients	was	 analyzed	 in	 real-time	 using	 the	 latest	 technology	
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with	 the	 Seahorse	 XFe96	 analyzer	 and	 compared	 to	 a	 meticulously	 matched	 HC	
participant	cohort.		
It	 could	 be	 shown	 that	 CD4+	 T	 cells	 from	MS	 patients	 display	 a	 significantly	 decreased	
basal	mitochondrial	oxygen	consumption	rate.	Parameters	of	mitochondrial	function	like	
maximal	 respiration,	 cellular	 spare	 respiratory	 capacity	 as	 well	 as	 ATP	 production	 also	
showed	decreased	levels	in	the	MS	patient	cohort.	Only	measurements	of	mitochondrial	
proton	leakage	were	comparable	between	both	cohorts.	These	results	allude	to	reduced	
mitochondrial	 function	 in	 CD4+	 T	 cells	 from	MS	 patients.	 Furthermore,	 the	 analysis	 of	
glycolytic	activity	showed	decreased	levels	in	CD4+	T	cells	from	MS	patients-	hence,	these	
cells	 are	 not	 compensating	 decreased	 mitochondrial	 activity	 by	 increasing	 glycolysis.	
Contrary	 to	 the	observed	effects	 in	CD4+	T	cells,	CD8+	T	cells	 from	MS	patients	 showed	
metabolic	parameters	of	oxygen	consumption	as	well	as	glycolytic	activity	comparable	to	
those	 of	 the	 HC	 participant	 cohort.	 Interestingly,	 the	 observed	 effects	 in	 decreased	
immunometabolic	activity	are	CD4+	T	cell	specific	in	the	RRMS	patient	cohort.	
First	studies	on	immune	cell	metabolism	in	MS	patients	have	been	published	in	the	past	
three	 years.	 The	 study	 by	 La	 Rocca	 and	 colleagues	 detected	 decreased	 mitochondrial	
oxygen	 consumption	 rate	activity	 as	well	 as	 glycolytic	 activity	 in	 TCR-stimulated	PBMCs	
from	RRMS	patients	without	treatment	compared	to	HC	controls	[120].	No	difference	was	
found	 between	 HC	 and	 INF-β1a	 treated	 patients,	 however	 there	 were	 detectable	
differences	 in	mitochondrial	 respiration	between	 the	no-treatment	and	 INF-β1a	patient	
groups.	 Limitations	of	 the	 study	are	 that	mitochondrial	 respiration	of	 the	no-treatment	
cohort	 was	 analyzed	 in	 eleven	 patients	 only	 and	 compared	 to	 non-matched	 HC	
individuals.	 Whole	 PBMCs	 were	 analyzed	 and	 no	 distinction	 between	 different	 cell	
populations	 was	 made.	 Additionally,	 the	 authors	 did	 not	 consider	 sex	 effects,	 BMI,	
smoking	status	or	physical	or	psychological	 comorbidities.	No	 fasting	blood	draws	were	
analyzed.	Nevertheless,	 the	 study	provides	 first	 crucial	 data	on	emerging	differences	 in	
energy	metabolism	in	 immune	cells	 from	MS	patients	and	hints	to	 influences	of	current	
state	of	the	art	RRMS	medication	and	immunometabolic	function.		
The	current	study	sheds	 light	 into	the	mechanisms	of	 immunometabolic	dysfunctions	 in	
sorted	 CD4+	 and	 CD8+	 T	 cells	 from	 MS	 patients	 and	 allows	 conclusions	 about	 the	
mechanisms	contributing	to	MS	disease.	The	decrease	in	oxygen	consumption	and	overall	
mitochondrial	activity	observed	in	CD4+	T	cells	may	be	associated	with	impairments	in	the	
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ETC	 in	 MS	 patients.	 In	 their	 2015	 study,	 De	 Riccardis	 and	 colleagues	 analyzed	 ETC	
complexes	 and	 cellular	 respiration	 in	 CD4+	 T	 cells	 from	 twelve	 unmedicated	 RRMS	
patients	 and	 compared	 the	 data	 to	 eight	 age-matched	 healthy	 individuals	 [121].	 The	
authors	detected	decreased	protein	 levels	of	ETC	complexes	 I	and	 IV	 in	RRMS	patients.	
These	 findings	 were	 associated	 with	 decreased	 oxygen	 consumption	 rates	 and	 ATP-
production	 levels	 in	 CD4+	 T	 cells	 from	 RRMS	 patients	 as	 well	 as	 increased	 levels	 of	
glycolysis	and	glycolysis-derived	ATP.	While	the	study	provides	a	relatively	low	number	of	
MS	patients	and	HC	participants,	 it	provides	crucial	data	on	ETC	impairments.	 Increased	
glycolytic	 activity	 was	 accompanied	 by	 increased	 GLUT1	 protein	 levels	 as	 well	 as	
increased	 lactate	 production,	 which	 the	 authors	 describe	 as	 a	 potential	 hint	 to	 an	
energetic	switch	from	OXPHOS	to	glycolysis	in	the	observed	cohort.		
To	the	best	of	knowledge,	detailed	mitochondrial	analyses	of	sorted	CD8+	T	cells	from	MS	
patients	 have	 not	 been	 published	 to	 date.	 Complementing	 the	 observed	 effects	 of	
impaired	mitochondrial	complex	function	in	CD4+	T	cells	by	De	Riccardis	and	colleagues,	it	
may	 be	 assumed	 that	 similar	 dysfunctions	 could	 have	 related	 effects	 in	 CD8+	 T	 cells.	
However,	detailed	analyses	have	to	follow.		
In	addition	to	cellular	analyses,	serum	tests	contributed	findings	of	metabolic	dysfunction	
in	MS.	In	2013,	Braidy	and	colleagues	showed	increased	NADH	levels	in	serum	from	RRMS	
patients	 compared	 to	 healthy	 individuals.	 The	 impairment	 in	 complex	 I	 (NADH	
dehydrogenase)	 ETC	 activity	 observed	 by	 De	 Riccardis	 [152]	 alludes	 to	 potential	
connections	between	this	ETC	complex	impairment	and	increased	NADH	serum	levels	in	
patients.	 Taken	 together,	 these	 results	 strengthen	 the	 findings	 on	 immunometabolic	
dysfunctions	 in	 MS	 patients	 and	 should	 be	 taken	 into	 consideration	 when	 finding	
therapeutic	targets	in	future	investigations.		
Furthermore,	common	MS	symptoms	and	co-morbidities	including	fatigue	and	depression	
could	 be	 associated	 with	 impaired	 mitochondrial	 energy	 production,	 suggesting	 that	
dysregulated	 energy	 metabolism	 in	 immune	 cells	 may	 impact	 other	 organ	 systems,	
tissues	 and	 cells	 and	with	 that	 contribute	 to	 systemic	 effects.	 Likewise,	 adaptations	 in	
energy	metabolism	in	CD4+	T	cells	may	be	due	to	potential	dysregulations	in	other	cells,	
tissues	and	organ	systems.	Here,	the	complex	 interaction	of	the	central	nervous	system	
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and	 the	 immune	 system	 is	 most	 noteworthy	 and	 has	 comprehensively	 been	 reviewed	
[153]–[155].	
The	significantly	decreased	 levels	of	ATP	production	 in	CD4+	T	cells	 in	 the	current	study	
are	 due	 to	 decreased	 OXPHOS	 activity	 [86].	 Specific	 data	 of	 glycolytic	 ATP-production	
could	not	be	generated	with	the	applied	method.	However,	in	CD4+	T	cells	of	MS	patients,	
the	decrease	in	basal	and	maximal	glycolytic	activity	accompanied	by	decreased	OXPHOS	
leads	to	the	assumption	that	the	cellular	energy	production	via	both	main	cellular	energy	
pathways	is	decreased	in	general	and	no	compensatory	switch	from	OXPHOS	to	glycolysis	
occurs.	The	decrease	 in	OXPHOS	and	glycolytic	activity	could	be	described	as	an	overall	
decreased	cellular	 fitness	of	CD4+	T	cells	 from	MS	patients.	The	 reduced	cellular	 fitness	
can	be	also	observed	in	the	significantly	decreased	rate	of	non-mitochondrial	respiration	
in	CD4+	T	cells	from	MS	patients.	Non-mitochondrial	respiration	data	entails	the	pentose	
phosphate	pathway	as	well	as	glutaminolysis	and	amino	acid	metabolism,	the	 later	also	
contributing	 to	 citrate	 cycle	 energy	 production.	 Furthermore,	 maximal	 respiration	 and	
with	that	spare	respiratory	rates	did	not	reach	levels	detected	in	HC	participants,	which	
furthermore	 indicates	 decreased	 fitness	 levels	 of	 CD4+	 T	 cells	 from	 MS	 patients	 and	
comprehensive	impairments	in	cellular	energy	production.			
Adiele	et	al.	comprehensively	reviewed	the	 latest	 findings	on	 immunometabolic	defects	
related	to	MS	disease	in	their	2017	review	[156].	The	authors	systematically	discuss	key	
findings	including	the	contributing	factors	of	metal	metabolism	as	well	as	dysfunctions	in	
mitochondrial	 and	 oxygen	 metabolism	 on	 a	 cellular	 level	 in	 the	 blood	 and	 CNS.	 The	
research	articles	cited	provide	broad	evidence	that	metabolic	aspects	have	strong	effects	
on	 MS	 disease	 prevention,	 course	 and	 progression.	 The	 biochemical	 and	 molecular	
defects	 involve	 comprehensive	 pathways	 and	 signaling	 cascades	 and	 with	 that	 require	
future	studies	to	clarify	the	mechanism	of	metabolic	dysfunctions	in	MS	disease.	
Future	immunometabolic	analyses	will	build	on	the	ones	presented	in	the	current	study	
and	provide	more	data	on	cellular	energy	consumption,	e.g.	more	detailed	CD4+	and	CD8+	
T	cell	subtype	analyses.	Furthermore,	longitudinal	clinical	study	analyses	of	remission	and	
relapse	phases	 including	the	 impact	of	 treatment	as	well	as	disease	monitoring	via	MRI	
imaging	will	shed	light	onto	the	interaction	of	the	CNS	and	immunometabolic	regulation	
in	MS	patients.		
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Comprehensive	 laboratory	 analyses	 of	 protein	 and	 gene	 expression	 as	 well	 as	 routine	
blood	testing	performed	with	the	MS	patient	and	HC	participant	samples	from	the	DENIM	
study	 help	 to	 allude	 to	 potential	 causes	 of	 the	 observed	 cellular	 dysfunction	 in	 energy	
metabolism	in	T	cells	of	MS	patients	and	are	subsequently	discussed.	
	
4.4 CD4+	and	CD8+	T	cell	Subpopulations	from	MS	Patients	Express	
Increased	Levels	of	the	Mitochondrial	Membrane	Protein	CPT1a		
In	 this	 thesis,	 it	 could	 be	 shown	 that	 the	mitochondrial	membrane	 protein	 CPT1a	was	
significantly	 increased	 in	 all	 CD4+	 T	 cell	 subpopulations	 (Th1,	 Th2,	 Th17,	 Th1/17,	 Tregs)	
and	CD8+	effector	T	cell	subsets	in	the	MS	patient	cohort	compared	to	the	HC	participant	
cohort.	Memory	T	 cells	of	MS	patients	 showed	CPT1a	protein	 levels	 comparable	 to	 the	
ones	detected	in	the	HC	participant	cohort.	These	findings	are	observed	for	the	first	time	
in	 a	 human	MS	 study	 and	 hint	 to	 significant	 functional	 impairments	 in	 cellular	 energy	
metabolism	and	the	mitochondrial	membrane	protein.	Conventional	CD4+	T	cells	showed	
increased	 levels	 of	 CPT1a,	 a	 trend	 towards	decreased	 IL7-Rα	 and	no	 changes	 in	 IL2-Rα	
expression	in	MS	patients.	Furthermore,	cellular	PD-1	expression	analyses	did	not	reveal	
alterations	 in	 PD-1	 expression	 in	 T	 cell	 subpopulations	 in	 MS	 patients.	 Therefore,	 the	
observed	 findings	 in	metabolic	dysfunction	and	CPT1a	protein	expression	 in	CD4+	T	cell	
subsets	 were	 not	 accompanied	 by	 modified	 PD-1	 expression	 levels	 in	 MS	 patients.	
Routine	 blood	 analyses	 indicated	 a	 trend	 toward	 decreased	 serum	 HDL	 levels	 in	 MS	
patients	 adding	 to	 potential	 impairments	 in	 fatty	 acid	 utilization.	 Moreover,	 it	 was	
analyzed	 whether	 modified	 gene	 expression	 complements	 the	 observed	 metabolic	
effects.	CPT1a	and	GLUT1	as	well	as	key	inflammatory	genes	TNFα,	NFκB1	and	NFκB3	did	
not	reveal	an	adapted	profile	in	CD4+	and	CD8+	T	cells	in	MS	patients.	Finally,	correlation	
analyses	of	CPT1a	protein	abundance	in	CD4+	T	cells	from	MS	patients	revealed	a	negative	
correlation	 with	 the	 disease	 progression	 index.	 These	 data	 hint	 to	 a	 decrease	 of	 the	
detected	elevated	cellular	CPT1a	with	increasing	disability	and	MS	disease	duration	over	
time.	
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Various	 metabolic	 alterations	 may	 be	 causative	 of	 the	 observed	 increase	 in	 CPT1a	
expression	in	MS	patients’	T	cell	subpopulations	and	the	accompanied	overall	decrease	in	
mitochondrial	 respiration	 in	 CD4+	 T	 cells.	 T	 cell	 subpopulations	 may	 compensate	 the	
dysfunctional	protein	by	increasing	its	abundance	and	with	that	potentially	accumulate	a	
multitude	 of	 dysfunctional	 protein	 that	 is	 preventing	 regular	 mitochondrial	 respiration	
and,	overall,	hindering	cellular	signaling	 feedback	pathways	 involved	 in	CPT1a	signaling.		
In	 line	with	 the	described	 effects	 of	 energy	metabolism	on	 immune	 cells,	 the	 group	of	
Nieland	 showed	 that	 EAE	 symptoms	 can	 be	 alleviated	 completely	 by	 inhibiting	 CPT1a	
[157],[158].	 The	 group	 used	 etomoxir	 to	 inhibit	 CPT1a,	 thus	 decreasing	 mitochondrial	
fatty	acid	respiration	and	reversing	clinical	symptoms.	They	describe	their	findings	in	part	
by	 analyzing	 CPT1a	 mutations	 and	 show	 that	 MS	 patients	 frequently	 do	 not	 have	
mutations	 in	CPT1a,	while	healthy	 individuals	 frequently	show	CPT1a	mutations	 leading	
to	 reduced	or	overall	deleted	activity	of	 the	protein	 [158],[159].	The	group	 tested	mice	
and	rats	and	treated	them	with	either	etomoxir	or	INF-β	as	a	control.	The	animals	treated	
with	 the	 CPT1a	 inhibitor	 showed	 down-regulated	 inflammatory	 responses,	 ameliorated	
EAE	 symptoms	 as	 well	 as	 remyelination	 of	 CNS	 neurons	 compared	 to	 INF-β	 treated	
animals.	 The	 authors	 conclude	 that	 CPT1a	 mutations	 in	 humans	 may	 protect	 from	
developing	MS.	 Furthermore,	 the	 results	of	 etomoxir	 treatment	 in	mice	and	 rats	might	
provide	first	 insights	 into	the	benefit	of	targeting	 lipid	metabolism	for	therapy	and	with	
that	 alleviating	 MS	 symptoms	 and	 progression.	 Interestingly,	 Shriver	 and	 Manchester	
showed	 a	 similar	 effect	 in	 EAE-induced	 mice	 where	 etomoxir	 treatment	 ameliorated	
disease	 symptoms	 and	 induced	 a	 decrease	 in	 pro-inflammatory	 cytokine	 production	 as	
well	as	CNS	inflammation	[160].		
Raud	 and	 colleagues	 most	 recently	 published	 data	 on	 differing	 effects	 of	 the	 CPT1a	
inhibitor	 etomoxir	 on	 regulatory	 and	 memory	 T	 cells	 [161].	 The	 authors	 showed	 that	
CPT1a	is	not	required	for	effector	and	memory	T	cell	responses	as	well	as	the	suppressive	
function	of	regulatory	T	cells.	They	hint	to	potential	CPT1a-independent	off	target	effects	
of	 etomoxir	 and	 with	 that	 suggest	 additional	 pathways	 involved	 in	 mitochondrial	
impairments	in	EAE-induced	mice,	which	require	further	detailed	analyses.	Especially	the	
effect	 of	 etomoxir	 dose	 in	 varying	 T	 cell	 subtypes	 requires	 further	 analyses.	 Here,	
differing	cellular	CPT1a	protein	abundance	 in	 specific	T	cell	 subtypes	may	contribute	 to	
etomoxir	effects	and	should	be	taken	into	consideration.	
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In	addition	to	potential	mutations	and	the	involvement	of	signaling	pathways,	metabolic	
impairments	 in	 T	 cell	 subsets	may	 also	 involve	 impairments	 in	CPT1a	mRNA	 to	protein	
translation	processes.	To	date,	common	modifications	in	gene	to	protein	translation	are	
known.	 They	 include	 post-transcriptional	 and	 post-translational	 processes	 or	 subunit	
protein	modifications	 (comprehensively	 reviewed	 in	 [71],[162]–[164]).	 Increased	 CPT1a	
protein	 abundance	 may	 signal	 the	 inhibition	 of	 CPT1a	 gene	 transcription	 and	 protein	
translation.	 Furthermore,	mitochondrial	morphology	modifications	 involving	 fusion	 and	
fission	 processes	 that	 have	 most	 recently	 been	 described	 in	 the	 context	 of	
immunometabolism	in	T	cells	[63]	may	provide	explanations	for	the	observed	difference	
in	 mRNA	 and	 protein	 abundance	 of	 CPT1a.	 Buck	 and	 colleagues	 describe	 that	
mitochondrial	 fission	 seems	 essential	 for	 increased	mitochondrial	 energy	 production	 in	
effector	T	 cells	 [63].	A	decrease	 in	mitochondrial	 respiratory	capacity	may	 therefore	be	
associated	 with	 compromised	 mitochondrial	 fission	 and	 fusion	 processes	 as	 well	 as	
mitochondrial	protein	abundance.	Furthermore,	impaired	mitophagy	processes	leading	to	
increased	 cellular	 ROS	 levels	 and	 damaged	 mitochondria	 as	 described	 by	 Pua	 and	
colleagues	may	 influence	T	 cell	 function	with	 increased	mitochondrial	DNA	and	protein	
abundance	[68].	However,	future	analyses	require	additional	detailed	detection	methods	
like	 immunohistochemical	 and	 microscopy	 analyses	 to	 detect	 potential	 mitochondrial	
morphology	alterations	and	CPT1a	protein	levels	in	MS	patients	T	cells.		
The	availability	of	 fatty	acids	 is	essential	 for	 their	 transport	 into	mitochondria	by	CPT1a	
and	 with	 that	 energy	 production	 via	 OXPHOS.	 In	 this	 thesis,	 the	 MS	 patient	 cohort	
showed	a	trend	of	decreased	HDL	serum	levels	compared	to	the	HC	participant	cohort.	In	
MS	 disease,	 the	 contributions	 of	 metabolic	 pathways	 including	 lipid	 metabolism	 to	
disease	 progression	 have	 been	 studied.	 Corthals	 comprehensively	 reviewed	
immunometabolic	 alterations	 in	MS	 and	 proposes	 a	 new	 framework	 for	 understanding	
MS	 disease	 as	 a	 dysfunctions	 of	 lipid	 metabolism	 [165].	 In	 short,	 Corthals	 suggests	 a	
skewed	homeostasis	of	lipid	metabolism	in	immune	cells	during	acute	phase	MS	and	pro-
inflammatory	processes	 leading	to	 increased	cellular	oxidative	stress	and	demyelination	
of	 CNS	neurons.	HDL	 as	well	 as	 associated	 signaling	proteins	have	been	described	 as	 a	
potent	anti-inflammatory	agent	essential	in	cellular	protective	processes	and	contributor	
of	 lipid	metabolism	 in	MS	 disease	 [166]–[169].	 Decreased	 HDL	may	 therefore	 indicate	
reduced	 cellular	 protection	 from	 pro-inflammatory	 signaling	 processes	 and	 cellular	
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damage.	Furthermore,	first	studies	with	ketogenic	diet	(low	in	carbohydrates)	and	fasting	
have	 proven	 protective	 in	 human	 MS	 and	 murine	 EAE	 models	 [109],[170],[171].	
Therefore,	the	contributions	of	diet	in	MS	disease	should	be	taken	into	consideration.	The	
effects	 of	 glucose	 and	 lipids	 from	 diet	 in	 MS	 patients	 may	 present	 future	 targets	 to	
potentially	assist	MS	immunomodulatory	drugs	and	possibly	alleviate	disease	progression	
by	 enhancing	 anti-inflammatory	 immunometabolic	 cell	 function.	 Here,	 the	 benefit	 of	 a	
fasting	diet	and	autophagy	processes,	essential	in	the	removal	of	cellular	waste	products	
and	self-renewal,	should	be	considered.	
Various	research	groups	studied	the	 interactions	between	 immunometabolism	and	pro-
inflammatory	signaling	in	T	cells.	The	results	of	this	thesis	showed	no	alterations	in	pro-
inflammatory	and	metabolic	gene	expression	levels	in	CD4+	or	CD8+	T	cells	of	MS	patients,	
which	may	be	due	to	the	fact	that	the	observed	patients	were	all	in	remission	and	in	the	
non-active	 disease	 phase.	 Increased	 pro-inflammatory	 signaling	 has	 been	 observed	 in	
activated,	proliferating	and	stimulated	T	cells	and	has	even	been	shown	to	contribute	to	
effector	 T	 cell	 subset	 distinguishments	 [172]	 and	 metabolic	 adaptations	 [173].	
Furthermore,	 effector	 T	 cell	 responses	 and	 overall	 cellular	metabolic	 adaptations	 have	
been	shown	to	be	regulated	by	AMPK	signaling	cascades	[174]	including	NFκB	and	TNFα	
pathways,	 which	 are	 central	 pro-inflammatory	 signaling	 pathways	 involved	 cellular	
activation	and	TCR	stimulation.	Cretenet	and	colleagues	have	shown	that	TCR-stimulated	
CD4+	 helper	 and	 CD8+	 effector	 T	 cell	 subsets	 display	 distinct	 immunometabolic	 profiles	
with	 upregulated	Glut1	 expression	 levels	 [172].	 This	 alludes	 to	 the	 assumption	 that,	 in	
addition	 to	 fatty	acid	metabolism,	adaptations	 in	metabolic	pathways	 including	glucose	
metabolism	are	crucial	for	T	cell	activation	and	proliferation.	CD4+	or	CD8+	T	cells	of	MS	
patients	in	relapse	and	active	disease	state	may	therefore	present	altered	metabolic	and	
pro-inflammatory	gene	expression	levels	and	should	be	considered	in	future	analyses.	
Furthermore,	 PD-1	 receptor	 analyses	 were	 performed	 on	 T	 cell	 subpopulations.	 The	
results	complemented	the	data	on	CPT1a	protein	expression	 in	T	cell	subsets	as	well	as	
metabolic	assay	analyses	of	CD4+	and	CD8+	T	cells.		To	date,	to	the	best	of	knowledge,	PD-
1	 expression	 on	 T	 cell	 subpopulations	 alongside	 of	 phenotypic	 analyses	 has	 not	 been	
analyzed	 in	MS	patients.	 	 In	autoimmunity,	 co-inhibitory	T	cell	 receptors	 including	PD-1	
have	been	shown	to	be	crucial	 regulators	 in	the	prevention	of	auto-reactivity	 [106]	and	
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effective	 in	 determining	 cellular	 exhaustion	 in	 auto-immunity	 [104],[146],[175].	 T	 cell	
exhaustion	is	described	to	include	the	loss	of	effector	function,	the	inability	to	transition	
to	 quiescence	 or	memory	 phenotypes,	 a	 transformed	 transcriptional	 profile	 as	 well	 as	
alterations	in	energy	metabolic	signaling	[176].	Especially	PD-1	receptors’	direct	signaling	
interplay	 with	 energy	 pathways,	 TCR	 signaling	 and	 the	 potential	 to	 modify	 cellular	
metabolic	 programs	 in	 T	 cells	 has	 been	 demonstrated	 [177].	 	 Interestingly,	 various	
research	 groups	 have	 described	 immunometabolic	 alterations	 during	 PD-1-mediated	 T	
cell	 exhaustion	 in	 CD8+	 T	 cells.	 Here,	 upregulated	 PD-1	 has	 been	 shown	 to	 drive	 T	 cell	
exhaustion	 in	 chronic	 viral	 infection	 [178],	 a	mechanism	 that	 has	 been	 assumed	 to	 be	
involved	in	MS	disease	development	and	progression	[179].	The	persistent	stimulation	of	
the	TCR,	a	mechanism	of	T	cell	exhaustion,	is	attenuated	by	PD-1	engagement	leading	to	
the	 inhibition	 of	 downstream	 pro-inflammatory	 signaling	 cascades	 involving	 PI3K	 and	
AKT.	The	PI3K-AKT	signaling	cascade	is	a	central	cellular	signaling	pathway	involved	in	e.g.	
cellular	 growth,	 proliferation	 and	 glucose	 metabolism.	 Furthermore,	 Patsoukis	 et	 al.	
showed	 in	 their	 2015	 study	 that	 PD-1	 ligation	 inhibits	 amino	 acid	 transport	 and	
metabolism	 as	 well	 as	 glycolysis,	 while	 inducing	 OXPHOS,	 FAO	 and	 upregulated	 CPT1a	
expression	[177].		
In	the	analyzed	MS	patient	cohort	of	the	current	study,	elevated	CPT1a	protein	levels	in	T	
cell	 subsets	 and	 decreased	 OXPHOS	 and	 glycolysis	 levels	 in	 CD4+	 T	 cells	 were	 not	
accompanied	 by	 differential	 expression	 of	 PD-1.	 Moreover,	 mRNA	 expression	 analyses	
involving	the	PI3K-AKT	signaling	cascades	also	showed	no	difference	in	gene	expression.	
Additional	surface	proteins	indicating	cellular	exhaustions	may	be	an	additional	choice	for	
future	 analyses	 in	MS	 patients	 in	 remission	 and	 could	 therefore	 provide	more	 insights	
into	potential	T	cell	exhaustion	and	its	interplay	with	metabolic	signaling	cascades.	
Finally,	 it	 was	 interesting	 to	 detect	 a	 trend	 of	 decreased	 IL7-Rα	 and	 unaltered	 IL2-Rα	
expression	 in	 conventional	 CD4+	 T	 cells	 from	MS	 patients	 in	 the	 DENIM	 study.	 Various	
research	 groups	 have	 shown,	 that	 IL-7	 cytokine	 binding	 to	 IL7-Rα	 induces	 a	 negative	
feedback	 loop	 including	 the	 down	 regulation	 and	 internalization	 of	 the	 IL-7Rα	 and	
suppression	of	IL-7Rα	gene	expression	[180].	Lawson	and	colleagues	demonstrated	in	the	
murine	 EAE	 model	 that	 IL-7	 is	 essential	 for	 optimal	 CD4+	 T	 cell	 activation	 processes	
including	TCR	stimulation	and	down	stream	signaling	via	STAT5	and	AKT	cascades	[181].	
The	authors	showed	that	by	blocking	the	IL7-Rα,	EAE	could	be	prevented	and	ameliorated	
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and	the	expansion	and	activation	of	autoantigen-specific	CD4+	T	cells	could	be	inhibited.	
This	may	 lead	 to	 the	conclusion	 that	 low	 IL-7Rα	 levels	may	be	beneficial	 in	MS	disease	
progression.	 Furthermore,	 polymorphisms	 have	 been	 described	 for	 the	 IL7-Rα	 [182]	 as	
well	 as	 the	 IL2-Rα	 [183]	 gene	 in	 MS	 patients.	 The	 authors	 show	 that	 in	 murine	 EAE	
models	 and	 human	 analyses,	 these	 genetic	 variants	 contribute	 to	 MS	 disease	
susceptibility.	Gregory	and	colleagues	discuss	their	findings	in	part	by	stating	that	the	IL7-
R	is	essential	in	B	and	T	cell	differentiation	and	therefore	a	potential	gene	target	for	MS	
development	 [182].	 Wang	 and	 colleagues	 state	 that	 IL-2	 is	 essential	 in	 T	 cell	 growth,	
proliferation	and	function	and	alterations	in	its	IL2-Rα	may	be	associated	with	MS	disease	
susceptibility	 and	progression.	However,	 the	 authors	 furthermore	discuss	 that	 previous	
studies	 on	 the	 IL2-Rα	 gene	 yielded	 conflicting	 results	 where	 polymorphisms	 showed	
associations	with	MS	and	others	did	not	detect	associations.		
Interestingly,	for	RRMS,	an	anti-IL-2R	antibody	was	approved	by	the	European	Medicinal	
Agency	(EMA)	in	2016	as	a	therapeutic	drug	(Daclizumab	beta),	which	has	been	shown	to	
be	 effective	 in	 preventing	 IL-2R	 signaling	 [184]–[186]	 and	 with	 that	 effector	 T	 cell	
activation	[13].	However,	extensive	side	effects	in	more	than	8000	treated	RRMS	patients	
have	 been	 reported	 until	 March	 2018	 in	 Germany	 and	 the	 EMA	 withdrew	 the	 drug’s	
authorization	[187].		
Taken	together,	past	studies	on	 IL2-Rα	and	 IL7-Rα	gene	analyses	have	shown	promising	
results	in	MS	patients.	The	observed	trend	of	decreased	IL7-Rα	expression	in	the	current	
study	 also	 hints	 to	 alterations	 in	 this	 receptor	 and	 potential	 effects	 on	MS	 patients	 in	
remission.	 Future	 evaluations	 should	 also	 consider	 gene	 expression	 analyses	 to	 further	
clarify	the	associations	with	T	cell	function	in	MS	disease.		
To	analyze	a	potential	association	between	MS	disease	severity	and	duration	(progression	
index)	with	CPT1a	protein	expression,	correlation	analyses	were	performed.	The	results	
suggest	 decreasing	 CPT1a	 protein	 abundance	 in	 CD4+	 T	 cells	 with	 increasing	 disease	
course	and	severity	 in	 the	MS	patient	cohort	compared	 to	 the	HC	participant	cohort.	A	
study	by	Koffman	et	al.	points	out	the	limitations	of	the	progression	index	and	that	it	may	
be	misleading	when	used	for	very	short	or	very	 long	disease	durations	[188].	To	further	
analyze	 the	 associations	 between	MS	 disease	 severity	 and	 duration	 and	 CPT1a	 protein	
levels	in	T	cell	subsets,	larger	cohort	analyses	could	be	considered	including	patients	with	
longer	courses	of	disease.	However,	the	correlation	results	 indicate	alterations	 in	CPT1a	
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protein	 abundance	 over	 time	 in	 the	 observed	MS	 patient	 cohort	 compared	 to	 the	 HC	
participant	cohort.	To	the	best	of	knowledge,	such	results	have	not	been	reported	to	date	
and	may	add	to	indications	of	alterations	in	immunometabolic	function	in	MS	patients.	
	
4.5 HPA	Axis	Activity	Corresponds	between	MS	Patients	and	HC	
Participants	While	GR	and	GILZ	Gene	Expression	is	Altered	in	CD4+	and	
CD8+	T	cells		
In	 order	 to	 detect	 CNS-mediated	 stress	 response	 mechanisms	 and	 their	 impact	 on	
immunometabolic	 function	 in	 MS	 patients,	 salivary	 cortisol	 level	 as	 well	 as	 gene	
expression	 analyses	 of	GR	 and	GILZ	 mRNA	 were	 performed.	 The	 MS	 patients	 and	 HC	
participants	were	free	of	psychological	comorbidities	including	major	depressive	disorder	
as	 well	 as	 clinically	 significant	 fatigue	 that	 may	 impact	 CNS-related	 analyses.	 Similar	
morning	 and	 evening	 cortisol	 levels	 were	 observed	 in	 MS	 patients	 compared	 to	 HC	
participants,	while	gene	expression	analyses	showed	altered	profiles	 in	CD4+	and	CD8+	T	
cells.	Here,	MS	patients	showed	significantly	 increased	GILZ	mRNA	levels	 in	CD4+	T	cells	
and	significantly	decreased	GR	levels	in	CD8+	T	cells.		
Alterations	 in	 salivary	 cortisol	 abundance	 throughout	 the	 day	 allude	 to	 impairments	 in	
CNS-mediated	 stress	 response	 mechanisms	 potentially	 affecting	 cellular	 energy	
metabolism	and	immune	response	mechanisms.	In	MS	disease,	the	chronic	activation	of	
immune	response	mechanisms	may	impact	this	sensitive	stress	response	system,	or	vice	
versa,	 and	 further	 deepen	 the	 understanding	 of	 the	 relationship	 of	 CNS	 and	 immune	
system	interactions	in	MS	disease	onset	and	progression.	A	study	by	Gold	et	al.	showed	
that	 salivary	 cortisol	 levels	are	not	altered	between	HC	participants	and	non-depressed	
MS	patients	[122].	The	authors	further	analyzed	MS	patients	with	associated	depressive	
symptoms	and	detected	elevated	evening	cortisol	 levels	compared	to	HC	participants.	A	
study	 by	 Powell	et	 al.	 demonstrated	 elevated	morning	 cortisol	 levels	 in	 RRMS	patients	
compared	 to	 HC	 participants	 [189].	 The	 authors	 further	 demonstrated	 that	 reported	
fatigue	levels	were	associated	with	lower	morning	cortisol	levels	in	MS	patients,	however,	
the	group	could	not	 show	a	causal	 relationship	between	 fatigue	symptoms	and	cortisol	
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levels.	 Similar	 results	 of	 increased	 morning	 cortisol	 levels	 in	 MS	 patients	 and	 disease	
progression	 have	 been	 shown	 by	 Kern	et	 al.	 [190],[191].	 The	 results	 of	 the	mentioned	
studies	 demonstrate	 that	 alterations	 in	 HPA	 axis	 activity	 may	 be	 associated	 with	
symptoms	 like	 fatigue	 and	 comorbidities	 like	MS-associated	 depression	 in	MS	 patients	
and	 not	 directly	 associated	 to	 MS	 disease.	 The	 DENIM	 study	 examined	 patients	 in	
remission,	without	major	 physical	 comorbidities	 and	psychological	 illnesses,	which	may	
be	 an	 indicator	 of	 the	 observed	 levels	 of	 morning	 and	 evening	 cortisol	 that	 were	
comparable	to	the	ones	measured	in	the	HC	participant	cohort.	
While	 cortisol	 levels	were	 comparable	 between	 both	 cohorts	 in	 the	 current	 study,	MS	
patients	showed	alterations	 in	GR	and	GILZ	gene	expression	 levels	 in	MS	patients’	CD4+	
and	 CD8+	 T	 cells.	 One	 of	 the	 major	 targets	 of	 anti-inflammatory	 GILZ	 signaling	 is	 the	
inhibition	of	pro-inflammatory	NFκB	signaling.	In	the	current	study,	CD4+	T	cells	from	MS	
patients	displayed	elevated	GILZ	levels	 independent	of	altered	GR	and	NFκB	expression,	
which	hints	to	signaling	mechanisms	that	involve	additional	cellular	networks	that	should	
be	analyzed	in	future	studies.	Additionally,	GILZ	has	been	shown	to	possess	anti-apoptotic	
effects	 involved	 in	 the	 regulation	 of	 T	 cell	 activation	 and	 preventing	 TCR-activated	
apoptosis	 [97].	This	prevention	of	TCR	activation	has	also	been	shown	to	prevent	NFκB	
activation	 and	 nuclear	 translocation	 to	 further	 initiate	 pro-inflammatory	 cell	 signaling	
cascades	 [97].	 The	 downregulation	 of	 the	 GR	 was	 observed	 in	 immune	 cells	 that	 are	
preventing	 extracellular	 GC	 binding	 with	 respect	 to	 TCR	 activation	 (comprehensively	
reviewed	 in	 [192]),	 thereby	 inhibiting	 CNS-mediated	GC	 influence	 and	 the	 induction	 of	
anti-inflammatory	 signaling.	 Furthermore,	 T	 cell	 cortisol	 response	 and	 resistance	by	GR	
downregulation	has	been	shown	to	be	altered	in	the	murine	EAE	model.	CNS	infiltrates	of	
T	 cells	 in	 EAE-induced	 mice	 showed	 increased	 GC	 resistance	 with	 downregulated	 GR	
which	preceded	CNS	infiltration	and	clinical	symptoms	[193].		
The	 data	 provided	 in	 the	 current	 study	 resulted	 from	 peripheral	 blood-derived	 T	 cells	
from	 MS	 patients	 in	 remission	 without	 major	 comorbidities	 and	 medications.	 The	
observed	 modifications	 in	 GR	 and	 GILZ	 gene	 expression	 allude	 to	 alterations	 in	
glucocorticoid	 signaling	 responses	 and	 should	 be	 analyzed	 further	 to	 provide	 potential	
associations	with	steroid	treatment	response	in	MS	relapse	phases.	
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Taken	 together,	 the	 analysis	 of	 CNS	 hormone	 regulation	 and	 intracellular	 signaling	
pathways	are	indispensable	when	analyzing	the	interaction	of	CNS	and	immunometabolic	
mechanisms	in	MS	disease	and	frequent	comorbidities	like	depression	and	fatigue.	
	
4.6 B	cells	and	NK	cells	show	Modified	Phenotype	Profiles	and	CPT1a	
Protein	Levels	in	MS	Patients	versus	HC	Participants	
Accompanying	the	comprehensive	T	cell	analyses,	B	cells,	NK	cells	and	monocytes	were	
studied	 in	 order	 to	 obtain	 energy	 metabolic,	 phenotypic,	 protein	 level	 and	 gene	
expression	data	 for	 the	MS	patient	and	HC	participant	 cohorts.	 It	 could	be	 shown,	 that	
the	metabolic	profile	of	non-CD4+/CD8+	T	cells	(mainly	composed	of	B	cells,	NK	cells	and	
monocytes)	from	MS	patients	complements	the	one	of	the	HC	cohort	with	the	exception	
of	a	trend	toward	increased	basal	ECAR	values	in	MS	patients.	Furthermore,	an	increased	
TNFα	mRNA	expression	was	detected	 in	non-CD4+/CD8+	T	cells	accompanied	by	a	trend	
toward	increased	CPT1a	mRNA	expression.	Detailed	phenotypic	analyses	were	performed	
to	 define	 the	 cellular	 composition	 of	 the	 non-CD4+/CD8+	 T	 cell	 fraction	 analyzed	 in	
metabolic	 and	 gene	 expression	 assays.	Here,	 a	 strikingly	 increased	 frequency	 of	 B	 cells	
and	regulatory	NK	cells	as	well	as	decreased	frequency	of	cytotoxic	NK	cells	was	observed	
in	 the	MS	 patient	 cohort	 compared	 to	 the	 HC	 participant	 cohort.	 CPT1a	 protein	 levels	
were	 increased	 in	 NK	 cell	 subsets	 but	 not	 in	 B	 cells	 of	MS	 patients.	 Finally,	monocyte	
subpopulations	did	not	show	altered	phenotypic	data	or	CPT1a	protein	expression	in	MS	
patients.		
While	 MS	 is	 generally	 considered	 a	 T	 cell-mediated	 disease	 and	 comprehensively	
described	 in	 this	 thesis,	 B	 cells	 have	 gained	 substantial	 interest	 in	MS	 research.	 To	 the	
best	 of	 knowledge,	 to	 date,	 studies	 have	 not	 analyzed	 or	 shown	 potential	 metabolic	
alterations	of	B	cells	in	MS	patients.	
In	 2018	 first	 murine	 studies	 on	 B	 cell	 metabolism	 have	 been	 published.	 Clarke	 et	 al.	
compared	bioenergetically	more	active	innate-like	tissue	resident	B1	B	cells	to	B2	B	cells	
that	are	continuously	produced	in	the	bone	marrow	and	are	a	distinct	B	cell	subset	from	
B1	B	cells	[194].	The	authors	observed	metabolic	adaptations	including	increased	OXPHOS	
																																	Discussion		
109	
	
and	glycolysis	as	well	as	exogenous	fatty	acid	dependency	in	B1	B	cells	compared	to	B2	B	
cells.	 	 Clarke	 and	 colleagues	 conclude	 that	 B1	 B	 cells	 adapted	 their	 specific	 functional	
properties	to	the	metabolic	requirements	in	their	tissue-resident	environment.	Mendoza	
and	colleagues	showed	increased	OXPHOS	and	aerobic	glycolysis	upon	germinal	center	B	
cell	 response	 accompanied	 by	 the	 activation	 of	 the	 PI3K-AKT-mTORC1	 pathway	 and	
increased	gene	expression	involving	glucose	metabolism	[195].	Moreover,	as	observed	in	
T	cells	and	TCR	signaling,	cellular	fate	is	dependent	on	B	cell	metabolic	programming	and	
mitochondrial	 activation	 involving	 downstream	 B	 cell	 receptor	 signaling	 cascades	
including	 NFκB	 and	mTORC1	 as	well	 as	mitochondrial	 ROS	 production.	 This	 effect	was	
demonstrated	 by	 Tsui	 and	 colleagues	 in	 their	 2018	 study	 with	 murine	 cells	 [196].	
Impairments	 in	 B	 cell	 metabolism	 and	 activation	 following	 antigen	 exposure	 can	
immediately	 impact	 helper	 T	 cell	 fate	 since	 B	 cells	 function	 as	 APCs	 and	 helper	 T	 cells	
provide	a	secondary	signal	for	strong	B	cell	activation	[196].		
The	 effect	 of	 increased	 B	 cell	 populations	 in	 MS	 patients,	 as	 observed	 in	 the	 current	
study,	 has	 also	been	discussed	by	other	 research	 groups.	 Their	 role	 in	MS	has	become	
evident	by	 the	 success	of	α-CD20	 therapy	 (e.g.	 ocrelizumab,	 rituximab)	 [197].	Baecher-
Allan	 and	 colleagues	discuss	 the	beneficial	 effect	 of	α-CD20	 therapy	by	 the	deletion	of	
pro-inflammatory	 B	 cell	 subsets	 that	 is	 driving	 the	 activation	 of	 T	 cells	 via	 antigen	
presentation	[2].	Furthermore,	they	discuss	the	possibility	of	α-CD20	treatment	to	target	
mature	naïve	and	memory	B	cells	leaving	plasma	cells	and	immature	B	cells	unaffected	in	
MS	 patients.	 Interestingly,	 the	 balance	 of	 pro-inflammatory	 B	 cells	 secreting	 e.g.	 IL-6,	
TNFα,	GM-CSF	and	anti-inflammatory	B	cells	secreting	IL-10	and	IL-35	has	been	shown	to	
be	 altered	 in	MS	 patients	with	 an	 increased	 pro-inflammatory	 phenotype	 [198].	 Li	 and	
colleagues	 describe	 a	 GM-CSF	 memory	 B	 cell	 subset	 that	 is	 increased	 in	 MS	 patients	
compared	to	healthy	individuals.	Increased	GM-CSF	secretion	by	B	cells	from	MS	patients	
has	been	demonstrated	to	induce	increased	Th1	and	Th17	development	and	with	that	T	
cell	activation	[198].	The	authors	show	that	upon	α-CD20	therapy,	the	imbalance	of	GM-
CSF	secreting	B	cells	and	anti-inflammatory	IL-10	secreting	B	cells	could	be	reversed	and	
address	the	potential	of	selective	targeting	of	B	cell	subsets	in	MS	disease.	Hauser	et	al.	
showed	 that	 α-CD20	 therapy	 correlates	 with	 decreased	 pro-inflammatory	 cytokine	
secretion	and	the	absence	of	memory	B	cells	in	MS	patients	[199].	Duddy	and	colleagues	
demonstrated	that	the	ratio	of	memory	and	naïve	B	cell	subsets	is	altered	in	MS	patients	
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contributing	to	disease	activity	[55].	The	authors	confirmed	data	showing	that	human	B	
cell	 subsets	 display	 distinct	 cytokine	 profiles	 with	 anti-inflammatory	 IL-10	 production	
almost	exclusively	observed	in	naïve	B	cells	and	pro-inflammatory	TNFα	and	lymphotoxin	
production	attributed	 to	memory	B	cells.	Duddy	et	al.	 showed	that	MS	patients	display	
decreased	IL-10	production	compared	to	healthy	individuals.	
In	 this	 thesis,	 T	 cell	were	 the	 central	 objective	 and	 B	 cell	 subpopulations	 could	 not	 be	
further	 analyzed.	 Future	 analyses	 require	more	detailed	experiments	 to	promote	B	 cell	
subtype	distinguishments	and	B	cell	sorting	for	comprehensive	metabolic	analyses	in	MS	
patients.	 Here,	 the	 role	 of	 B	 cells	 contributing	 to	 T	 cell	 metabolic	 alterations	 and	
immunometabolic	 adaptations	 should	 be	 considered	 closely	 as	 well	 as	 the	 interplay	
between	B	and	T	cell	subpopulations.	
In	addition	to	B	cells,	NK	cells	have	also	been	shown	to	contribute	to	autoimmunity	and	
to	 regulate	 and	 inhibit	 T	 cell	 survival	 in	 MS	 patients.	 In	 the	 current	 study,	 CD56bright	
CD16low	regulatory	NK	cells	were	increased	and	cytotoxic	CD56low	CD16bright	NK	cells	were	
decreased	 in	MS	patients	 compared	 to	HC	participants.	 Cytotoxic	 CD56low	 CD16bright	NK	
cells	compromise	about	90%	of	NK	cells	 in	 the	peripheral	blood	and	are	 found	 in	much	
lower	 frequency	 in	 tissues	 compared	 to	 CD56bright	 CD16low	 regulatory	 NK	 cells	 [2].	
Increases	 in	 CD56bright	 CD16low	 regulatory	 NK	 cells	 were	 observed	 to	 correlate	 with	
immunomodulatory	and	 immunosuppressive	 treatment	response	 in	MS	patients	on	 IL2-
Rα	 therapy	 (daclizumab)	 including	 reductions	 in	 brain	 inflammation	 [200].	 Increased	
CD56bright	CD16low	regulatory	NK	cell	frequencies	have	also	been	shown	in	MS	patients	on	
INFβ	treatment	[201].	While	reductions	in	CD56bright	CD16low	regulatory	NK	cell	frequency	
have	been	associated	with	relapse	rate	[202].	Furthermore,	 it	was	shown	that	CD56bright	
CD16low	 regulatory	 NK	 cells	 possess	 a	 reduced	 ability	 to	 inhibit	 the	 proliferation	 of	
autologous	activated	CD4+	T	cells	in	untreated	MS	patients,	which	the	authors	describe	as	
possibly	relating	to	dysfunctions	 in	this	NK	cell	subset	or	a	reduced	sensitivity	of	CD4+	T	
cells	from	MS	patients	[186].		
Taken	together,	these	observations	provide	form	data	on	the	contributions	of	this	innate	
cell	 type	 to	MS	 disease.	 The	 elevated	 CPT1a	 levels	 observed	 in	 the	MS	 cohort	 of	 the	
DENIM	 study	 have	 been	 described	 for	 the	 first	 time	 in	 NK	 cell	 subsets	 and	 provide	
primary	data	on	potential	that	require	further	investigations.		
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Monocytes,	 as	 a	 main	 cellular	 component	 of	 the	 non-CD4+/CD8+	 T	 cell	 fraction	
investigated	 in	 this	 study	 should	 finally	 be	mentioned.	 In	 RRMS,	monocytes	 have	 been	
shown	to	induce	T	and	B	cell	responses,	contribute	to	immunoregulation	as	well	as	pro-
inflammatory	cytokine	secretion	and	CNS	infiltration	[203]–[205].	In	the	samples	analyzed	
as	 part	 of	 the	DENIM	 study,	 no	phenotypic	 alterations	 or	 adapted	CPT1a	 expression	 in	
monocyte	subsets	were	detect	in	the	MS	patient	cohort	compared	to	the	HC	participant	
cohort.	 To	 the	 best	 of	 knowledge,	 CPT1a	 expression	was	 analyzed	 for	 the	 first	 time	 in	
monocyte	 subpopulations	 in	 a	 human	 MS	 study	 and	 presents	 primary	 data	 on	 the	
mitochondrial	membrane	protein	expression	 in	 these	 cell	 subsets.	Conclusively,	while	T	
cell	subsets	and	NK	cells	displayed	altered	CPT1a	protein	expression	levels,	this	could	not	
be	 observed	 in	 MS	 monocyte	 subtypes.	 These	 findings	 may	 allude	 to	 metabolic	
adaptations	 highly	 specific	 to	 immune	 cell	 subsets	 in	 MS	 disease	 and	 require	 more	
detailed	investigations.	
The	 gene	 expression	 analyses	 of	 the	 non-CD4+/CD8+	 T	 cell	 fraction	 performed	 in	 the	
current	 study	 hint	 to	 pro-inflammatory	 activation	 processes	 associated	 with	 increased	
TNFα	mRNA	expression.	Furthermore,	slightly	increased	basal	glycolytic	rates	and	CPT1a	
mRNA	expression	were	detected.	However,	along	with	monocyte	populations,	 the	non-
CD4+/CD8+	T	cell	fraction	entails	B	and	NK	cell	subsets.	Therefore,	while	this	data	provides	
first	 insight	 into	 immunometabolic	 alterations	 in	 the	 cell	 types	 making	 up	 the	 non-
CD4+/CD8+	 T	 cell	 fraction,	 succeeding	 metabolic	 analyses	 of	 sorted	 B	 cell,	 NK	 cell	 and	
monocyte	subsets	should	be	investigated	in	detail.		
	
Taken	together,	future	metabolic	assays	as	well	as	protein	and	gene	expression	analyses	
will	 further	 deepen	 the	 understanding	 of	 immunometabolic	 signaling	 cascades	 in	
monocytes,	 B	 and	 NK	 cell	 subtypes	 and	 their	 contribution	 to	 the	 extensive	 alterations	
observed	in	T	cell	subpopulations	in	MS	patients	and	their	potential	influence	on	disease	
development	and	progression.	
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Limitations,	Strengths,	Outlook	
While	 the	 DENIM	 study	 provides	 a	 robust	 MS	 patient	 and	 carefully	 matched	 HC	
participant	 cohort,	 there	 are	 limitations	 that	 require	 mentioning.	 The	 diversity	 of	
medications	 taken	 by	 the	 MS	 patients	 did	 not	 allow	 valid	 and	 significant	 statistical	
analysis	 regarding	 the	 effect	 of	 individual	 types	 of	 medications	 on	 the	 analyzed	
immunometabolic	 functions.	 Furthermore,	 sex	 differences	 could	 not	 be	 statistically	
analyzed	due	to	the	limited	MS	patient	and	HC	participant	sample	size.	In	future	clinical	
studies	the	effect	of	medication	and	sex	should	be	examined	carefully	whenever	possible	
due	 to	 the	 strong	 evidence	 of	 both	 factors	 influencing	 MS	 disease	 susceptibility,	
development	and	progression	[206]–[209].	 It	 is	 important	to	note	that	the	DENIM	study	
provided	 comprehensive	 data,	 however,	 the	 analyses	 performed	 were	 limited	 by	 the	
availability	of	biomaterial,	especially	of	sorted	T	cells.		
The	 blood	 samples	 were	 processed	 following	 strict	 standard	 operating	 procedures	
allowing	freezing	and	subsequent	pairwise	MS	patient	and	HC	participant	analyses	for	all	
laboratory	 techniques	 performed.	 The	 metabolic	 assay	 was	 also	 established	 after	
comprehensive	 testings.	 However,	 freezing	 procedures	 have	 been	 shown	 to	 impact	
immune	 cell	 quality	 [124]	 and	 analyzing	 fresh	 samples	 in	 metabolic	 assays	 may	 be	
desirable	in	order	to	receive	even	higher	quality	readouts.		
In	healthy	individuals,	different	T	cell	subpopulations,	e.g.	effector	T	cells,	memory	T	cells	
or	 Tregs,	 have	 been	 shown	 to	 rely	 on	 distinctive	 metabolic	 programs	 based	 on	 their	
specific	cellular	demands	and	requirements.	Therefore,	future	studies	should	analyze	MS	
patients’	CD4+	 and	CD8+	 T	 cell	 subpopulations	 to	narrow	down	specific	 cell	 subsets	and	
observe	differences	in	metabolic	function.	Considering	the	alterations	in	frequencies	of	B	
cells	and	NK	cell	subpopulations	in	MS	patients,	more	detailed	cell	subset	phenotyping	of	
B	 cells,	 including	 the	 memory	 compartment,	 should	 be	 performed	 as	 well	 as	
comprehensive	 immunometabolic	 profile	 analyses	 in	 order	 to	 further	 investigate	 their	
effect	on	MS	disease	progression.		
The	study	was	limited	by	flow	cytometry	capacity	and	including	additional	inflammatory	
markers	like	IL-17	or	IL-6	would	provide	further	information	about	the	pro-inflammatory	
characteristics	of	T	cell	subpopulations.	Furthermore,	serum	analyses	of	e.g.	IL-6,	IFNγ,	IL-
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17	or	TNFα	 as	potent	pro-inflammatory	cytokines	 in	MS	 involved	 in	neuroinflammation	
and	adaptive	and	innate	immune	cell	activation	[210]	could	also	be	completed	to	provide	
additional	information	about	markers	of	systemic	inflammation	and	associations	with	MS	
disease	progression.		
More	 comprehensive	 RNA	 analysis	 techniques	 including	 microarray	 analyses	 may	 be	
considered	in	future	investigations	allowing	a	more	comprehensive	exploration	of	genes	
and	with	that	providing	information	about	signaling	cascades	involving	inflammatory	and	
metabolic	 signaling.	 Here,	 the	 difference	 of	CPT1a	 mRNA	 gene	 expression	 and	 protein	
abundance	 should	 be	 considered	 to	 help	 to	 understand	 the	 impact	 on	 immune	 cell	
function,	especially	 in	CD4+	T	 cells.	Additional	protein	quantification	methods,	e.g.	 SDS-
PAGE	 (sodium	 dodecyl	 sulfate-polyacrylamide	 gel	 electrophoresis)	 and	 Western	 Blot	
analyses	 or	 broad	 proteomic	 screenings	 for	 CPT1a	 will	 add	 quantitative	 data	 to	 the	
observed	results.	Immunohistochemical	microscopy	analyses	of	CPT1a	as	well	as	staining	
mitochondria	 would	 also	 provide	 quantitative	 data	 on	 CPT1a	 abundance	 and	
mitochondrial	 morphology	 within	 T	 cell	 subpopulations.	 This	 data	 could	 allude	 to	
potential	impairments	in	mitochondrial	fusion,	fission	and	mitophagy	processes	and	their	
impact	on	 immunometabolic	function	 in	MS	patients.	Additionally,	sequencing	of	CPT1a	
may	be	performed	complementing	 the	 results	 in	 the	EAE	animal	model	 [157],[211]	and	
potentially	detecting	SNPs	in	the	CPT1a	gene.	
	
In	 upcoming	 clinical	 studies,	 it	 will	 be	 interesting	 to	 see	 how	 the	 inflammatory	 and	
metabolic	 profile	 changes	 in	 phases	 of	 relapses	 in	 RRMS	 patients	 and	 how	 the	
mitochondrial	 signaling	 pathways	 including	 the	 CPT1a	 protein	 may	 be	 altered	 during	
disease	 progression.	 Furthermore,	 the	 involvement	 of	 different	 energy	 pathways	 in	
immune	cell	subpopulations	in	relapses	should	be	analyzed	to	broaden	the	understanding	
of	 the	 interplay	 between	 cellular	 energy	 metabolism	 and	MS	 disease	 progression	 and	
finally	 lead	 to	potential	 therapeutic	 targets.	 Finally,	MRI	 imaging,	 as	 the	most	 common	
biomarker	 for	 MS	 disease	 [2],	 could	 also	 be	 taken	 into	 consideration	 to	 monitor	 and	
correlate	disease	progression	and	immunometabolic	parameters.	
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List	of	Abbreviations		 	
Table	18:	List	of	Abbreviations.	
acetyl-CoA	 Acetyl-coenzyme	A		
ADP	 Adenosine	Diphosphate	
APC	 Antigen	Presenting	Cell	
APC	 Allophycocyanin	(flow	cytometry)	
ATP	 Adenosine	Triphosphate	
BAI	 Beck’s	Anxiety	Inventory		
BDI-II	 Beck’s	Depression	Inventory	Version	II	
BSA	 Bovine	Serum	Albuminum	
CD	 Cluster	of	Differentiation	
cDNA	 Complementary	Deoxyribonucleic	Acid	
CPT1a	 Carnitine	palmitoyltransferase	I	isoform	a	
CIS	 Clinically	Isolated	Syndrome	
CRF	 Case	Report	Form	
CTQ	 Childhood	Trauma	Questionnaire	
DC	 Dendritic	Cell	
DNA		 Deoxyribonucleic	Acid	
DMSO	 Dimethylsulfoxide	
DSM-V	 Diagnostic	and	Statistical	Manual	of	Mental	Disorders	Version	5		
EAE	 Experimental	Autoimmune	Encephalomyelitis	
FACS	 Fluorescence	Activated	Cell	Sorting	
FAD	 Flavin	Adenine	Dinucleotide		
FADH2	 Flavin	Adenine	Dinucleotide	H2	
FCC-A	 Forward	Scatter	Area	
FCS	 Fetal	Calf	Serum	
FCCP	 Carbonyl	cyanide-4-(trifluoromethoxy)phenylhydrazone	
FoxP3	 Forkhead	Box	P3	
FSMC	 Fatigue	Scale	for	Motor	and	Cognitive	Function	
FSS	 Fatigue	Severity	Scale	based	on	Krupp	
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Teff	 Effector	T	cell	
EDSS	 Expanded	Disability	Status	Scale	
FACS	 Fluorescently	Activated	Cell	Sorting	
GILZ	 Glucocorticoid-induced	Leucine	Zipper	
GLUT1	 Glucose	Transporter	1	
GR	 Glucocorticoid	Receptor	
HALEMS	 Hamburger	Lebensqualitätsfragebogen	
HPA	axis	 Hypothalamic-pituitary-adrenal	axis	
IFNγ	 Interferon	γ	 	
Ig	 Immunoglobulin	
IPO8	 Importin	8	
IL	 Interleukin	
LTα	 Lympho	toxin	α	
MACS	 Magnetic	Affinity	Cell	Sorting	
MADRS	 Montgomery-Åsberg	Depression	Rating	Scale	
MDD	 Major	Depressive	Disorder	
MFI	 Median	Fluorescent	Intensity	
MHC-I	 Major	Histocompatibility	Complex	class	I	
MHC-II	 Major	Histocompatibility	Complex	class	II	
MFSC	 Multiple	Sclerosis	Functional	Composite	
M.I.N.I.	 Mini	International	Neuropsychiatric	Interview	German	version	
5.0.0	DSM-IV	
mRNA	 Messenger	Ribonucleic	Acid	
MS	 	 Multiple	Sclerosis	
NAD	 Nicotinamide	Adenine	Dinucleotide		
NADH	 Nicotinamide	Adenine	Dinucleotide	H	
NK	cell	 Natural	Killer	Cell	
NK	T	cell	 Natural	Killer	T	cell	
NFκB1	 Nuclear	factor	'kappa-light-chain-enhancer'	of	activated	B-cells	
subunit	1	
NR3C1	 Nuclear	receptor	subfamily	3	group	C	member	1	
Oral	SDMT	 Oral	Symbol	Digit	Modality	Test	
PBS	 Phosphate	Buffered	Saline	
Abbreviations	
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PBMC	 Peripheral	Blood	Mononuclear	Cells	
PE	 Phycoerythrin	
PPMS	 Primary	Progressive	Multiple	Sclerosis	
RELA	 RELA	proto-oncogene,	NFκB	subunit	
RNA	 Ribonucleic	Acid	
RORγt	 retinoic	acid	receptor-related	orphan	nuclear	receptor	γt	
RRMS	 Relapsing	Remitting	Multiple	Sclerosis	
RPMI	medium	 Roswell	Park	Memorial	Institute	1640	Medium	
SPMS	 Secondary	Progressive	Multiple	Sclerosis	
SCC-A	 Side	Scatter	Area	
TBP	 TATA	Box	Binding	Protein	
TCM	 Central	memory	T	cell	
TCR	 T	cell	Receptor	
TEM	 effector	memory	T	cell	
TEMRA	 terminally	differentiated	effector	memory	cells	re-	expressing	CD45RA		
Th0	 T	helper	cell	Type	1	
Th1	 T	helper	cell	Type	1	
Th2	 T	helper	cell	Type	2	
Th17	 T	helper	cell	Type	17	
Th1/17	 T	helper	cell	Type	1/17	
TN	 naïve	T	cell	
TNF	 Tumor	Necrosis	Factor	
T	reg	 regulatory	T	cell	
TSC22D3	 TSC22	domain	family	member	3	
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150.	 Planas	 R,	 Jelcĭć	 I,	 Schippling	 S,	 Martin	 R,	 Sospedra	 M.	 Natalizumab	 treatment	
perturbs	memory-	and	marginal	zone-like	B-cell	homing	in	secondary	lymphoid	organs	in	
multiple	sclerosis.	Eur.	J.	Immunol.	2011.DOI:	10.1002/eji.201142108.	
	
References	
127	
	
151.	Haegele	KF,	Stueckle	CA,	Malin	J-P,	Sindern	E.	Increase	of	CD8+	T-effector	memory	
cells	in	peripheral	blood	of	patients	with	relapsing-remitting	multiple	sclerosis	compared	
to	healthy	controls.	J.	Neuroimmunol.	2007.DOI:	10.1016/j.jneuroim.2006.09.008.	
152.	 Witte	 ME,	 Mahad	 DJ,	 Lassmann	 H,	 van	 Horssen	 J.	 Mitochondrial	 dysfunction	
contributes	 to	 neurodegeneration	 in	 multiple	 sclerosis.	 Trends	 Mol.	 Med.	 2014.DOI:	
10.1016/j.molmed.2013.11.007.	
153.	 Mähler	 A,	 Steiniger	 J,	 Bock	 M,	 Brandt	 AU,	 Haas	 V,	 Boschmann	 M,	 Paul	 F.	 Is	
Metabolic	 Flexibility	 Altered	 in	 Multiple	 Sclerosis	 Patients?	 PLoS	 One.	 2012.DOI:	
10.1371/journal.pone.0043675.	
154.	Mao	 P,	Reddy	 PH.	 Is	multiple	 sclerosis	 a	mitochondrial	 disease?	Biochim	 Biophys	
Acta.	2010.DOI:	10.1016/j.bbadis.2009.07.002.	
155.	 Mathur	 D,	 López-Rodas	 G,	 Casanova	 B,	 Burgal	 Marti	 M.	 Perturbed	 glucose	
metabolism:	 insights	 into	 multiple	 sclerosis	 pathogenesis.	 Front.	 Neurol.	 2014.DOI:	
10.3389/fneur.2014.00250.	
156.	 Adiele	 RC,	 Adiele	 CA.	 Metabolic	 defects	 in	 multiple	 sclerosis.	 Mitochondrion.	
2017.DOI:	10.1016/j.mito.2017.12.005.	
157.	Nieland	JD,	Nieland	JG,	Nielsen	S.	CPT1	inhibitor	significantly	 induce	remyelination	
and	 neuroprotection	 in	 Multiple	 Sclerosis	 by	 a	 dual	 mode	 of	 action.	 In:	 2015	 Annual	
Meeting	 of	 the	 Consortium	 of	 Multiple	 Sclerosis	 Centers	 (CMSC).;	 2015.	 Available	 at:	
https://cmsc.confex.com/cmsc/2015/webprogram/Paper3802.html.	
158.	Mørkholt	AS,	Kastaniegaard	K,	Trabjerg	MS,	Gopalasingam	G,	Niganze	W,	Larsen	A,	
Stensballe	 A,	 et	 al.	 Identification	 of	 brain	 antigens	 recognized	 by	 autoantibodies	 in	
experimental	 autoimmune	encephalomyelitis-induced	 animals	 treated	with	 etomoxir	 or	
interferon-β.	Sci.	Rep.	2018.DOI:	10.1038/s41598-018-25391-y.	
159.	Mørkholt	 A.,	 Larsen	 A,	 Issazadeh	 S,	 Nieland	 JG.,	 Nielsen	 S,	 Nieland	 JD.	 Highly	
effective	 treatment	of	multiple	 sclerosis	by	blocking	 the	 lipid	metabolism.	 In:	European	
Committee	for	Treatment	and	Research	 in	Multiple	Sclerosis	(ECTRIMS).	ECTRIMS	Online	
Library;	 2016.	 Available	 at:	 https://onlinelibrary.ectrims-
congress.eu/ectrims/2016/32nd/146081/anne.mrkholt.highly.effective.treatment.of.mult
iple.sclerosis.by.blocking.the.html?f=media=3.	
160.	Shriver	LP,	Manchester	M.	 Inhibition	of	 fatty	acid	metabolism	ameliorates	disease	
activity	in	an	animal	model	of	multiple	sclerosis.	Sci.	Rep.	2011.DOI:	10.1038/srep00079.	
161.	Raud	B,	Roy	DG,	Divakaruni	AS,	Tarasenko	TN,	Franke	R,	Ma	EH,	Samborska	B,	et	
al.	 Etomoxir	 Actions	 on	 Regulatory	 and	 Memory	 T	 Cells	 Are	 Independent	 of	 Cpt1a-
Mediated	Fatty	Acid	Oxidation.	Cell	Metab.	2018.DOI:	10.1016/j.cmet.2018.06.002.	
162.	 Iwasaki	 S,	 Ingolia	 NT.	 The	 Growing	 Toolbox	 for	 Protein	 Synthesis	 Studies.	 Trends	
Biochem.	Sci.	2017.DOI:	10.1016/j.tibs.2017.05.004.	
163.	Kaufman	RJ.	Regulation	of	mRNA	translation	by	protein	folding	in	the	endoplasmic	
reticulum.	Trends	Biochem.	Sci.	2004.DOI:	10.1016/j.tibs.2004.01.004.	
164.	Tahmasebi	S,	Khoutorsky	A,	Mathews	MB,	Sonenberg	N.	Translation	deregulation	in	
human	disease.	Nat.	Rev.	Mol.	Cell	Biol.	2018.DOI:	10.1038/s41580-018-0034-x.	
References	
128	
	
165.	Corthals	AP.	Multiple	Sclerosis	 is	Not	a	Disease	of	the	Immune	System.	Q	Rev	Biol.	
2016.	
166.	 Burger	 D,	 Dayer	 J.	 High-density	 lipoprotein-associated	 apolipoprotein	 A-I:	 the	
missing	 link	 between	 infection	 and	 chronic	 inflammation?	 Autoimmun	 Rev.	 2002.DOI:	
10.1016/S1568-9972(01)00018-0.	
167.	Marsillach	J,	Camps	J,	Ferré	N,	Beltran	R,	Rull	A,	Mackness	B,	Mackness	M,	et	al.	
Paraoxonase-1	 is	 related	 to	 inflammation,	 fibrosis	 and	PPAR	delta	 in	 experimental	 liver	
disease.	BMC	Gastroenterol.	2009.DOI:	10.1186/1471-230X-9-3.	
168.	Sladkova	V,	Mareš	J,	Lubenova	B,	Zapletalova	J,	Stejskal	D,	Hlustik	P,	Kanovsky	P.	
Degenerative	 and	 inflammatory	markers	 in	 the	 cerebrospinal	 fluid	 of	multiple	 sclerosis	
patients	with	 relapsing-remitting	course	of	disease	and	after	clinical	 isolated	syndrome.	
Neurol	Res.	2011.DOI:	10.1179/016164110X12816242542535.	
169.	 Sundaram	 M,	 Yao	 Z.	 Recent	 progress	 in	 understanding	 protein	 and	 lipid	 factors	
affecting	 hepatic	 VLDL	 assembly	 and	 secretion.	Nutr.	Metab.	 2010.DOI:	 10.1186/1743-
7075-7-35.	
170.	 Storoni	M,	 Plant	 GT.	 The	 Therapeutic	 Potential	 of	 the	 Ketogenic	 Diet	 in	 Treating	
Progressive	Multiple	Sclerosis.	Mult.	Scler.	Int.	2015.DOI:	10.1155/2015/681289.	
171.	Kim	DY,	Hao	 J,	 Liu	R,	Turner	G,	Shi	 FD,	Rho	 JM.	 Inflammation-Mediated	Memory	
Dysfunction	and	Effects	of	a	Ketogenic	Diet	in	a	Murine	Model	of	Multiple	Sclerosis.	PLoS	
One.	2012.DOI:	10.1371/journal.pone.0035476.	
172.	Cretenet	G,	Clerc	I,	Matias	M,	Loisel	S,	Craveiro	M,	Oburoglu	L,	Kinet	S,	et	al.	Cell	
surface	Glut1	 levels	distinguish	human	CD4	and	CD8	T	 lymphocyte	subsets	with	distinct	
effector	functions.	Sci.	Rep.	2016.DOI:	10.1038/srep24129.	
173.	Dimeloe	S,	Burgener	A-V,	Grählert	J,	Hess	C.	T-cell	metabolism	governing	activation,	
proliferation	 and	 differentiation;	 a	 modular	 view.	 Immunology.	 2016.DOI:	
10.1111/imm.12655.	
174.	Blagih	J,	Coulombe	F,	Vincent	E,	Dupuy	F,	Galicia-Vázquez	G,	Yurchenko	E,	Raissi	T,	
et	 al.	 The	 Energy	 Sensor	 AMPK	 Regulates	 T	 Cell	 Metabolic	 Adaptation	 and	 Effector	
Responses	In	Vivo.	Immunity.	2015.DOI:	10.1016/j.immuni.2014.12.030.	
175.	McKinney	 EF,	 Lee	 JC,	 Jayne	 DRW,	 Lyons	 P	 a.,	 Smith	 KGC.	 T-cell	 exhaustion,	 co-
stimulation	 and	 clinical	 outcome	 in	 autoimmunity	 and	 infection.	 Nature.	 2015.DOI:	
10.1038/nature14468.	
176.	Wherry	E.	T	cell	exhaustion.	Nat	Immunol.	2011.	
177.	Patsoukis	N,	Bardhan	K,	Chatterjee	P,	Sari	D,	Liu	B,	Bell	LN,	Karoly	ED,	et	al.	PD-1	
alters	T-cell	metabolic	reprogramming	by	inhibiting	glycolysis	and	promoting	lipolysis	and	
fatty	acid	oxidation.	Nat.	Commun.	2015.DOI:	10.1038/ncomms7692.	
178.	Bengsch	B,	Johnson	AL,	Kurachi	M,	Odorizzi	PM,	Pauken	KE,	Attanasio	J,	Stelekati	E,	
et	 al.	 Bioenergetic	 Insufficiencies	 Due	 to	 Metabolic	 Alterations	 Regulated	 by	 the	
Inhibitory	 Receptor	 PD-1	 Are	 an	 Early	 Driver	 of	 CD8+	 T	 Cell	 Exhaustion.	 Immunity.	
2016.DOI:	10.1016/j.immuni.2016.07.008.	
	
References	
129	
	
179.	Belbasis	L,	Bellou	V,	Evangelou	E,	Ioannidis	J,	Tzoulaki	I.	Environmental	risk	factors	
and	 multiple	 sclerosis:	 an	 umbrella	 review	 of	 systematic	 reviews	 and	 meta-analyses.	
Lancet	Neurol.	2015.DOI:	10.1016/S1474-4422(14)70267-4.	
180.	 Faller	 E,	 Ghazawi	 F,	 Cavar	 M,	 MacPherson	 P.	 IL-7	 induces	 clathrin-mediated	
endocytosis	of	CD127	and	subsequent	degradation	by	the	proteasome	in	primary	human	
CD8	T	cells.	Immunol	Cell	Biol.	2016.DOI:	10.1038/icb.2015.80.	
181.	 Lawson	 B,	 Gonzalez-Quintial	 R,	 Eleftheriadis	 T,	 Farrar	 M,	 Miller	 S,	 Sauer	 K,	
McGavern	D,	et	al.	 Interleukin-7	 is	 required	for	CD4+	T	cell	activation	and	autoimmune	
neuroinflammation.	Clin.	Immunol.	2015.DOI:	10.1016/j.clim.2015.08.007.	
182.	Gregory	 SG,	 Schmidt	 S,	 Seth	P,	Oksenberg	 JR,	Hart	 J,	 Prokop	A,	 Caillier	 SJ,	et	 al.	
Interleukin	7	receptor	α	chain	(IL7R)	shows	allelic	and	functional	association	with	multiple	
sclerosis.	Nat.	Genet.	2007;	39:1083–1091.DOI:	10.1038/ng2103.	
183.	 Wang	 L-M,	 Zhang	 D-M,	 Xu	 Y-M,	 Sun	 S-L.	 Interleukin	 2	 Receptor	 Alpha	 Gene	
Polymorphism	and	Risk	of	Multiple	Sclerosis:	a	Meta-analysis.	J.	Int.	Med.	Res.	2011.DOI:	
10.1177/147323001103900505.	
184.	Gross	CC,	Schulte-Mecklenbeck	A,	Rünzi	A,	Kuhlmann	T,	Posevitz-Fejfár	A,	Schwab	
N,	 Schneider-Hohendorf	 T,	 et	 al.	 Impaired	 NK-mediated	 regulation	 of	 T-cell	 activity	 in	
multiple	sclerosis	is	reconstituted	by	IL-2	receptor	modulation.	Proc	Natl	Acad	Sci	U	S	A.	
2016.DOI:	10.1073/pnas.1524924113.	
185.	Kappos	L,	Wiendl	H,	Selmaj	K,	Arnold	DL,	Havrdova	E,	Boyko	A,	Kaufman	M,	et	al.	
Daclizumab	HYP	versus	Interferon	Beta-1a	in	Relapsing	Multiple	Sclerosis.	N.	Engl.	J.	Med.	
2015.DOI:	10.1056/NEJMoa1501481.	
186.	Laroni	A,	Armentani	E,	Kerlero	de	Rosbo	N,	Ivaldi	F,	Marcenaro	E,	Sivori	S,	Gandhi	
R,	et	al.	Dysregulation	of	 regulatory	CD56bright	NK	cells/T	 cells	 interactions	 in	multiple	
sclerosis.	J.	Autoimmun.	2016.DOI:	10.1016/j.jaut.2016.04.003.	
187.	 European	 Medicine	 Agency	 EMA.	 Zinbryta.	 2018.	 Available	 at:	
https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta	 [Accessed	 January	
21,	2019].	
188.	 Koffman	 J,	 Gao	 W,	 Goddard	 C,	 Burman	 R,	 Jackson	 D,	 Shaw	 P,	 Barnes	 F,	 et	 al.	
Progression,	 Symptoms	 and	 Psychosocial	 Concerns	 among	 Those	 Severely	 Affected	 by	
Multiple	Sclerosis:	A	Mixed-Methods	Cross-Sectional	Study	of	Black	Caribbean	and	White	
British	People.	PLoS	One.	2013.DOI:	10.1371/journal.pone.0075431.	
189.	 Powell	 DJH,	 Moss-Morris	 R,	 Liossi	 C,	 Schlotz	 W.	 Circadian	 cortisol	 and	 fatigue	
severity	 in	 relapsing-remitting	 multiple	 sclerosis.	 Psychoneuroendocrinology.	 2015.DOI:	
10.1016/j.psyneuen.2015.03.010.	
190.	Kern	S,	Krause	I,	Horntrich	A,	Thomas	K,	Aderhold	J,	Ziemssen	T.	Cortisol	Awakening	
Response	 Is	 Linked	 to	 Disease	 Course	 and	 Progression	 in	Multiple	 Sclerosis.	PLoS	 One.	
2013.DOI:	10.1371/journal.pone.0060647.	
191.	Kern	S,	Schultheiß	T,	Schneider	H,	Schrempf	W,	Reichmann	H,	Ziemssen	T.	Circadian	
cortisol,	 depressive	 symptoms	 and	 neurological	 impairment	 in	 early	 multiple	 sclerosis.	
Psychoneuroendocrinology.	2011.DOI:	10.1016/j.psyneuen.2011.04.004.	
References	
130	
	
	
192.	 Van	 Laethem	 F,	 Baus	 E,	 Smyth	 LA,	 Andris	 F,	 Bex	 F,	 Urbain	 J,	 Kioussis	 D,	 et	 al.	
Glucocorticoids	 Attenuate	 T	 cell	 Receptor	 Signaling.	 J.	 Exp.	 Med.	 2001.DOI:	
10.1084/jem.193.7.803.	
193.	Gold	SM,	Sasidhar	M	V.,	Lagishetty	V,	Spence	RD,	Umeda	E,	Ziehn	MO,	Krieger	T,	et	
al.	 Dynamic	 Development	 of	 Glucocorticoid	 Resistance	 during	 Autoimmune	
Neuroinflammation.	J.	Clin.	Endocrinol.	Metab.	2012.DOI:	10.1210/jc.2012-1294.	
194.	 Clarke	 AJ,	 Riffelmacher	 T,	 Braas	 D,	 Cornall	 RJ,	 Simon	 AK.	 B1a	 B	 cells	 require	
autophagy	 for	 metabolic	 homeostasis	 and	 self-renewal.	 J.	 Exp.	 Med.	 2018.DOI:	
10.1084/jem.20170771.	
195.	Mendoza	P,	Martínez-Martín	N,	Bovolenta	ER,	Reyes-Garau	D,	Hernansanz-Agustín	
P,	Delgado	P,	Diaz-Muñoz	MD,	et	al.	R-Ras2	is	required	for	germinal	center	formation	to	
aid	 B	 cells	 during	 energetically	 demanding	 processes.	 Sci.	 Signal.	 2018.DOI:	
10.1126/scisignal.aal1506.	
196.	Tsui	C,	Martinez-Martin	N,	Gaya	M,	Maldonado	P,	Llorian	M,	Legrave	NM,	Rossi	M,	
et	al.	Protein	Kinase	C-beta	Dictates	B	Cell	Fate	by	Regulating	Mitochondrial	Remodeling,	
Metabolic	 Reprogramming,	 and	 Heme	 Biosynthesis.	 Immunity.	 2018.DOI:	
10.1016/j.immuni.2018.04.031.	
197.	Greenfield	AL,	Hauser	SL.	B-cell	Therapy	for	Multiple	Sclerosis:	Entering	an	Era.	Ann.	
Neurol.	2017.DOI:	10.1002/ana.25119.	
198.	 Li	 R,	 Rezk	 A,	 Miyazaki	 Y,	 Hilgenberg	 E,	 Touil	 H,	 Shen	 P,	 Moore	 CS,	 et	 al.	
Proinflammatory	 GM-CSF-producing	 B	 cells	 in	 multiple	 sclerosis	 and	 B	 cell	 depletion	
therapy.	Sci.	Transl.	Med.	2015.DOI:	10.1126/scitranslmed.aab4176.	
199.	Hauser	SL,	Chan	JR,	Oksenberg	JR.	Multiple	sclerosis:	Prospects	and	Promise.	Ann.	
Neurol.	2013.DOI:	10.1002/ana.24009.	
200.	Bielekova	B,	Catalfamo	M,	Reichert-Scrivner	S,	Packer	A,	Cerna	M,	Waldmann	TA,	
McFarland	 H,	 et	 al.	 Regulatory	 CD56bright	 natural	 killer	 cells	 mediate	
immunomodulatory	 effects	 of	 IL-2R	 alpha-targeted	 therapy	 (daclizumab)	 in	 multiple	
sclerosis.	Proc.	Natl.	Acad.	Sci.	2006.DOI:	10.1073/pnas.0601335103.	
201.	 Saraste	 M,	 Irjala	 H,	 Airas	 L.	 Expansion	 of	 CD56Bright	 natural	 killer	 cells	 in	 the	
peripheral	blood	of	multiple	 sclerosis	patients	 treated	with	 interferon-beta.	Neurol.	 Sci.	
2007.DOI:	10.1007/s10072-007-0803-3.	
202.	Morandi	B,	Bramanti	P,	Bonaccorsia	I,	Montalto	E,	Oliveri	D,	Pezzino	G,	Navarrab	
M,	 et	 al.	 Role	 of	 natural	 killer	 cells	 in	 the	 pathogenesis	 and	 progression	 of	 multiple	
sclerosis.	Pharmacol.	Res.	2008.DOI:	10.1016/j.phrs.2007.11.003.	
203.	Fiedler	SE,	George	JD,	Love	HN,	Kim	E,	Spain	R,	Bourdette	D,	Salinthone	S.	Analysis	
of	IL-6,	IL-1β	and	TNF-α	production	in	monocytes	isolated	from	multiple	sclerosis	patients	
treated	 with	 disease	 modifying	 drugs.	 J	 Syst	 Integr	 Neurosci.	 2017.DOI:	
10.15761/JSIN.1000166.	
	
	
References	
131	
	
204.	 Waschbisch	 A,	 Schröder	 S,	 Schraudner	 D,	 Sammet	 L,	 Weksler	 B,	 Melms	 A,	
Pfeifenbring	S,	et	al.	Pivotal	Role	 for	CD16	+	Monocytes	 in	 Immune	Surveillance	of	 the	
Central	Nervous	System.	J.	Immunol.	2016.DOI:	10.4049/jimmunol.1501960.	
	
205.	 Christensen	 JR,	Börnsen	 L,	Hesse	 D,	Krakauer	M,	 Sørensen	 PS,	 Søndergaard	 HB,	
Sellebjerg	 F.	 Cellular	 sources	 of	 dysregulated	 cytokines	 in	 relapsing-remitting	 multiple	
sclerosis.	J.	Neuroinflammation.	2012.DOI:	10.1186/1742-2094-9-215.	
206.	Dunn	 SE,	 Lee	 H,	Pavri	 FR,	 Zhang	MA.	 Sex-Based	 Differences	 in	Multiple	 Sclerosis	
(Part	I):	Biology	of	Disease	Incidence.	2015.DOI:	10.1007/7854_2015_371.	
207.	Dunn	SE,	Gunde	E,	Lee	H.	Sex-Based	Differences	in	Multiple	Sclerosis	(MS):	Part	II :	
Rising	 Incidence	 of	 Multiple	 Sclerosis	 in	 Women	 and	 the	 Vulnerability	 of	 Men	 to	
Progression	of	this	Disease.	2015.DOI:	10.1007/7854_2015_370.	
208.	 Kipp	 M,	 Beyer	 C.	 Impact	 of	 sex	 steroids	 on	 neuroinflammatory	 processes	 and	
experimental	 multiple	 sclerosis.	 Front.	 Neuroendocrinol.	 2009.DOI:	
10.1016/j.yfrne.2009.04.004.	
209.	Miller	 DH,	 Fazekas	 F,	Montalban	 X,	Reingold	 SC,	 Trojano	M.	 Pregnancy,	 sex	 and	
hormonal	 factors	 in	 multiple	 sclerosis.	 Mutiple	 Scler.	 J.	 2014.DOI:	
10.1177/1352458513519840.	
210.	Göbel	K,	Ruck	T,	Meuth	S.	Cytokine	signaling	in	multiple	sclerosis:	Lost	in	translation.	
Mult.	Scler.	J.	2018.DOI:	doi.org/10.1177/1352458518763094.	
211.	Mørkholt	AS,	Wiborg	O,	Nieland	 JGK,	Nielsen	S,	Nieland	 JD.	 Blocking	of	 carnitine	
palmitoyl	 transferase	1	potently	 reduces	 stress-induced	depression	 in	 rat	 highlighting	 a	
pivotal	role	of	lipid	metabolism.	Sci.	Rep.	2017.DOI:	10.1038/s41598-017-02343-6.	
212.	Tombaugh,	T.	A	comprehensive	Review	of	the	Paced	Auditory	Addition	Test	(PASAT).	
Archives	of	Clinical	Neuropychology.	2006.	DOI:	10.1016/j.acn.2005.07.006.	
213.	Kurtzke,	JF.	Rating	neurologic	impairment	in	multiple	sclerosis:	An	expanded	
disability	status	scale	(EDSS).	Neurology.	1983.	DOI:	10.1212/wnl.33.11.1444.	
214.	Rudick	R.,	Antel	J.,	Confavreux	C.,	Cutter	G.,	Ellison	G.,	Fischer	J.,	et	al.	
Recommendations	from	the	National	Multiple	Sclerosis	Society	Clinical	Outcomes	
Assessment	Task	Force.	1997.	Ann	Neurol.	DOI:	10.1002/ana.410420318.		
215.	Margraf	J,	Ehlers	A.	Beck	Angst	Inventar	(BAI).	Manual.	Pearson	Assessment	GmbH.		
2007.		
216.	Hautzinger	M,	Keller	F,	Kühner	C.	Das	Beck	Depressions	Inventar	-	BDI-II.	Frankfurt:	
Harcourt	Test	Services.	2006.	
217.	Penner	IK,	Raselli	C,	Stöcklin	M,	Opwis	K,	Kappos	L,	Calabrese,	P.	The	Fatigue	Scale	
for	Motor	and	Cognitive	Functions	(FSMC):	Validation	of	a	new	instrument	to	assess	
multiple	sclerosis-related	fatigue.	Mul	Scler.	2009.	DOI: 10.1177/1352458509348519.	
218.	Krupp,	LB,	LaRocca,	NG,	Muir-Nash,	J,	Steinberg,	AD.	The	fatigue	severity	scale.	
Application	to	patients	with	multiple	sclerosis	and	systemic	lupus	erythematosus.	Arch	
Neurology.	1989.	DOI: 10.1001/archneur.1989.00520460115022.	
References	
132	
	
219.	Gold	SM,	Heesen	C,	Schulz	H,	Guder	U,	Mönch	A,	Gbadamosi	J,	Buhmann	C,	Schulz	
KH.	Disease	specific	quality	of	life	instruments	of	the	Human	Quality	of	Life	Questionnaire	
in	Multiple	Sclerosis	(HAQUAMS).	Mul	Scler.	2001.	DOI: 10.1177/135245850100700208.	
220.	Bernstein	DP,	Stein	JA,	Newcomb	MD,	Walker	E,	Pogge	D,	Ahluvalia	T,	Stokes	J,	
Handelsman	L,	Medrano	M,	Desmond	D,	Zule	W.	Development	and	validation	of	a	brief	
screening	version	of	the	Childhood	Trauma	Questionnaire.	Child	Abuse	and	Negl.	2003.		
 
 
	
	
	
	
	
	
	
	
	
Figure	Index	
133	
Figure	Index	
Figure	1:	Stages	and	disease	progression	in	Multiple	Sclerosis.	 _____________________	2	
Figure	2:	Overview	of	main	cellular	energy	pathways.		___________________________	20	
Figure	3:	Display	of	the	mitochondrial	electron	transport	chain.	 ___________________	23	
Figure	4:	Metabolism	drives	the	life	cycle	of	T	cells.	_____________________________	27	
Figure	5:	Model	of	Immunometabolic	Signaling.	________________________________	34	
Figure	6:	Seahorse	XFe	96	Analyzer	assay	test	analyses	for	cell	density		
determination	shows	increases	in	OCR	with	increasing	PBMC	numbers.	______	51	
Figure	7:	Seahorse	XFe	96	Analyzer	metabolic	assay	cellular	adherence	testing	shows		
no	difference	in	OCR	measurements	with	or	without	PDL	plate	coating.	______	53	
Figure	8:	Seahorse	XFe	96	Analyzer	metabolic	assay	PBMC	stimulation	testing		
with	α-CD3	and	α-CD28.		 __________________________________________	54	
Figure	9:	Gating	strategy	for	panel	1	of	phenotyping	analyses	to	determine	
																	memory	subtypes	in	CD4+	and	CD8+	T	cells.	____________________________	59	
Figure	10:	Gating	strategy	for	panel	2	of	phenotyping	analyses	to	determine		
CD4+	helper	T	cells	and	CD8+	T	cell	subtypes.	 __________________________	60	
Figure	11:	Gating	strategy	for	panel	3	of	phenotyping	analyses	to	determine		
regulatory	T	cells	in	CD4+	T	cells.	____________________________________	61	
Figure	12:	Gating	strategy	for	panel	4	of	phenotyping	analyses	to	determine		
B	cells	and	NK	cells.	______________________________________________	61	
Figure	13:	Gating	strategy	for	panel	4	of	phenotyping	analyses	to	determine		
monocyte	subpopulations.	 ________________________________________	62	
Figure	14:	Expression	of	PD-1	and	CPT1a	in	CD4+	T	cell	subpopulations.	_____________	63	
Figure	15:	Overview	of	PBMC	phenotyping	based	on	flow	cytometry	gating	in		
MS	patients	and	HC	participants.	 ___________________________________	64	
Figure	16:	Within	group	comparisons	of	differential	blood	parameters	in		
MS	patients	and	HC	participants.	 ___________________________________	70	
Figure	17:	Within	group	comparisons	of	differential	blood	parameters	HDL,	LDL	and		
CRP	in	MS	patients	and	HC	participants.	______________________________	70	
Figure	18:	Within	group	comparisons	in	the	HC	participant	cohort	showed	adapted		
metabolic	profiles	in	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells.	___	72	
Figure	19:	Impaired	metabolic	profile	of	CD4+	T	cells	in	MS	patients	compared	to		
HC	participants.	_________________________________________________	73	
Figure	20:	Metabolic	profile	of	mitochondrial	respiratory	capacity	dos	not	differ	
	in	CD8+	T	cells	from	MS	patients	compared	to		HC	participants.	___________	74	
Figure	21:	Metabolic	profile	of	mitochondrial	respiratory	capacity	does	not	differ	in		
non-CD4+/CD8+	T	cells	from	MS	patients	compared	to	HC	participants.	_____	75	
Figure	22:	Changes	in	Extracellular	Acidification	Rates,	between	group	analyses	of		
MS	patient’s	and	HC	participant’s	CD4+	T	cells,	CD8+	T	cells	and		
non-CD4+/CD8+	T	cells.	 ___________________________________________	77	
Figure	Index	
134	
Figure	23:	Energy	graphs	OCR	vs.	ECAR	in	CD4+	T	cells,	CD8+	T	cells	and	
non-CD4+/CD8+	T	cells	in	MS	patients	and	HC	participants.	_______________	78	
Figure	24:	T	cell	and	monocyte	subpopulations	show	no	differences	in	frequency		
between	MS	patients	and	HC	participants.	____________________________	80	
Figure	25:	Flow	cytometry	isotype	control	staining	for	CPT1a	coupled	AlexaFluor®488		
antibody	in	CD4+	and	CD8+	T	cells.	 __________________________________	81	
Figure	26:	CD4+	T	cells	and	CD4+	helper	T	cell	subpopulations	show	increased	MFI		
of	CPT1a	analyzed	by	flow	cytometry.	 _______________________________	82	
Figure	27:	CD4+	regulatory	T	cell	subpopulations	show	increased	CPT1a	MFIs	as		
analyzed	by	flow	cytometry.	_______________________________________	83	
Figure	28:	CD8+	T	cell	subpopulations	showed	increased	MFI	for	CPT1a	in		
flow	cytometry.	_________________________________________________	84	
Figure	29:	PD-1	expression	levels	in	CD4+	and	CD8+	T	cells	from	MS	patients	and		
HC	participants.	_________________________________________________	85	
Figure	30:	Conventional	CD4+	T	cells	show	a	trend	towards	decreased	IL7-Rα	and	no	
changes	in	IL2-Rα	expression	in	MS	patients	compared	to	HC	participants.	__	86	
Figure	31:	Analysis	mRNA	gene	expression	in	CD4+	T	cells,	CD8+	T	cells	and	
non-CD4+/CD8+	T	cells	from	MS	patients	and	HC	participants..	 ___________	88	
Figure	32:	Analysis	GR	and	GILZ	mRNA	gene	expression	in	CD4+	T	cells,	CD8+	T	cells		
and	non-CD4+/CD8+	T	cells	from	MS	patients	and	HC	participants.	 ________	89	
Figure	33:	No	difference	in	morning	and	evening	salivary	cortisol	levels	between		
MS	patients	and	HC	participants.	 ___________________________________	90	
Figure	34:	Correlation	analyses	between	MS	disease	progression	index	and	
metabolic	and	flow	cytometric	data	in	CD4+	and	CD8+	T	cells.	_____________	91	
Figure	35:	Within	group	comparisons	of	differential	blood	parameters	in		
MS	patients	and	HC	participants..	__________________________________	135	
Figure	36:	CD4+	and	CD8+	memory	T	cell	subpopulations	do	not	show	differences	
	in	frequency	between	MS	patients	and	HC	participants..	 _______________	136	
Figure	37:	CD4+	CD8+	T	cell	subpopulations	based	on	chemokine	receptor	expression		
do	not	show	differences	in	frequency	between	MS	patients	and	
HC	participants.	________________________________________________	136	
Figure	38:	Increased	frequency	of	B	cells	in	live	lymphocytes	population	in		
MS	patients	compared	to	HC	participants.	___________________________	137	
Figure	39:	Frequency	of	cytotoxic	and	regulatory	NK	cells	n	NK	cell	population	in	
MS	patients	shows	significant	differences	compared	to	HC	participants.	___	137	
Figure	40:	CD4+	and	CD8+	memory	subpopulations	analyzed	by	flow	cytometry		
for	CPT1a	MFI.	_________________________________________________	138	
Figure	41:	B	cells,	NK	cells	and	monocyte	subpopulations	analyzed	by		
flow	cytometry	for	CPT1a	MFI.	____________________________________	138	
Figure	42:	Depression	and	Immune	System	(DENIM)	study	flyer	front	layout	and	text.	 139	
Figure	43:	Depression	and	Immune	System	(DENIM)	study	flyer	inside	layout	and	text.	140	
Table	Index	
135	
Table	Index	
Table	1:	CD4+	helper	T	cell	and	memory	cell	subtypes,	transcription	factors,	
															cytokine	profiles,	phenotype	and	natural	function.	_______________________	14	
Table	2:	Inhibitors	of	mitochondrial	electron	transport	chain	complexes..	____________	24	
Table	3:	CD4+	T	cell	subtypes	and	energy	metabolic	features..	_____________________	28	
Table	4:	Inclusion	and	exclusion	criteria	of	the	clinical	study	Depression	and	Immune	
	System	for	RRMS	patients	and	healthy	control	participants.	________________	38	
Table	5:	Clinical	assessments	of	MS	patients	and	HC	participants	in	a	study	site	visit	
			in	the	clinical	study	Depression	and	Immune	Function.	____________________	39	
Table	6:	Laboratory	equipment.	_____________________________________________	41	
Table	7:	Glass	and	plastic	equipment.	 ________________________________________	42	
Table	8:	Reagents,	chemicals	and	analysis	kits.	_________________________________	43	
Table	9:	RNA	isolation	and	cDNA	synthesis	kits	and	reagents.	 _____________________	44	
Table	10:	qRT-PCR	materials	and	reagents.	a	___________________________________	45	
Table	11:	List	of	antibodies	used	for	Magnetically	Activated	Cell	Sorting	(MACS)	and		
flow	cytometry.	__________________________________________________	46	
Table	12:	Four	antibody	panels	for	cell	phenotyping	and	PD-1	and	CPT1a	analysis.	 ____	47	
Table	13:	Software.	_______________________________________________________	48	
Table	14:	Seahorse	XFe	96	analyzer	mitochondrial	stress	test	kit	analysis	protocol.	_____	56	
Table	15:	Seahorse	Analyzer	Parameter	Calculations	for	OCR	and	ECAR	using	the		
mitochondrial	stress	test	kit.	 _______________________________________	57	
Table	16:	MS	patients’	and	healthy	control	participants’	cohort	characteristics.	_______	68	
Table	17:	Immunomodulatory	medications	taken	by	MS	patients.	__________________	69	
Table	18:	List	of	Abbreviations.	 ____________________________________________	114	
Table	19:	DENIM	study	routine	blood	analysis	parameters.	 ______________________	135	
Supplements	
136	
Supplements	
Figure	 35:	Within	 group	 comparisons	 of	 differential	 blood	 parameters	 in	MS	patients	 and	HC	
participants.	 Whole	 blood	 was	 analyzed	 in	 a	 certified	 routine	 laboratory:	 Labor	 Berlin,	 Berlin,	
Germany.	 Blood	 was	 drawn	 after	 a	 12	 hour	 fasting	 period	 and	 analyzed	 on	 the	 same	 day.	
basophils:	 n=28	 pairs.	 	 Wilcoxon	 signed-rank	 test	 with	 medians	 with	 interquartile	 ranges	 are	
displayed.	,	HC:	healthy	control,	MS:	multiple	sclerosis.	
Routine	Blood	Analyses	
Table	19:	DENIM	study	routine	blood	analysis	parameters.	Collected	from	each	RRMS	
patient	and	HC	participant	in	standard	EDTA	tubes.	The	blood	analysis	was	performed	
after	fasting	for	12	hours.
	Differential	blood	analysis	
Erythrocytes	
Leukocytes	
Hemoglobin	
Hematocrit	
MCV	
MCH	
MCHC	
RDW	CV	percent	
Thrombocytes	
MPV	
Neutrophils	absolut	
Lymphocytes	absolut	
Monocytes	absolut	
Eosinophils	absolut	
Basophils	absolut	
Neutrophils	percent	
Immature	granulocytes	percent	
Lymphocytes	percent	
Monocytes	percent	
Basophils	percent	
Immature	granulocytes	absolute	
Eosinophils	percent	
Clinical	chemistry	
LDL	
HDL	
CRP	
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Appendix	
Flow	Cytometry	Analyses	
Figure	36:	CD4+	and	CD8+	memory	T	 cell	 subpopulations	do	not	 show	differences	 in	 frequency	
between	 MS	 patients	 and	 HC	 participants.	 Between	 group	 analyses	 of	 MS	 patients	 and	 HC	
participants,	n=28	pairs.	T	cells	are	%	of	live	T	cells	in	CD3+	T	cell	population.	CD4+	T	cells:	naïve,	
CM,	EM,	TEMRA,	all	p≥0.52.	CD8+	T	cells:	naïve,	EM,	TEMRA,	all	p≥0.32.		CD8+	CM	T	cells,	p=0.06.	
Wilcoxon	signed-rank	test,	medians	with	interquartile	ranges	are	displayed.	CM:	central	memory,	
EM:	 effector	 memory,	 TEMRA:	 terminally	 differentiated	 effector	 memory	 cells	 re-	 expressing	
CD45RA,	HC:	healthy	control,	MS:	multiple	sclerosis.	
Figure	37:	CD4+	CD8+	T	cell	subpopulations	based	on	chemokine	receptor	expression	do	not	show	
differences	 in	 frequency	between	MS	patients	and	HC	participants.	Between	group	analyses	of	
MS	patients	and	HC	participants,	n=29	pairs.	%	of	live	T	cells	in	CD3+	T	cell	population	shown.	CD4+	
T	cell	subpopulation:	Th0,	p=0.75.	Th1,	p=0.64.	Th2,	p=0.76.	Th17,	p=0.92.	Th1/17,	p=0.62.	CD8+	T	
cell	 subpopulations:	 CCR4+,	 p=0.31.	 CCR6+,	 p=0.03.	 CXCR3+,	 p=0.83.	Wilcoxon	 signed-rank	 test,	
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medians	 with	 interquartile	 ranges	 are	 displayed.	 CCR:	 CC	 chemokine	 receptor,	 CXCR3:	 CXC	
chemokine	receptor3,	Th:	helper	T	cell,	HC:	healthy	control,	MS:	multiple	sclerosis.		
Figure	 38:	 Increased	 frequency	 of	 B	 cells	 in	 live	 lymphocytes	 population	 in	 MS	 patients	
compared	to	HC	participants.	Between	group	analyses	of	CD20+	CD56+	B	cells	of	MS	patients	and	
HC	 participants,	 n=29	 pairs,	 p=0.0086.	 Displayed	 values	 in	 the	 flow	 cytometry	 blots	 are	
frequencies	 of	 CD20+	 cells	 expressed	on	 live	 lymphocytes	 from	a	 representative	MS	patient-HC	
participant	pair.	Wilcoxon	signed-rank	test,	medians	with	 interquartile	ranges	are	displayed.	HC:	
healthy	control,	MS:	multiple	sclerosis.	
Figure	39:	 Frequency	of	 cytotoxic	and	 regulatory	NK	cells	n	NK	 cell	population	 in	MS	patients	
shows	 significant	 differences	 compared	 to	 HC	 participants.	 Between	 group	 analyses	 of	 MS	
patients	 and	 HC	 participants,	 n=29	 pairs.	 (A)	 Flow	 cytometry	 blot	 of	 CD16+	 CD56+	 cells	 of	 a	
representative	MS	patient-HC	participant	pair.	Displayed	values	are	 frequencies	of	CD56+	CD16+	
cytotoxic	NK	cells	and	CD56+	CD16-	regulatory	NK	cells	expressed	as	a	percentage	of	live	CD56+	NK	
cells.	(B)	Percentage	of	cytotoxic	NK	cells	(p=0.0003)	and	regulatory	NK	cells	(p=0.0003)	between	
MS	patients	and	HC	participants.	Wilcoxon	signed-rank	test,	medians	with	interquartile	ranges	are	
displayed.	NK	cell:	Natural	Killer	cell,	HC:	healthy	control,	MS:	multiple	sclerosis.	
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Figure	40:	CD4+	and	CD8+	memory	subpopulations	analyzed	by	 flow	cytometry	 for	CPT1a	MFI.	
Between	group	analyses	 for	MS	patients	and	HC	participants	are	shown.	n=28	pairs.	CD4+	T	cell	
subpopulations:	 naïve:	 p=0.12.	 CM:	 p=0.15.	 EM:	 p=0.41.	 TEMRA:	 p=0.88.	 CD8+	 T	 cell	
subpopulations:	 naïve:	 p=0.18.	 CM:	 p=0.11.	 EM:	 p=0.27.	 TEMRA:	 p=0.69.	Wilcoxon	 signed-rank	
test,	medians	with	interquartile	ranges	are	displayed.	CM:	central	memory,	EM:	effector	memory,	
TEMRA:	 terminally	 differentiated	 effector	 memory	 cells	 re-	 expressing	 CD45RA,	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
Figure	41:	B	cells,	NK	cells	and	monocyte	subpopulations	analyzed	by	flow	cytometry	for	CPT1a	
MFI.	 (A)	Between	group	analyses	 for	MS	patients	and	HC	participants	are	 shown.	n=29	pairs.	B	
cells	 p=0.40.	 cytotoxic	 NK	 cells.	 regulatory	 NK	 cells.	 CD14++	 CD16-	 classical	 monocytes.	 CD14++	
CD16+	intermediate	monocytes	n=27	pairs.	CD14+	CD16++	non-classical	monocytes	n=27	pairs.	(B)	
CPT1a	expression	in	the	corresponding	cell	subsets	of	a	representatice	MS	patients-HC	participant	
pair.	Wilcoxon	 signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	MFI:	 Median	
Fluorescent	Intensity,	NK	cell:	Natural	Killer	cell,	HC:	healthy	control,	MS:	multiple	sclerosis.	
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DENIM	Study	Flyer	
Figure	42:	Depression	and	Immune	System	(DENIM)	study	flyer	front	layout	and	text.	Prepared	
for	 information	 purposes	 for	 Multiple	 Sclerosis	 patient	 and	 healthy	 control	 participant	
recruitment.	
Appendix	
141	
Figure	43:	Depression	and	Immune	System	(DENIM)	study	flyer	inside	layout	and	text.	Prepared	
for	 information	 purposes	 for	 Multiple	 Sclerosis	 patient	 and	 healthy	 control	 participant	
recruitment.	
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DENIM	Study	Case	Report	Form	
The	following	pages	include	the	representative	full	case	report	form	(CRF)	used	with	the	
RRMS	patients,	who	were	included	in	the	Depression	and	Immune	System	(DENIM)	study	
and	 went	 through	 the	 clinical	 assessment.	 HC	 participants	 received	 the	 same	 CRF	
excluding	the	MS-specific	tests	EDSS,	MFSC	and	HALEMS.	The	MS	patients	each	received	a	
DENIM	BMS	(abbreviated	for	Berlin	Multiple	Sclerosis)	and	the	HC	participants	received	a	
DENIM	BHC	(abbreviated	for	Berlin	Healthy	Control)	study	case	number.	Additionally,	the	
telephone	screening	forms	are	included,	also	representative	for	the	MS	patient	cohort.	To	
protect	copyrights,	most	questionnaires	or	assessments	are	not	printed	here.	
Telefon	Screening	
Study	Nurse	&	Studienärztin/-arzt	CRF	
PASAT	[212]	
EDSS	[135]	&	MSFC	[214]	
oraler	SDMT	[134]	
Merkblatt	zur	Speichelabgabe	
Fragebögen	Studienproband/-in:	BAI	[133,	216],	BDI-II	[132,	217],	FSMC	[220],	FSS	
[221],	HALEMS	[222],	CTQ	[223]	
Psychiatrische	klinische	Anamnese:	MINI	[131],	MADRS	[130]	
  



 "')*5
%&''#"*"	!!*"*")#"9	:
8
##&)
 #"'&""






	
,)(()



(/,2#3,<@@@@@@@@@@@@@@@@@@@@@@@@@@@@


 
)*!5

¬¼¬¼=¬¼¬¼=¬F¼¬D¼¬E¼¬¼




/0#<+,--#)(0(
''0( 0(%/#)(–

  )"),/<

2
#)/"





































 
 
 
 
/0#<+,--#)(0(
''0( 0(%/#)(–

  )"),/<

 3 
 #"'&""

0/(!,0>	,,===


#&')  "; 
&)*
Mein Name ist … Ich bin wissenschaftliche(r) Mitarbeiter(in) in einem 
),-"0(!-+,)$%/ ( , ",#/=  # "( ,#/- ( #(, (,( /0#
2)( 0(- '  # ,) = 0& /#&!()''(: -3!( 31,( 3#, 
"((
-", !,( #( 3#/, /0# 2),-/&&(= 
( #-, /0# !"/ - 0' (
0-''("(!2)' #	!

=##&("'#-/ ,#3#&&#!=


 *;
")'*"
0("-/'*"/ #" 
"((!,(#((%0,5(,&#%1,#&0(
&0 ,/0#!(=#/0# #(/"! (#('),!(>),'#//!

",,"&-///0(0' --/#,GE>F/0((=,,'#(!#((/0'J=GD
",0(0' --/#(&0/("'0(#((0,)&)!#-"(/,-0"0(!-)3#
- (/3),/( #(#!, ,!*!(= - 3,( " !")
2,,#"/ 0( # 3,( " "& ' &/)  " )= 1, 
",
#&("',"&/(##(0 3(-(/-"#!0(!#(	*"2)n 30 €=



#&*'')/*""
+& *"'& )* ') ' /-"" "#)-"4 ''  "+)&"
&'""69<=)*""")'''":



)6"#;! 
/1,&#"3#,
"((&&-0"()"#('&0- 1",&#",%&,/:3((#
#0(--#(=*(&!#!!"  	"#&!)#""*"'&) &
#&!/*	&!&!"6

",/(3,(+-0)()4'#-#,/!-+#",/0(0-!3,//=

 "!3 	(#-)3#/()",!(9*(((#-#"#(#&("'2),-/&&(9


  )       
 !& "   ( !
*********************************************************
$,	 $"&'***(***(***********************
! )
&"&'


Æ-(+" &$&
 
(



 
 
 
 
/0#<+,--#)(0(
''0( 0(%/#)(–

  )"),/<

 4 
	/-#"(
",,,--/3-!(,/9A 1,"'&#!/="(3#,$#,--(#'4-/'B
'< @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
/,.<@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
//><@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
&=A,0 B<@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@&=A+,#2/B<@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
'#&,--<@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@

&/,<@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@*&)')*!<@@@@@@@@@@@@@@@@@@@@@@@@@@@@@


"'*"/
"(((0(!,(#(+,,!(50
",'')'(/(('#5#(#-"(0-/(-/&&(=
	!$)"#! ''&"4	"" )"'*$&!""
&&"*",#&4&)3     

<6 /"'&*')"9!#!")":

3#"/<@@@@@@@@@@@@@,*.<@@@@@@@@@@@@@
<@@@@@@@@@@@@@A
ൌ ீ௘௪௜௖௛௧௞௚ୋ୰Úéୣ୫ଶ ;
dGDB

	(#'#5#(#-",%,(%0(!(:#%/0&&'#%'(/*-
"(&/3,(?!-"(2)(,9     $ (#(

&"9@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@

"'(#,5#/#%'(/9(($:3&"9
(3&",)-#-9
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@

&&-$<	/-#"#((&/5/(-"-)(/(/3-(
",,#%/#)(
2,(,/9$(#(
 
 
 
 
/0#<+,--#)(0(
''0( 0(%/#)(–

  )"),/<

 5 

&&-$<	/-#"#((&/5/(-"-)(/(/3-(
",,?#%/#)(
2,(,/9$(#(

	(##((&/5/(G)(/(),/#-)(%)''(9   $(#(

,(#,#/-#('&-//#)(,#(#(',(%("0-9   $(#(

,0'9@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@

#!/#&/5/
'+ 0(!'",&-G)(/50,1%9    $(#(

=6 -"&')
((#("3(!,-" /0-!-"&)--(3,(9  $(#(

G=+,--#)(()==%'.)&'&&"*""7"&! 5 $(#(
,9@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
G=+,--#)(()==%'.)&'&&"*""&&#""7&#"5$(#(
#2#&+#-)(9@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
#/,0'9@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
(/#+,--#29@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@

>. HALEMS Items 40. & 41. „Stimmung“:
HD=
""0-/:/3-50/0(= E F G H I

HE=	(#-#"#((&/5/(F)"((('#-/( E F G H I
!(0(#'#-/#/-!-+,#'#,/),
,1%/! 1"&/9


>6 &*"&–))"&*/"*"/*!&!",#&')  "2
!0//'#/EB0",&"-:FB("&-&'#:GB	#,/(%-=-/<+ &>((>,(!

	
Æ


")'*"'&""'
	
<



9     $(#(
 

,!,,)(((0'',<
?@@@@@@@@@@@@@@@@@@@
 Studie: Depression und Immunfunktion – DENIM   
Kohorte: BMS 
6 
  

%#'#,"./#:
*+,,#('/'
&&/' /'$.#('?
@
=("(+.
./3/+,A./#'+4.#'<=+4.–
	









-)(()



./#'+4.#'<=+4.:>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
?	@


./3/+,:>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
?	@





 
./&:

¬¼¬¼;¬¼¬¼;¬F¼¬D¼¬E¼¬¼

 
 
 
/0#:+-..#)(0(
''0( 0(%/#)(–

  )")-/:
F
 



































 
 
 
/0#:+-..#)(0(
''0( 0(%/#)(–

  )")-/:
G
 
&*/,"+#.#..–"$%#,.     +%#!.8

B; +(''#' (+&.#('/'#'1+,.''#,+$%+/'!  $ (#(
C; ./3/+,:
F;E&0/("'A#!(      $ (#(
F;F	#+#.//#)./#''(     $ (#(
F;G        $ (#(
F;H)-&-.#)(      $ (#(
F;I)--&#((-0 (      $ (#(
F;J)-."0(!.&0/(.)-1-!(   $ (#(
F;KH&#2//(:#(%&;-%&//#((1%0'."&!  $ (#(
F;L-)((,0#//0(!#((1%0'."&!   $ (#(
D; ./#'+4.#'<=+4.'.+,/"/'!/''&',:
G;E        $ (#(
 G;F('(.')!- #<#%'(/    $ (#(
G;G

        $ (#(
G;H        $ (#(
G;I==+# #-.      $ (#(
E; .#'.<#'#!',.'#!&#.'%#./'!/+"./3/+,:
I;E-!)!(')!- #      $ (#(
I;F
        $ (#(
I;G
=

        $ (#(
I;H        $ (#(
I;I        $ (#(
I;J	        $ (#(
I;K        $ (#(

-/9/0'       '/0#(+-.)(&

"-6#/&0/("' /-/9(&&#.)&/#)(')-+-.)(&

/0'#(!(!&#2//('    +#"&2--#//2)(
 
 
 
/0#:+-..#)(0(
''0( 0(%/#)(–

  )")-/:
H
 
#',"%/,,$+#.+#'

./#<-/#(/<#(63#."(FD=JI"-&/8 $ (#( o
./"/#(%&#(#."!.#"-/#!().."0 *-'#!0&/#+&%&-).8 $ (#( o

./-
dGD8 $ (#( o
-."#(/ - /#(/ (1"/-( ?"-0(!.%-(6 '"- &. EF /0((@ 60-
/0#8
$ (#( o
/,,"%/,,$+#.+#'
0- # #''0(')0&/)-#." )- #''0(.0++-..#2 "-+# #( (
&/6/(.".)(/(!(-/8
(#( $ o

./#&/6/
'+ 0(!3(#!-&.-#)(/"-8 (#( $ o
./()-/#%)./-)#/"-+##((&/6/(MD!(2)-#(."&0..8 (#( $ o
./( #( ( &/6/( L )"( #( #( %/#*. -%-(%0(! ?-%&/0(!9
!(=-'=
( %/9);;@8
(#( $ o
./"/#("3(!-." /8
1-((-(#"/60/-  (
(#(

$ o
#!/)-&!#(- )&!((-%-(%0(!(2)-8
+#&+.#<( &&.&#(
"#6)+"-(#<0/#.'0.<#+)&--%-(%0(!(<'(6
"0'<0+0.<(- (/61(&#" -%-(%0(! 0. ' -"0'/#."(
)-'(%-#.
#/.'&&#/0.
	
<	+/#/#.=
( %/#)(
)-)(-	-6-%-(%0(!<	-6#( -%/
"&!( &&
)+ 2-&/60(!'#/-(%("0.0 (/"&/

(#(
(#(
(#(
(#(
(#(
(#(
(#(
(#(

$
$
$
$
$
$
$
$

o
o
o
o
o
o
o
o
#!/#("(&0(!'#/ )&!((#%'(/(2)-:(/#+.5")/#%9
(/#+-..#29
(.0&#(9(/#+#&+/#%
(#( $ o
#/ . %&#(#."=('(./#." )- +-%&#(#." 	#(3#. 0  #(
)-!."#"/ 2)( -&2(/' #%'(/(=9 -)!(= 0(<)-
&%)")&0.0.#'&/6/("-8
(#( $ o

%%,%%#',"%/,,$+#.+#'/'$#'/,,"%/,,$+#.+#'4/.+  '9
$''+.#'.#'#./##'!,"%(,,'2+'7
 
 
 
/0#:+-..#)(0(
''0( 0(%/#)(–

  )")-/:
I
 
./3/+,:
 

)+*+!+)-  >>>>>>>>>>>' 	0 ./& '!  >>>>>>>>>>>'

2#".  >>>>>>>>>>>%! #%%'/& '!  >>>>>>>>>>>'


   >>>>>>>>>>>%!<'N %/.+/$>>>>>>>><>>>>>>>''	!




PASAT Testversion A, Version 3 s 
             Testversion B, Version 3 s 
¬  ¼¬  ¼ / ¬J¼¬D¼ sek.  

(+%+,#(' ¬  ¼¬  ¼ / ¬M¼¬D¼ sek. 

#''/-/#(/!&#"6#/#!()"((-(#(/-2(/#)(&&(/0#(
/#&83&":>>>>>>>>>>>>>>>>>


(#( $


&0/(/("' 1-(+,"/'!0-"! 1"-/8
ED4ED'#=	+-#(-*"-"(
E4E-0'-*"-"(
$ (#(
&0/(/("' 1-(++%#'0-"! 1"-/8
E4F':%&;&0/#&P#  ;9E4G'#=	+-#(+&.'9	9 $ (#(
--<#/#(/<#(60'#/+0(%/-&0/(/("''0".+'8 $ (#(
(("/-<#/#(/<#(.&/6/&/3.!!..(8
"-6#/¬¼¬¼¬¼¬¼ /0': ¬¼¬¼;¬¼¬¼;¬F¼¬D¼¬E¼¬¼
  
=
(+ ?E;/-%@ ¬¼¬¼9¬¼¬¼.

?F;/-%@ ¬¼¬¼9¬¼¬¼.
M	)'#((/	( &#(%.-"/.   ¬  ¼¬  ¼ , ¬  ¼¬  ¼ s   ¬  ¼¬  ¼ , ¬  ¼¬  ¼ s 
M	(#"/=)'#((/
	(
&#(%.
-"/.   ¬  ¼¬  ¼ , ¬  ¼¬  ¼ s   ¬  ¼¬  ¼ , ¬  ¼¬  ¼ s 
 
 
 
/0#:+-..#)(0(
''0( 0(%/#)(–

  )")-/:
J
 

./#'+4.#'<=+4.
'&',

+,.&'# ,..#('+:)(/:>>>>>>>>>>>>>>"-:>>>>>>>>>>>>>>

./&+=#!'(,:)(/:>>>>>>>>>>>>>>"-:>>>>>>>>>>>>>>

#.,%%1('#'+&#%#''&',8    $ (#(
3-8>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

"/'&',#''%.4.'BC('.':
5'+/)'/#%: /0': '#..#)(8 #;2;8 //#)(-8

 ¬¼¬¼;¬F¼D¬¼¬¼
  

(#(


 ¬¼¬¼;¬F¼D¬¼¬¼
  

(#(


 ¬¼¬¼;¬F¼D¬¼¬¼
  $

(#(


 ¬¼¬¼;¬F¼D¬¼¬¼
  

(#(



&&/'&(/%#+'#$&'.$./%%
#..'$+/4'92''4/.+  ' #.2''8
)+4)(FD'!  
)+4)(HD'!  
# FF  
# HH  
2)(4  
/ -)(<4/2#  
5.-#</&#60'  
#&(5<#(!)&#')  
0!#)<-# &0()'#  
 #-<0'-/  
'/-  
&!-#5  
(-  

 
 
 
/0#:+-..#)(0(
''0( 0(%/#)(–

  )")-/:
K
 

$./%%#$&'./'#.&'#'*+*+.


!%#.+$+'$/'!'

 /+(,../,

 	       
        

%",8 (,#,8 #.2''8
  
  
  
  
  
  
  
  
  
  
  
  
%"8 #.2''8
 
 
 
 
 
 
 
 Studie: Depression und Immunfunktion – DENIM   
Kohorte: BMS 
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DENIM - Studie 
PASAT  
Baseline 
1 von 1
Bitte Patientencode 
________________________________________________ 
ausfüllende Person (BLOCKBUCHSTABEN) 
Datum:  
⎣⎦⎣⎦.⎣⎦⎣⎦.⎣⎦⎣⎦ 
DENIM-BMS______ 
NeuroCure, AG Neuroimmunologie, Charité 
EDSS + MSFC Verlaufsdokumentation 
Patientenname:   Datum: ___________________________ 
_________________________     Untersucher: ______________________ 
  
Bitte Patientencode aufkleben 
NeuroCure, AG Neuroimmunologie, Charité 
EDSS + MSFC Verlaufsdokumentation 
P  atientenname: 
Bitte Patienten______________________code aufkleben ___
  Datum: ___________________________ 
  Untersucher: ______________________ 
Studie: Depression und Immunfunktion - DENIM 
Kohorte: BMS 
Neuro Cure Clinical Research Center Pat. ID: DENIM-BMS: __ 
Datum: _  _ 
oraler SDMT - Symbol Digit Modalities Test - Patientenblatt 
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